The Sonic hedgehog and Wnt signalling pathways in interstitial lung disease and CD4⁺T cell activation by Stewart, Gareth Alexander
The Sonic Hedgehog and Wnt Signalling
Pathways in Interstitial Lung Disease and
CD4+ T cell activation
Gareth Alexander Stewart
A thesis submitted for the degree ofDoctor ofPhilosophy
University ofEdinburgh, 2003





The Sonic Hedgehog (Shh) signalling pathway plays an important role in lung
development where it promotes branching morphogenesis through epithelial-
mesenchymal interactions. Increased Shh expression promotes epithelial and
mesenchymal proliferation in vitro and in vivo. TGFp is also expressed in embryonic
lung where it acts to inhibit branching morphogenesis. TGFP overexpression results
in lung hypoplasia, a similar phenotype to that seen in Shh'A mutants; suggesting that
Shh and TGFP have opposing roles. Evidence to date would suggest that although
TGFP and Shh may not directly interact in lung development, they probably have
common targets and may function in a shared regulatory circuit.
Interstitial lung disease (ILD) is the end result of a multiplicity of pathological
processes. It has been recently proposed that the commonest form, Idiopathic
Pulmonary Fibrosis (IPF) or Usual Interstitial Pneumonia (UIP), is due to abnormal
wound healing in the lung, characterized by epithelial-fibroblast interactions; a
process similar to foetal lung branching and epithelialization. TGFP has been
strongly linked with ELD in both animal models and human disease. Based on the
link between TGFP and Shh in lung morphogenesis, the initial aim of this thesis was
to determine whether or not Shh signalling was upregulated in ILD. The work
presented confirms that Shh and TGFP expression are increased in the airway
epithelium of fibrotic but not non-fibrotic lung both in the murine FITC model of
ILD and in biopsy sections from patients with IPF. Expression of Patched (Ptc), the
Shh receptor, is unchanged in epithelial cells. Notably, Ptc is present both in alveolar
macrophages and lymphocytic infiltrates. However, there is no discernible difference
in the fibrotic response in the lungs of mice containing heterozygous mutations of
Gli2 and 3, used as models of dysregulated Shh signalling, nor in mice treated with
intra-tracheal SPC-Shh cDNA.
The Shh pathway has recently been shown to play a role in thymocyte development.
The findings presented demonstrate that both Shh and Ptc are expressed in human T
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cells. In addition, upregulation of Shh signalling enhances and blocking of
endogenous Shh inhibits T cell receptor mediated T cell activation, respectively, as
determined by proliferation, cytokine production and CD25 and CD69 expression.
Wnt signalling is also thought to play a role in lung branching morphogenesis. It is
known to interact both with Shh signalling and TGF(3. However, using presently
available antibodies, there is no evidence of upregulation ofWnt signalling in ILD.
In an attempt to drive the Wnt Pathway, a replication-deficient adenovirus expressing
Dvll (Ad5-MCMV-Dvll) was successfully rescued. Although the virus drives Dvll
mRNA and protein expression in vitro and in vivo, it does not consistently mimic
Wnt signalling, nor does it appear to affect Shh or TGF(3 signalling. Furthermore
such Dvll overexpression has little effect on cell proliferation either in vitro or in
vivo, and does not cause lung fibrosis in mice.
Thus Shh signalling appears to be upregulated in fibrotic lung in mice and humans.
However the work presented does not define whether or not the pathway plays a
specific role in the pathogenesis of ILD. There is also no evidence relating Wnt
signalling or Dvll upregulation to ILD. Finally, Shh is shown to influence TCR
mediated signalling and clonal expansion. It may be that damaged epithelial cells and
the immune system communicate via this pathway.
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1.1 Aims of Thesis
The aims of the research reported in this PhD thesis were to investigate the role of
the Sonic hedgehog (Shh) and Wnt (Wnt) signalling pathways in the pathogenesis of
Interstitial Lung Disease (ELD), and the effects of Shh signalling on human CD4+ T
cell activation. As will be discussed, both of these pathways play a role in branching
morphogenesis of the developing lungs. Upregulation of either is associated with
increased cell proliferation, and they are known to interact both with each other and
with the profibrotic cytokine TGFp. Furthermore, they are emerging as potential
mediators in an increasing number of cell functions and disease processes in mature
species. Such features prompted the study described.
This introduction begins with quite detailed descriptions of the Shh and Wnt
signalling pathways, with particular reference to their roles in lung development, cell
proliferation, disease processes and interactions with genes such as TGF(3. Recent
work relating Shh to the developing immune system is also discussed. The clinical
features, pathogenesis and management of ILD are then addressed, followed by an
introduction to the FITC rodent model of pulmonary fibrosis. A brief summary of T
cell receptor mediated T cell activation precedes a concluding description of the
rationale behind, and application of, adenoviral gene therapy.
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1.2 The Sonic Hedgehog Signalling Pathway
1.2.1 THE HEDGEHOG PATHWAYS
1.2.1.1 The Hedgehog (Hh) Pathway in Drosophila
Hh was first identified as one of the segment polarity genes in Drosophila, which are
so called because mutations in these genes disrupt the pattern and polarity of the
larval segments \ The larval cuticle becomes covered in spiky processes called
denticles in Hh homozygotes 2; thus the name "hedgehog". Drosophila only have a
single Hh gene, which is expressed in the posterior cells of each segment and
activates expression of the Wnt family gene wingless (wg) in the adjacent anterior
cells 3. Hh induces the expression of secondary signals, wg and decapentaplegic
(dpp, a member of the TGF(3 superfamily) during postembryonic limb formation 4'5,
which function as morphogens required in pattern formation 6'7; a morphogen being
an organizing molecule that emanates from a localized source and diffuses away to
form a concentration gradient. Indeed Hh itself is thought to act as a morphogen 8'9,
eliciting differential responses at different concentrations.
Hh encodes a 46kDa native protein that initially undergoes signal peptide cleavage to
a 39kDa form, followed by an autoproteolytic cleavage into a 19kDa amino-terminal
peptide (N-Hh) and a 26kDa carboxy-terminal peptide (C-Hh) 10. This second
cleavage is dependant upon a conserved domain within the carboxy-terminus 10,1 \
The N-Hh remains associated with the cell surface whilst the C-Hh diffuses from the
cell. Only the N-Hh peptide has been shown to have signalling activity 11,12 This
association of N-Hh is dependent on its covalent attachment to a cholesterol moiety
in the membrane, which is catalysed by intramolecular cholesterol transferase
activity of C-Hh 13,14 It would appear that active signalling requires cleavage and
binding to cholesterol 13. Why hedgehog undergoes cholesterol modification is
unclear. It has been suggested that it may be involved in directing intracellular
transport within epithelia 15. In addition, cholesterol may affect the movement ofHh,
-28-
which may in turn influence long-range signalling 16. Cell culture studies have also
produced evidence for a degree of palmitoylation of hedgehog 17.
Hh interacts with a receptor complex comprising Patched (Ptc) and Smoothened
(Smo) 18. Ptc is a segment polarity gene encoding a twelve-transmembrane protein
with two large extracellular loops 19'20. In vertebrates, Ptc has been shown to bind to
the Sonic Hedgehog protein (Shh) with high affinity 18'21, a function dependant on
the extracellular domains 21. Smo, another segment polarity gene, encodes a seven-
transmembrane protein that shares homology with G protein coupled receptors 22. In
contrast to Ptc, there is no in vitro evidence of physical interaction between
vertebrate Smo and Hh proteins 18. It would therefore appear that Ptc and not Smo is
the Hh receptor. However, whilst remaining constitutively active in the combined
r)'l rir) 'JA
absence of Ptc and Hh , Hh signalling is dependent on Smo ' . In the absence of
the Hh ligand, Ptc inhibits Smo signalling, through modification of the Smo protein
25, and thus prevents constitutive activation of the Hh pathway 26. Hedgehog binding
to Ptc represses its activity leading to the derepression of Smo and ligand
independent Hh signalling by Smo 26(Figure 1.1). This is most likely due to a
conformational change rather than dissociation of the Ptc-Smo receptor complex, as
the association of the two proteins is unaffected by Hh signalling 18.
Paradoxically Hh signalling induces expression of its own receptor, Ptc 14'27. It has
been shown that the absence of Ptc causes the Hh signal to spread further from its
source, whereas upregulating Ptc restricts movement28. This would imply that Hh is
normally sequestered by Ptc; a feature that would allow Hh to restrict its own
movement, which may have further implications on short and long-range signalling.
Therefore Ptc serves both to antagonise Hh signalling through inhibition of Smo
signalling and sequestration ofHh itself.
So how does Hh control transcription in Drosophilal A crucial element is Cubitus-
Interruptus (Ci), a zinc finger transcription factor homologous to the vertebrate Gli
factors 29 However, unlike Gli's in vertebrates 30, Ci transcription is independent of
Hh signalling 31; control is therefore post-transcriptional. Ci, which is subject to
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proteolytic cleavage , exists as either a full length (Ci-155) or a truncated form (Ci-
75). Importantly Ci-155 overexpression has been shown to activate Hh targets such
as dpp, Ptc and wg , whilst Ci-75 can act as a transcriptional repressor 32. It is
therefore not surprising that Ci-75 is predominant in cells in the absence of Hh
signalling. Following Hh induction Ci cleavage is blocked with a resultant
accumulation in the Ci-155 form before its transport to the nucleus 37 The
transcriptional activation domain 34 and binding site for CREB binding protein
(CBP), necessary for Hh target gene activation 38, are lost during cleavage from Ci-
155 to Ci-75 32'34(Figure 1).
A model proposed by P.W.Ingham 39(Figure 1.1) suggests that Hh signalling may be
modulating Ci phosphorylation, preventing Ci ubiquitination and cleavage (to Ci-75)
by the proteasome pathway 40. Indeed a number of protein kinase A (PKA)
phosphorylation sites have been identified in vertebrate Gli proteins 38'41. In addition
PKA is inactivated in a number of wing duplication mutations 27(phenotype
consistent with Hh activation), and mutations of likely Ci phosphorylation sites result
in increased Ci-155 stability and activity 41. These observations imply that PKA
controls Ci phosphorylation, under the regulation of Hh signalling. However as
upregulation ofPKA does not suppress Hh signalling it seems more likely that PKA
is working in parallel, rather than downstream of, Hh42.
Ci is normally found as part of a large high molecular weight complex along with the
kinase related protein, costal-2 (Cos2)43, and the serine-threonine kinase, fused
(Fu)44. This complex docks at microtubules, possibly through the action of Cos2.
This association allows targeting of Ci to the proteasome for cleavage to take place.
Moreover the binding of this complex to the microtubule is controlled by Hh
signalling, the complex detaching upon Hh activation 44 Thus Hh signalling prevents
association of the complex to the proteasome and cleavage into Ci-75 (Figure 1.1).
How Hh causes this dissociation is unknown. As Fu is epistatically upstream of
Cos2, Smo may directly activate Fu, which in turn may inhibit Cos2 . When a
fourth component of the complex, Suppressor of Fused [Su(Fu)] protein is
eliminated, Fu activity is no longer necessary 46. Thus, although Su(Fu) antagonises
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Fu activity, Hh signalling can function normally when neither is present. Su(Fu)
binds cytoplasmic Ci-155. Loss of Su(Fu) enhances ectopic Hh target gene
expression, in keeping with its role as an antagonist of Ci-155 function 42. However,
Su(Fu) has paradoxical effects: while antagonising Ci-155 function, it also increases
cellular Ci-155 independently of Ci proteolysis. To explain this it has been suggested
that Su(Fu) prevents the maturation of Ci-155 from its stable cytoplasmic inactive
form into a nuclear active one 42.
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Figure 1.1: The Hedgehog Signalling Pathway in Drosophila. Figure taken
from review article by P.W. Ingham "Transducing Hedgehog: the story so
far" (1998)39
Negatively acting components are shown in red, positively acting components in
green. Note: in above figure patched is represented as PTC and ptc, hedgehog
as HH and hh, and smoothened as SMO.
(A) In the absence of Hh (or HH) induction, the activity of Smo (or SMO) is
inhibited by Ptc (or PTC) probably through their physical association. Full-length
Ci forms a complex with Fu, Cos-2 and Su(fu), via which it associates with
microtubules. This association leads to targeting of Ci to the proteasome where
it is cleaved to release the transcriptional repressing form Ci75. The
phosphorylation of Ci155 promotes its cleavage, either by promoting association
with the Cos-2-Fu or by promoting ubiquitination (or both). Although Ci75
translocates to the nucleus, it is also found in association with Fu and Cos-2. It
is not clear whether it dissociates from the complex prior to translocation; there
is, however, no evidence that Cos-2 enters the nucleus. The intracellular
distribution of Fu protein has not been determined. (B) When Hh binds to Ptc,
the inhibitory effect on Smo is suppressed. The resulting activation of Smo
leads, by an unknown mechanism (but possibly via a heterotrimeric G protein
signal), to the dissociation of the Fu-Cos-2-Ci complex from microtubules.
Cleavage of Ci155 is blocked; this or a related form of Ci then presumably enters
the nucleus to activate transcription of Ptc, wg, dpp and other unidentified target
genes in association with CREB binding protein (CBP).
-32-
1.2.1.2 The Sonic Hedgehog Pathway
Many of the features of Hedgehog Signalling described in Drosophila are preserved
in mammals. There are three Hh homologues in mammals: Sonic hedgehog (Shh),
Desert hedgehog (Dhh) and Indian hedgehog (Ihh). Dhh is largely expressed in testes
where it regulates spermatogenesis, and it organizes the perineurium around
peripheral nerves; whilst Ihh coordinates chondrocyte maturation and proliferation
during endochondral skeleton development 47"49. However Shh is the best known of
the mammalian homologues; it is produced in many tissues with organizing
properties, including the CNS, limbs, eye 48,50"54 and, of particular relevance to this
thesis, the lungs 55'56. Like other hedgehog proteins, Shh undergoes autoproteolytic
cleavage into an amino-terminal (N-Shh) peptide responsible for activity, and a
carboxy-terminal (C-Shh) containing all auto-processing machinery 57. As in
Drosophila N-Shh remains membrane associated, by a palmitic acid at its N-
terminus 17and cholesterol at its C-terminus 13'14. Palmitoylation results in a 30-fold
increase in potency 17 Other properties of Hh relating to short and long-range
signalling also apply to Shh.
Shh also acts through a Ptc-Smo receptor complex. In fact much of the biochemical
characterization of Hh-Ptc-Smo interactions has been carried out in mammals and
vertebrates 18'21. Two Ptc homologues have been identified in mammals, known as
Ptc (or Ptcl) and Ptc2 58"60. Whilst mouse Ptcl and Ptc2 share only 56% identity,
their basic structure is similar; greatest variation is noted at the amino- and carboxy-
termini. Both are differentially expressed during epidermal development and Ptc2 is
co-expressed with Shh in epithelial cells. Although they may have different functions
both Ptc genes are modulated by Shh signalling 59.
Similarities between Hh and Shh signalling also exist in the cytoplasm. Shh
counteracts PKA activity 61, and Fu and Su(Fu) homologues have been isolated and
linked to the Shh pathway 62-65. In addition, Shh signalling is related to Ci
homologues, the Gli factors; as discussed below.
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Target genes of Hh signalling appear to be conserved. Shh activates Bmp2 (Bone
morphogenetic protein 2) and Bmp4 (dpp vertebrate homologues), as well as
transcription of its own receptor Ptc 60'66-70
1.2.1.3 The Gli's
Three homologues of Ci (Glil, Gli2 and Gli3) have been identified in humans and
mice 7I'72. The Gli proteins share high homology in their five zinc finger domains,
but limited homology outside of this region 73. Their partial redundancy and often
overlapping domains of expression has made it difficult to define precisely their
individual features and functions. Unlike Ci in Drosophila, the Gli genes are
transcriptionally regulated by Shh protein. Ectopic Shh expression induces Glil but
represses Gli3 30'74"77. Xenopus Gli2 is induced by Shh in the CNS, but this is not the
case in mouse lungs 56'78.
As in Ci control there are post-transcriptional interactions between Shh and Gli's.
Biochemical studies have indicated that mouse Gli2 and Gli3 have activator and
repressor activities, like Ci, whereas Glil only has activator function and may not be
processed post-transcriptionally 79'80. It therefore follows that Glil functions solely as
an activator in Hh signalling 81. Gli2 has been shown to act as a repressor in floor
plate induction 78 and as an activator in transgenic flies and frog embryos 78'81. Gli3
has been shown to repress Shh expression, and its inductive activity may be
independent of Shh 30,78'82,83. Together these results indicate that the Gli proteins
form a regulatory network that responds to Hh signalling and that Gli proteins have
distinct properties.
Somewhat surprisingly mice that lack Glil function are phenotypically normal. Glil
function is dispensable in mice if both copies of the Gli2 gene are present . It would
appear that Gli2 can compensate for the absence ofGlil, possibly by mimicking Glil
as a regulated activator 81. Mice with homozygous Gli2 mutations die at birth, have
numerous skeletal defects 85 and abnormal lungs 86. They have similarities to Shh
mutant mice suggesting that GH2 functions downstream of Shh . It has recently
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been shown that a low level of Glil can rescue all Shh signalling events in Gli2
mutants , why endogenous compensation does not normally occur is less clear. Gli3
mutant mice have many abnormalities including CNS and lung defects, and
Polydactyly . Aspects of these phenotypes are similar to Shh gain of function
effects, and Shh expression is upregulated 78'83, implying a role for Gli3 in repressing
Shh. GU2/GU3 double mutants have more extreme skeletal and lung defects than
either homozygous phenotype, indicating overlapping functions of Gli2 and Gli3
85,86
1.2.1.4 Hedgehog-interacting protein (Hip)
In 1999, Chuang and McMahon91 isolated a 2.7 kilobase clone, which bound to Shh,
Ihh and Dhh in a mouse limb bud cDNA library screen. As the 700 amino acid
protein encoded by this cDNA bound all three mammalian Hedgehog proteins, the
gene was called Hedgehog-interacting protein {Hip). Hip is a transmembrane
glcoprotein, which directly interacts with N-Shh. In the developing mouse Hip is
well placed to participate in Shh signalling, as it is consistently expressed in
mesenchyme adjacent to Shh expressing epithelium, in several organs including the
lungs. Hip, like Ptc, is a general transcriptional target of Hh signalling. It appears
that upregulation ofHip by Hh signals attenuates further Hh signalling91.
1.2.2 THE SHH PATHWAY IN LUNG DEVELOPMENT
Mammalian lung morphogenesis begins as a ventral outpouching of the foregut
endoderm into the surrounding splanchnic mesoderm. Primitive buds produce the left
and right primary bronchi before primary bronchial buds divide asymmetrically
giving rise to 2 left and 3 right secondary bronchi (later lobar bronchi) in humans; 1
left and 4 right in mice. These secondary bronchi branch further within the
pulmonary mesenchyme to complete lung formation. Branching morphogenesis of
the lung buds is dictated by epithelial-mesenchymal tissue interactions. Morphogens
and growth factors such as Shh are thought to control these processes.
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1.2.2.1 Shh
Shh is expressed in the trachea and lung endoderm in the developing mouse lung 55,
at low levels throughout the epithelium with higher levels in the growing distal buds
56,92,93■ Shh mutant (Shh') mice display serious foregut defects, with failure of
separation of the trachea and oesophagus into distinct tubes and hypoplastic lung
buds 5 '94. Each bud appears as a single lobe with loss of the normal extensive
network of air sacs and no sign of either epithelial branching or mesenchymal
proliferation. Proximal-distal lung epithelial differentiation is preserved, indicating
that Shh is specifically associated with branching morphogenesis 94. Mesenchymal
Ptc, Glil and Gli3 expression is downregulated in Shh'' mice. Shh overexpression,
under the control of a Surfactant Protein-C (SP-C) enhancer/promoter, results in an
increase in interstitial tissue due to increased proliferation of both epithelial and
mesenchymal cells, with the absence of functional alveoli. Cell differentiation is
maintained and Ptc expression is increased in these Shh transgenic mice, which die
soon after birth, presumably due to respiratory failure 56.
In addition to the above evidence linking Shh with branching morphogenesis, it also
seems to play a role in establishing left/right asymmetry of the lungs, and in
separation of trachea and oesophagus95'96.
1.2.2.2 Ptc
Ptc represses the transcription of Shh induced genes, including Glil and Ptc itself.
Derepression takes place on Shh binding. Ptc is expressed at high levels in the
developing lung mesenchyme, adjacent to terminal buds where Shh is expressed, and
at low levels in the distal epithelium. Ptc (Ptcl) null mutant mice die between
embryonic days (E) 9.0 and 10.5 due to neural and cardiac defects, just at the time
when lung development begins 97. Ptc and Shh mRNA levels decline towards birth
As already described, Ptc is upregulated when Shh is overexpressed and
-/- • 55,94
downregulated in the lung mesenchyme of Shh mice ' .
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1.2.2.3 Gli Family Members
All three of the Gli's are expressed in lung mesoderm at higher levels distally than
proximally, and not in the endoderm. Expression falls as development proceeds. Shh
overexpression results in Glil upregulation with no effect on either Gli2 or Gli3
expression 74.
As already mentioned Glil4' mutants are viable and normal84 GH2'A mutants die at
birth with severe skeletal and neural defects. The lungs appear together as a single
smaller lobe, and primary branching is defective in the right lung. There is normal
separation of the hypoplastic trachea and oesophagus, a reduction in mesenchymal
proliferation and normal terminal cell differentiation. As discussed, the Gli2~/~
phenotype is very similar to Shh4' mice, except trachea and oesophagus fail to
separate in the latter. In Gli2'A mouse lungs Ptc and Glil expression are reduced; Shh
is unaffected. Though Gli3 is normally regarded as a repressor of Shh signalling it is
unclear whether this holds for lung development 86,98. Gli3 (Gli3'/) mutant mice,
though viable, have smaller lungs with altered lobe shape 74 Expression of Shh, Ptc,
Glil and Gli2 is unchanged in these mice, suggesting that Gli3 may have more of a
supporting role in lung development rather than being crucial itself.
Glir/7Gli2+/~ double mutants normally develop multiple defects, small lungs and die
soon after birth. Glil+/7Gli2~/~ mutants have smaller lungs than Gli24' mice but do
form 2 lung buds. Glil+/7Gli2+/~ mice lung lobes appear normal, whilst GlirA/Gli2'A
mutants have 2 very small lobes, with branching. These various phenotypes imply
that Glil and Gli2 have overlapping lunctions during lung development. Gli2+/
/GU3+a double mutants are viable with no obvious defects. Gli2 /Gli3 mice
develop hypoplastic lungs with failure of separation of right and left lobes, and the
trachea and oesophagus do not separate. Gli2'/7Gli3/ mutants die at about El0.5
with no trachea, oesophagus or lung. These phenotypes illustrate the ability of Gli3
to compensate when Gli2 is absent86
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1.2.2.4 Shh and Bmp4
As described, Shh is able to activate Bmp4. In the developing lung Bmp4 is highly
expressed in the distal lung tips, as is Shh. However, whereas Shh is confined to
epithelial cells, Bmp4 is also expressed in the adjacent mesenchyme. Bmp4
overexpression in distal lung epithelium results in smaller lungs with reduced
epithelial branching and fewer, dilated air sacs 92. Shh expression is unaffected. In
addition Shh and Bmp4 overexpression produce different phenotypes, and Bmp4
expression is not significantly altered in Shh'A mutants 55'94. This argues against
Bmp4 being a direct mesenchymal target for Shh during mouse lung development.
As Bmp4-deficient mice die before lung bud formation they offer little more
information on the role ofBmp4 in lung development99. However overexpression of
the Bmp antagonist Noggin in distal lung epithelium results in a reduction in distal
epithelial and an increase in proximal cell types 10°, suggesting a role for Bmp4 in
controlling proximal-distal endoderm differentiation. Shh expression is unaffected,
which again is against a direct Shh-Bmp4 interaction in lung development.
1.2.2.5 Shh and Fibroblast Growth Factors
Fibroblast growth factors (FGF) are essential components in lung development.
FGF10 is expressed at high levels in the distal lung mesenchyme and plays a strong
role in branching morphogenesis 56'92, with FGF10 mRNA expression increasing
towards birth. FGF10 null mutants die at birth with lung and limb defects ' ; right
and left primary lung buds fail to form. A similar phenotype is displayed when the
proposed FGF 10 receptor, FGFR2, is knocked outI03. Shh has been shown to inhibit
FGF10 expression in vitro and in vivo 104'105 However other evidence linking the
two directly is conflicting I01'102, prompting Tuyl and Post to suggest that Shh and
FGF 10 actually function in parallel pathways in lung development.
FGF7 has been shown to play a role in lung branching 107 FGF7 null mutants appear
normal implying that any function played by FGF7 in lung development can be
maintained in its absence 108. Like FGF10, FGF7 expression increases through
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gestation . Shh induces FGF7 expression in vitro, and Shh and Ptc signals are
reduced around sites of FGF7 bead implantation in whole organ lung cultures These
findings are suggestive of a negative regulatory loop involving FGF7 and Shh.
Lebeche et al104 have suggested that FGFs, Shh, Bmp4 and TGFpi form a regulatory
circuit in lung development.
1.2.2.6 Shh and TGFp
TGFpi, 2 and 3, and the TGFP type I and II receptors, are expressed in embryonic
and foetal lung 110112 TGFpi and 2 both inhibit branching morphogenesis 112,113
TGFP3 null mutant mice develop an immature lung phenotype with excessive
mesenchyme later in gestation and often die shortly after birth 114. In contrast TGFpi
null mutant mice display a normal neonatal lung phenotype, which has been
attributed to maternal transplacental rescue. TGFpi overexpression, under control of
the SP-C promoter, results in a neonatal lethal phenotype characterised by general
lung hypoplasia with decreased saccule formation and epithelial differentiation 115.
Blocking TGFp type II receptor signalling stimulates lung morphogenesis and
blocking the TGFP type I receptor reduces the number of new branch points in
mouse lung in culture, resulting in lungs with long, tubular airways without branch
points 112. TGFpi and TGFP2, like Shh, inhibit FGF10 expression in vitro 104
Although TGFp and Shh may have not been directly linked in lung development,
they probably have common targets and may interact in a shared regulatory circuit as
suggested above 104
1.2.3 THE SHH PATHWAY AND CELL PROLIFERATION
Shh signalling is associated with proliferation of many cell types. With particular
relevance to the subject matter of this thesis, only epithelial cells and immune system
precursors are discussed.
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1.2.3.1 Shh overexpression in epithelial cells in vitro
As described by Parisi et al 116, Hh signalling appears to control epithelial cell
proliferation both in Drosophila and in vertebrates. In 1997 Fujita et al117 analysed
the Shh pathway in human lung squamous carcinoma cells (LK-2). They showed that
upregulation of the Shh pathway, induced by adding a His-tag fusion protein of the
amino-terminus of rat Shh (N-Shh) to the system, stimulated cell growth; N-Shh
being the active component of Shh signalling as described. In addition, an antibody
against the amino-terminus of Shh (anti-Shh-N) inhibited growth. They concluded
that Shh signalling allowed LK-2 cells to promote their own growth through an
autocrine mechanism. Shh signalling has also been shown to augment the
proliferative capacity of primary human keratinocytes, possibly by opposing cell
cycle arrest118.
1.2.3.2 Shh overexpression in vivo
Shh overexpression in vivo, under control of the SP-C promoter, results in increased
epithelial and mesenchymal cell proliferation in the developing lung 56. The pathway
appears to exert similar effects in other tissues as well. For example, Shh signalling
has been shown to stimulate epithelial proliferation and increase cell survival in the
developing tooth 119. Furthermore, in the skin the upregulation of Shh results in
epidermal hyperplasia and stimulates hair growth by inducing resting hair follicles to
118 120
enter anagen, the growth phase in mature follicles
1.2.3.3 The Shh Pathway in the Immune System
Using similar approaches to those employed in in vitro epithelial cell cultures, the
Shh pathway has recently been studied with respect to the developing immune
system. Outram et al studied the mammalian Hh pathways in mouse foetal and adult
thymus 121. They showed that many components of the pathways were present in
whole thymus, including Shh, Ihh (Dhh was not detected), Ptc, Smo, Hip, BMP4 and
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the Gli's. Following cell sorting, Shh was found only to be present in the epithelial
cells, and Smo and Ptc were detectable on the thymocyte populations. They
manipulated Shh signalling in thymic explant cultures by adding either a neutralizing
anti-Shh monoclonal antibody 5E1 122 or a modified (for optimal activity 17) human
recombinant Shh peptide (Octyl N-Shh). Their findings suggested that the 5E1
antibody, which blocked Shh signalling, increased thymocyte differentiation from
double negative to double positive, whereas the Shh peptide arrested thymocyte
development at the double negative stage. Therefore, it appears that Shh signalling
plays a role in thymocyte development.
Detmer at al 123 confirmed the presence of Ptc and Smo in a range of human
leukaemia cell lines and Ptc expression in normal marrow. They demonstrated that
blocking Shh signalling with cyclopamine, a known specific antagonist of Hh
signalling 124, inhibited erythroid colony formation and maturation. In the same
system, the addition of a N-Shh peptide had the opposite effect, causing increased
proliferation as indicated by larger colony size. They postulated that Hh signalling
regulated haematopoietic differentiation, and that aberrant signalling may contribute
to the development of leukaemia.
Subsequent work carried out by Bhardwaj et al125 employed the same 5E1 blocking
antibody and Octyl N-Shh peptide as above n\ but in the context of human
haematopoietic stem cells. It had already been shown that Bmp4, an established
target of Shh signalling, induced haematopoietic commitment in Xenopus embryos
126 and that human Bmp's could increase human stem cell survival 127. Bhardwaj et al
125
showed that Shh, Ptc and Smo are expressed in highly purified primitive human
blood cells, the precursors of myeloid and lymphoid blood cells . In addition,
blocking endogenous Shh (with the 5E1 antibody) inhibited cytokine-induced
proliferation of these haematopoietic progenitor cells, maintaining them in an
undifferentiated state. On the other hand, adding exogenous Shh (Octyl N-Shh)
augmented proliferation without affecting differentiation. They concluded that these
effects were mediated through Bmp4 induction.
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1.2.4 THE SHH PATHWAY IN DISEASE
Dysregulation of the Hh pathway is associated with a number of human diseases,
syndromes and malformations. Sporadic and inherited mutations of the Shh gene
have been shown to cause holoprosencephaly (HPE), a common dominant syndrome
affecting the head and face; which is also caused by other gene mutations affecting
Gli function 82-129. HPE also develops when Shh function is lost and in farm animals
exposed to the Shh antagonist, cyclopamine 124'130. Smith-Laemli-Opitz syndrome
patients, who are deficient in cholesterol biosynthesis, develop similar features 131.
Sporadic basal-cell carcinoma (BCC) is the most common skin cancer in Caucasians.
Mutations inactivating Ptc (Ptcl), and Smo mutations rendering it insensitive to Ptc
repression, have been detected in BCC 68-132-133 a majority of BCCs show GUI
expression, which may be involved in their formation and may be induced by the
above mutations 134 Ptc mutations have been associated with the familial basal cell
nevus syndrome (BCNS or Gorlin's syndrome) 135. A further two sporadic tumours
in BCNS, medulloblastoma (MB) and rhadomyosarcoma (RMS), may also be due to
Ptc mutations. They are certainly seen in mice with Ptc mutations, in which Gli is
expressed constituitively 68'97>136
Gli3 loss or misfunction results in several human syndromes. Gli3
happloinsufficiency causes Greig's cephalopolysyndactyly syndrome (GCPS),
characterized by many abnormalities including syndactyly, Polydactyly, and facial
and CNS defects 137 Mice with extra-toes (XtJ), in which Gli3 is mutated, develop a
similar phenotype 90. Gli3 protein truncations also result in Pallister-Hall syndrome
138 and postaxial Polydactyly type A 139, which both share phenotypic features with
GCPS. Indeed mutations of the Creb-binding protein (CBP) also result in defects
similar to GCPS, in the Rubinstein-Taybi syndrome 14°.
A number of human diseases associated with the Shh pathway, including some not










































Figure 1.2: The Human Sonic Hedgehog Signalling Pathway and related
diseases. Figure taken, with permission, from review article by E.H.
Villavicencio et al "The Sonic Hedgehog-Patched-Gli Pathway in Human
Development and Disease" (2000)141
Human Shh-Ptc-Gli pathway (left) and its links to human diseases (right). The
association of the human disease with malfunction of a given element in the
pathway is indicated by the matching colours of the boxes. The placement of the
elements of the pathway, as well as their role as a repressor (bars) or as an
activator (arrows), has been demonstrated in humans. The exceptions are that
interaction between human G//3 and CBP was demonstrated using mouse CBP,
human Gli genes were tested in frog and mouse cells, and mouse Gli2 protein
function is shown for completeness, although human G//2 has not been fully
characterized.
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1.3 The Wnt Signalling Pathways
1.3.1 WNTS AND THEIR RECEPTORS
1.3.1.1 Wnts
The term Wnt is an acronym for the orthologous genes wingless (wg), from
Drosophila, and WntI (previously int-1) from mouse 142'143 The gene family is large:
there are currently more than 20 Wnt isoforms. They encode secreted glycoproteins,
usually 350-400 amino acids in length, which in general appear to act as morphogens
7'144. Wnt genes are developmental molecules, regulating a variety of processes such
as cell fate specification, cell migration and cell polarity 145. Wg, a segment polarity
gene in Drosophila, plays a role in controlling a range of developmental events from
organization and patterning of the nervous system to tissues such as the wing and the
larval cuticle. Whilst the cuticle of a wild type larva displays denticle belts
alternating with naked regions, the cuticle of a Wg mutant larva is completely
covered with denticles \ Embyros mutant for downstream, cooperative genes show a
similar phenotype whilst mutant embryos with genes inhibitory to Wnt signalling,
such as zeste-white 3 (zw3), have the 'opposite' phenotype, namely a naked cuticle
146
Wnt] was identified as a site of insertion ofmammary tumour virus in mice where it
leads to epithelial hyperplasia and, occasionally, to adenocarcinomas in the mouse
mammary gland 145. Injection of WntI mRNA into blastomeres ofXenopus embryos
leads to duplication of body axis 147; a property which is shared by many, but not all,
members of the Wnt family. This distinction has lead to a division of Wnts into 2
functional classes: Wntl (eg Wntl/3a/8/8b), which induce axis duplication, and
Wnt5a (eg Wnt4/5a/ll), which do not, but do regulate morphogenetic cell
movements 148. Importantly however, Wnt5a can induce axis duplication if co-
injected with an appropriate receptor (frizzled) implying that specificity of
signalling is not solely dependent on the Wnt ligand.
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Wnts have been shown to stimulate three distinct signal transduction pathways; a P-
catenin dependent pathway, a pathway activating protein kinase C (PKC) through
raising intracellular Ca , and a rho GTPase mediated pathway. It has been suggested
that the Wntl class signal through the Wnt/p-catenin pathway and the Wnt5a class
through the Wnt/Ca2+dependent pathway I50.
1.3.1.2 Wnt Receptors
The diversity of responses seen with different Wnt ligands is to some extent due to
the repertoire of cell surface receptors. The Frizzled (Fz) gene family have been
shown to function as Wnt receptors 151"153, encoding seven-transmembrane proteins
with an amino-terminal cysteine-rich domain (CRD) that binds Wnt with high
affinity 154 Like Wnts themselves there are many Fz genes including Smo, a
component of the receptor complex in Hh signalling. Their overall structure
resembles that of G protein-coupled receptors. Though the evidence in favour of Fzs
as Wnt receptors is strong, other cell surface and extracellular molecules have been
implicated.
Heparin-sulfate proteoglycans are positive regulators of Wnt signalling in
Drosophila 155, probably functioning to facilitate ligand-receptor interactions or
ligand movement. In addition, low density lipoprotein receptor-related proteins
(LRPs) play essential roles in receiving Wnt signal 156"158. Unlike proteoglycans,
LRPs are essential for Wnt signalling. In the absence of the Drosophila LRP
homolog, Arrow, Fz cannot activate the signal transduction cascade 158. LRP6 and Fz
extracellular domains interact in the presence ofWntl, in keeping with their function
157
as co-receptors
There are also secreted Wnt antagonists known as secreted Frizzled-related proteins
(sFRPs). As their name suggests they share homology with Fz receptors, containing a
similar CRD domain but not the membrane spanning or intracellular sequences.
Frzbl (or sFRP3) binds Wnt directly and is capable of blocking axis duplication in
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Xenopus i.e. blocking Wnt signalling 159"161. Several different sFRPs are expressed in
a broad range of tissues during development where they appear to be able to
selectively block specific Wnts 162'163 They have been shown to bind to members of
the Wntl class but not, to date, to Wnt5a.
Two other unrelated secreted proteins, Wnt inhibitory factor-1 (WIF-1) and
Cerberus, bind to Wnts directly to inhibit their activity 164,165. Members of the
Dickkopf (Dkk) family influence the efficacy of Wnt signalling but, unlike other
antagonists, do not bind Wnts directly 166"168.
1.3.2 THE WNT/BETA-CATENIN PATHWAY
P-catenin is central to the function of the Wnt/p-catenin pathway. It is normally
found in two pools within the cell: one at the membrane associated with Cadherin
and the other in the cytoplasm 169. In the absence of Wnt signals P-catenin is
ubiquitinated and degraded by the proteasome pathways. Wnt binding and activation
prevents this ubiquitination, raising cytoplasmic P-catenin levels. This free signalling
pool of P-catenin enters the nucleus and forms a complex with members of the
Tcf/Lef family, which regulates target gene expression (see Figure 1.3). This whole
process is driven by a series of interactions between several intracellular proteins as
described below.
Four proteins (labelled the "destruction complex" 17°) promote P-catenin degradation
to maintain steady state low levels: GSK-3, Axin, APC and P-TrCP/Slimb. Axin and
APC bind P-catenin and GSK-3 to facilitate phosphorylation of p-catenin by GSK-3.
This promotes binding to p-TrCP/Slimb, which allows ubiquitination to take place
(see Figure 1.3).
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1.3.2.1 The "Destruction Complex"
Glycogen Synthase Kinase 3 (GSK-3), a serine-threonine kinase, acts as a negative
regulator of the Wnt/p-catenin pathway. Null mutations of GSK-3 and its Drosophila
homolog, zeste-white 3 (zw3), result in nuclear accumulation of P-catenin
(Armadillo) and activation of the Wnt/p-catenin pathway 171-174 GSK-3
phosphorylates several highly conserved serine and threonine sites in P-catenin,
contributing to its targeting to the proteasome for degradation 174
Axin interacts with APC, p-catenin, GSK-3 and Dishevelled. It possesses 2
conserved domains, an amino-terminal RGS (Regulator of G-protein Signalling) and
a carboxy-terminal DIX domain (found in Axin and Dishevelled 145). The RGS
domain allows binding to APC, a central region to P-catenin and GSK-3, and the
carboxy terminus facilitates interactions with Dishevelled. Axin acts as a bridge
between GSK-3 and P-catenin, allowing GSK-3-dependent phosphorylation and
degradation of P-catenin 175"177 Axin is itself a target for GSK-3 phosphorylation,
1 78 1 7Q
which improves the effectiveness of its binding to P-catenin
APC binds to P-catenin, GSK-3 and Axin. It was originally identified as a tumour
suppressor protein. It also appears to act as a negative regulator of P-catenin,
facilitating its phosphorylation and degradation in a similar manner to Axin 180-181.
However, APC overexpression in Xenopus mimics Wnt activation suggesting that
182
APC can also function as a positive regulator
Phosphorylated p-catenin specifically binds to P-TrCP/Slimb, a component of the
SCF ubiquitin ligase complex. Interaction with this complex results in P-catenin
ubiquitination and proteolysis by the 26S proteasome . In Drosophila, loss of P-
TrCP/Slimb causes accumulation of high levels of Armadillo {Drosophila homolog
of P-catenin) and Wnt activation, consistent with P-TrCP/Slimb s role as another
negative regulator of the Wnt/p-catenin pathway .
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1.3.2.2Dishevelled (Dsh)
Dsh is the most upstream intracellular component of the Wnt/p-catenin pathway. Its
mode of interaction with the Wnt/Wg receptors is poorly understood. It is a
phosphoprotein absolutely required for Wg signalling 186, which becomes more
highly phosphorylated when signalling is activated, when it appears to be recruited to
the cell membrane. Dsh overexpression, in the absence of Wg, leads to its
hyperphosphorylation and Arm accumulation, thus mimicking Wg signalling 187~189.
Dsh binding to Axin facilitates its interaction with zw3/GSK-3 190>191 It is thought to
downregulate zw3/GSK-3 activity via direct phosphorylation, and possibly indirectly
through inhibition ofAxin-stimulated effects 192.
1.3.2.3 GSK-3 Binding Protein (GBP)
GBP and its mammalian ortholog Fratl, like Dsh, act as positive regulators of the
Wnt/p-catenin pathway. Overexpression of GBP/Fratl in Xenopus induces axis
duplication, thereby mimicking Wnt/p-catenin signalling 193. GBP expression also
stabilizes P-catenin, probably through inhibition of GSK-3 activity. Dsh and GBP
have been shown to interact in vitro and in vivo. They have been identified in a
common, Wntl dependent, complex along with Axin and GSK-3 191.
It is therefore generally accepted that Dsh and GBP, activated by Wnt, inhibit GSK-
3-mediated P-catenin phosphorylation thereby stimulating P-catenin signalling and
function (see Figure 1.3)
1.3.2.4 Targets and Regulation
Following stabilisation cytoplasmic P-catenin migrates to the nucleus where it binds
to members of the Tcf/Lef family of transcription factors to form a complex, which
stimulates target gene expression 194 Tcfl (T-cell factor 1) was first cloned as a gene
encoding a T-cell-specific DNA-binding protein I95'196. Lefl (lymphoid-enhancer
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factor 1) is expressed by both B and T cell precursors 197. While there are several
mammalian Tcfs, Pangolin, most closely related to Tcfl, appears to be the only Tcf
gene in the Drosophila genome 198-199. Each Tcf contains a single DNA-binding high
mobility group (HMG) domain.
The mechanism of (3-catenin activated transcription remains unclear. Two regions of
(3-catenin have been shown to influence transcription, one at the amino-terminus and
one at the carboxy-terminus 198,200'201. In the absence of Wnt signalling, Tcf/Lef
proteins can prevent transcription ofWnt target genes ' . To act as repressors in
this manner they appear to require interactions with co-repressors such as Groucho
and CtBP (C-terminal Binding Protein) 204'205.
There are many targets ofWnt signalling including developmental genes (siamois,
twin and ultrabithorax 202'203'206"208), cell growth regulators (c-myc and cyclin-Dl 209"
21 *) and the metalloproteinase, matrilysin 212. Further examples are listed in Table 1.
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Figure 1.3: The Wnt Signalling Pathway. Taken, with permission, from
"The Wnt gene homepage" maintained by Roel Nusse
(www.ana.ed.ac.uk/rnusse/wntwindow.html)
Left panel: In the absence of Wnt signalling Axin, APC and zw3/GSK3
contribute to Arm/p-catenin ubiquitination
Right panel: Upon Wnt binding to Frizzled and LRP, Arm/p-catenin is released
form the "destruction complex" (see text). Cytoplasmic p-catenin then migrates
to the nucleus where it binds to members of the Tcf/Lef family of transcription
factors to form a complex, which in turn stimulates target gene expression
Abbreviations: LRP: low density lipoprotein receptor-related proteins; Dsh:
Dishevelled; GBP:GSK-3 Binding Protein; APC: Adenomatous Polyposis Coli;
zw3/GSK3: zeste-white 3/Glycogen Synthase Kinase 3; TCF:T cell factor; Arm:
Armadillo
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Gene Organism Effect Gene Organism Effect
CD44 Human up Bmp4 Xenopus down
c-jun Human up Connexin30 Xenopus
c-myc Human up Connexin43 Xenopus up
Cyclin D Human up engraiIed-2 Xenopus up
fra-1 Human up fibronectin Xenopus up
MMP-7 Human up myogenic bHLH Xenopus up
PPARdelta Human up Retinoic acid Xenopus
Tcf-1 Human up Siamois Xenopus up
uPAR Human up Twin Xenopus up
Brachury Mouse up Xnr3 Xenopus up
Cdxl Mouse up Dfrizzled2 Drosophila down
Cyclooxygenase2 Mouse up Dpp Drosophila down
MBTEB2 Mouse up Engrailed Drosophila up
Periostin Mouse down Shavenbaby Drosophila down
SFRP-2 Mouse up stripe Drosophila down
Stra6 Mouse up ubx Drosophila either
WISP Mouse up Wingless Drosophila either
Wrch-1 Mouse up Dharma/bozozok Zebrafish up
Connexin43 Mouse,Rat up nacre Zebrafish up
ret Rat up BetaTrCP up
Table 1: Target Genes ofWnt/p-catenin Signalling
Table lists identified target genes of Wnt/p-catenin Signalling Pathway. In each
case the gene, organism and the effect of increased pathway activity on
expression (up or down-regulated) is listed. Table adapted, with permission,




Less is known about this Wnt dependent pathway. As already described members of
the Wntl class signal preferentially through the Wnt/(3-catenin pathway and Wnt5a
through the Wnt/Ca2+ pathway 15°. In addition, Wnt5a factors have been shown to
antagonise the function of Wntl factors 213, implying an antagonistic effect of the
Wnt/Ca2+ on the Wnt/p-catenin pathway.
It appears that Fzs are capable of discriminating between different Wnt ligands, thus
determining which downstream pathway is activated in the cell. There are also two
functionally distinct classes of Fzs, which allow activation of either the Wnt/p-
catenin or the Wnt/Ca2+ pathway. It is possible that Fzs activating the Wnt/Ca2+
pathway do so through G-protein interactions, though it is unclear whether G-
proteins play a direct or indirect role in signalling 214. Besides modulating adhesion
and cell movements, the function this pathway plays in embryonic development is
unclear.
1.3 .4 DISHEVELLED
It has been recently shown that Dsh functions in at least two distinct signalling
pathways. As already described it is required for Wg signalling. However it also
plays a role in epithelial planar polarity (tissue polarity). Dsh null mutations in
Drosophila have phenotypes consistent with loss ofWg signalling 215, but the first
mutant reported (Dsh1) displayed planar polarity defects characterized by
misorientation of cells within epithelia in the wings, thorax and eyes. The random
arrangement of the hairs on the wing and thorax prompted the phenotype to be
named Dishevelled 216.
By genetic epistasis analysis Dsh has been placed downstream of Fz in polarity
signalling 2I5'216. Significantly, manipulation of other members of Wg signalling,
such as zw-3, Arm and Pangolin, does not affect planar polarity. The planar polarity
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signalling pathway downstream of Fz actually consists ofDsh and small GTPases of
the Rho family, leading to activation of the c-Jun N-terminal kinase/stress-activated
protein kinase (JNK/SAPK) cascade 188'217'218. Thus, a pathway distinct from the
Wnt/p-catenin and Wnt/Ca2+ pathways has emerged.
There are presently 3 murine and 3 human Dsh homologues referred to as (mouse or
human) Dvll to 3 219-221 There is 40-50% amino acid identity between Drosophila
Dsh and any of the murine Dvls, and 60-70% identity amongst murine Dvls. All
Dishevelled genes (including vertebrate and invertebrate homologues) have three
highly conserved domains. An amino-terminus DIX (Dishevelled-Axin) domain also
found in Axin, a central PDZ domain and a carboxy-terminus DEP (Dishevelled-
EGL-10-Pleckstrin) domain, which can also be found in factors involved in G protein
222 224 • • •
signalling " . The DEP domain is essential for polarity signalling, whereas the
DIX domain is dispensable. Conversely the DIX domain is crucial for Wg signalling,
in which most of the DEP domain is dispensable 188'217'225 Therefore Dsh may
preferentially activate one or other of these downstream pathways through its DEP
and DIX domains, though how this is controlled is not known.
Dvll null mutants have no obvious anatomical abnormalities and are viable and
fertile. However, they display abnormal social behaviour and several neurological
defects 226. Mutations in the other mouse Dvl genes have not yet been reported and
thus phenotypic effects remain unknown.
1.3.5 THE WNT PATHWAY IN LUNG DEVELOPMENT
1.3.5.1 The Wnt Pathway and the lungs
Whilst the most common sites for Wnt expression in mouse embryos are the limbs
and central nervous system 227,228; many are expressed in both embryonic and adult
235-
lung tissue 227>229-234 Similar expression has also been noted in human lung tissue
237 In common with related growth and differentiation factors, such as FGFs, TGF-P
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and Hh proteins, Wnts appear to be particularly important in controlling epithelial-
mesenchymal interactions involved in branching morphogenesis. Notably, though
Wnt2 is present in both adult and embryonic tissue, expression is higher in the latter
in keeping with a particular association between Wnt signalling and organogenesis.
Wnt2 and Wntl 1 are predominantly expressed in the developing lung mesenchyme,
consistent with Wnt signalling from mesenchymal cells to adjacent epithelium during
■ 229 231morphogenesis " . However no Wnt mutations to date have resulted in abnormal
lung development, which may be due to functional redundancy and overlap between
the many Wnts.
The three murine Dvl genes are widely expressed throughout the embryo and the
adult mouse, including the lungs, with maximal expression in the central nervous
219-221
system " . There is considerable overlap in this expression suggesting they have
redundant functions.
1.3.5.2 Wnt and Hedgehog Signalling
Wg is a target ofHh signalling 3, and Wnt5A expression is dependent upon Shh in the
developing hair follicle 238. It also appears that Wg maintains Hh expression in
Drosophila 239, and it has been proposed that Wnt7A, 10A and JOB may regulate Shh
in the developing limb and hair follicle 228>238. Thus the two pathways are capable of
upregulating each other, suggestive of a paracrine signalling loop between epithelial
and mesenchymal cells: Hh signalling from epithelium to mesenchyme and Wnt
from mesenchyme to epithelium.
1.3.5.3 Wnt and TGFp
Several studies, in Xenopus and Drosophila, have shown that cooperation between
the TGFp and Wnt/Wg signalling pathways plays a role in development 203'240'241.
Smads are signal transduction molecules critical for transmitting TGFP signals form
the cell surface to the nucleus 242. Smad4 is known as a common mediator Smad as it
is required for all TGFp superfamily signalling and Smad3 is specifically associated
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with TGFP receptors It has recently been shown that Smad4 interacts directly
with Tcf/Lefl and indirectly with P-catenin, and activation of the Wnt pathway alone
enhances the Smad4/ P-catenin interaction 244 Subsequent to this, interactions
between Smad3 and both Tcf/Lefl and Axin have also been demonstrated 245'246. In
addition, TGF(3-Wnt cooperation may also mediate carcinogenesis. When both
signalling cascades are altered there is an associated increase in progression of
benign adenomatous polyps to invasive carcinomas 247. Thus, it is possible that these
pathways may play combined roles in other TGFP related disease processes, such as
interstitial lung disease (ILD). This possible association prompted the experimental
work presented in Chapter 5.
1.3.6 THE WNT PATHWAY AND CELL PROLIFERATION
Wntl promotes proliferation of epithelial cells and fibroblasts both in vivo and in
r) AQ 1
vitro ' . Expression of other Wnts, such as Wnt5A and Wntll, has also been
• 7*17 7ST
associated with increased epithelial cell proliferation ' . In the immune system
Wnt proteins can stimulate pro-B cell proliferation via Lefl 254 In addition, Wnt
signalling promotes anti-apoptotic effects, in that Wntl inhibits chemotherapy-
induced apoptosis through P-catenin/Tcf mediated transcription 255. Furthermore,
ectopic P-catenin expression has been shown to inhibit apoptosis, and APC
overexpression (inhibiting P-catenin accumulation and Wnt signalling) induces
apoptosis in human colorectal cancer cells 256'257
However, it has been reported that the pathway can, in some circumstances, induce
pro-apoptotic effects. P-catenin and Tcf expression have been shown to promote
apoptosis in Drosophila, mouse and human cells 258 261. Related to this, Kim et al
showed that the apoptotic effect in NIH 3T3 fibroblasts was independent of Lefl,
implying that P-catenin may be interacting with other unknown proteins in this
respect. Finally, and of most relevance to this thesis, Stovel et al have recently
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demonstrated that overexpression ofDvl genes in COS-1 and C57MG cells results in
an APC-dependent apoptosis.
The role of Wnt signalling in cell proliferation and apoptosis therefore remains
ambiguous. It is likely that other, as yet unknown, mechanisms are also involved.
1.3.7 THE WNT PATHWAY IN DISEASE
1.3.7.1 Wnt Pathway and Cancer
As described, Wntl was originally identified as a preferred integration site for mouse
mammary tumour virus in breast carcinomas 142. Wntl transgenic mice develop
mammary epithelial hyperplasia and adenocarcinoma 263>264; and Wntl is capable of
transforming mammary epithelial cell lines in vitro 265,266. Though none have been
identified to date it is likely that Wntl mutations act as oncogenes in humans.
Germline APC mutations are associated with familial adenomatous polyposis (FAP),
267 268which results in colorectal polyps early in adult life ' . Somatic APC mutations
are linked with >80% of sporadic colorectal adenomas and carcinomas ' . In
addition, APC mutations have been implicated in aggressive fibromatosis and as a
genetic modifier of BRCA penetrance for breast cancer 271>272. (3-catenin has been
found to be highly mutable in a range of human cancers including endometrial,
hepatocellular and ovarian carcinoma, medulloblastoma, synovial sarcoma and
170
prostatic tumours
1.3.7.2 Wnt and Lung Disease
There are at present only a few preliminary studies linking Wnt signalling with
diseases of the lung. Differential display analysis has confirmed the presence of
sFrpl in emphysema but not in normal human lung tissue. In addition, mouse sFrpl
was detectable in the lungs of both transgenic and smoke-induced emphysema
models but not in normal adult mouse lung 273. It has also been suggested that the
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observed apoptosis in emphysema is secondary to sFrpl expression, though this has
i 274
not as yet been proven
Further more recent studies suggest that P-catenin may play a role in the
pathogenesis of pulmonary fibrosis, and in airway epithelial repair 275-276. These
preliminary observations were based on immunohistochemistry findings in mouse
model systems. In the former, P-catenin expression appeared to be downregulated in
the 'small airway epithelial cells' of mice with bleomycin-induced fibrosis 275.
Finally, in non-small cell lung cancer, high p-catenin expression was identified as a
significant and independent favourable prognostic factor, suggesting that, in these
tumours, P-catenin activation does not have the same oncogenic potential as it has in
other tumours such as colonic carcinomas or hepatomas 277
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1.4 Interstitial Lung Disease
1.4.1 EPIDEMIOLOGY AND CLINICAL FEATURES
Interstitial lung disease (ILD), or pulmonary fibrosis, is the end result of a
multiplicity of pathological processes, from infections to autoimmune diseases. It can
be associated with connective tissue diseases, dust or particle exposure, vasculitides
and drug toxicity amongst others. However in the largest single group of patients
with ILD the aetiology is unknown; hence the name idiopathic pulmonary fibrosis
(IPF), or crytogenic fibrosing alveoilitis (CFA).
Patients with IPF most commonly present between the ages of 50 and 70 years. It is
more common in men with an annual incidence (in the USA) of 10 per 100,000
compared with 7 per 100,000 women 278. Up to 3% of cases appear to cluster in
families, suggesting a genetic susceptibility in some patients 279. Although several
polymorphisms have been observed, there is no clear evidence of a specific genetic
abnormality 280 Up to 75% of patients with IPF are current or former smokers and
smoking has been epidemiologically linked with IPF, as a potential independent risk
081 7 87
factor ' . Several viral infections, especially those caused by the herpes virus
family, have been implicated but the evidence in support of a viral aetiology is
inconclusive 283-285. In addition, despite some associations with metal or dust
exposure, no industrial or environmental factor has been clearly linked to IPF 286.
Patients with IPF typically present with a history of exertional dyspnoea and a non¬
productive cough 287 Many have symptoms for at least 6 months before diagnosis.
On examination up to 50% have finger clubbing and lower zone inspiratory crackles
are audible on chest auscultation 288. Late in the course of the disease there may also
be clinical features of pulmonary hypertension and cor pulmonale. The typical chest
radiograph reveals bilateral lower zone peripheral reticular opacities, progressing to
peripheral honeycombing 289. Pulmonary function tests reveal a restrictive
impairment with a reduced carbon monoxide diffusing capacity . High resolution
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computerised tomography (CT) is used to image the lungs in greater detail. CT
appearances have been shown to correlate with physiological impairment and
fibrosis on lung biopsy291.
1.4.2 PATHOGENESIS
1.4.2.1 Pathology
The clinical label "idiopathic pulmonary fibrosis" is now reserved for a specific
group of patients with what is now termed usual interstitial pneumonia (UIP).
Histologically, UIP is characterized by a heterogeneous appearance comprising
alternating areas of normal lung, interstitial inflammation, fibroblastic foci, dense
fibrosis and "honeycomb lung", with a predilection for the peripheral subpleural
parenchyma 292. Honeycombing refers to densely fibrotic lung with macroscopically
characteristic visible spaces. Areas of scarring may be associated with significant
smooth muscle proliferation. The pleomorphic cellular infiltrate is largely composed
ofmonocytes and lymphocytes, which may form focal aggregates, and relatively few
granulocytes. There is alveolar wall thickening due to collagen deposition and loss of
type I alveolar epithelial cells (pneumocytes), with what appears to be a
compensatory hyperplasia of the type II pneumocytes (Figure 1.4 A and B)293.
Other idiopathic interstitial pneumonias display particular distinguishable histologic
features. Desquamative interstitial pneumonia (DIP) is notable for the cellular
appearance of biopsies due to marked alveolar macrophage accumulation and
pneumocyte hyperplasia. Fibroblastic foci and honeycombing are less prominent
features than in UIP 294 Acute interstitial pneumonia involves a diffuse
fibroproliferative response to alveolar injuries, with significant type II pneumocyte
hyperplasia, diffuse fibroblast and myofibroblast proliferation and alveolar septal
collapse with intra-alveolar exudates and hyaline membranes . Nonspecific
interstitial pneumonia is characterized by varying degrees of fibrosis and
inflammation evenly distributed throughout the lung 296.
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1.4.2.2 Original Hypothesis
A long held hypothesis of "inflammatory fibrosis" states that chronic inflammation
leads to lung injury and fibrogenesis, resulting in end-stage fibrotic scar 297. A recent
review by Selman et al argues that this may not be the case, suggesting an
alternative hypothesis.
Following an extensive literature review Selman et al 292 found little evidence that
inflammation is most prominent in the early stages of UIP, as had previously been
believed. In addition, the inflammatory component of UIP is usually mild, being
most closely associated with collagen deposition or honeycombing 298. They also
found evidence that that inflammation is not absolutely necessary for fibrosis.
Interleukin-10 deficient mice displayed more pronounced inflammation but less
fibrosis than wild type controls when treated with silica 299, and hyperoxia induced
mouse epithelial injury is sufficient to induce fibrosis in the absence of ongoing
inflammation 300. Most inflammatory markers have shown no real correlation with
disease stage or prognosis in IPF, including bronchoalveolar lavage (BAL) cell
constituents, gallium scanning and circulating immune complexes 301-304 Finally, in
contrast with other potentially fibrotic lung disorders, anti-inflammatory therapy
(glucocorticosteroids being the mainstay) yields only marginal or no responses in
patients with UIP 305"307.
1.4.2.3 Emerging Hypothesis
It has recently been proposed that UIP is actually due to abnormal wound healing in
the lung, distinguished by the absence of adequate reepithelialization and abnormal
292
myofibroblast behaviour, and characterized by epithelial-fibroblast interactions
In UIP the reeipthelialization of the alveolar epithelium appears to be inadequate.
The type II pneumocytes have a reduced capacity to restore damaged type I cells,
resulting in abnormal phenotypes, pulmonary surfactant abnormalities and alveolar
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308 310
collapse . In IPF the alveolar epithelial cells have been shown to strongly
express greater quantities of procoagulants and antifibrinolytics such as tissue factor
and plasminogen activator inhibitor-1 and -2 311"313, thereby impairing cell
movement in the extra cellular matrix fibrin and impeding repair. Epithelial cells in
IPF also express several profibrotic cytokines and growth factors such as platelet-
derived growth factor, TGFpi and tumour necrosis factor-a (TNFa)314"316.
It has been shown that the extent of fibroblastic foci within the injured lung is related
to the progression to dense fibrosis 298>317 Probably largely driven by factors released
from the epithelial cells, the fibroblasts progress through migratory and proliferative
to a final profibrotic phenotype (myofibroblast)317 It has also been shown that lung
fibroblasts and myofibroblasts from patients with IPF induce in vitro alveolar cell
death 3I8. Another proposed contributing factor to the failure of reepithelialization in
IPF is excessive alveolar cell apoptosis, particularly in areas adjacent to these
myofibroblast foci319.
The basement membrane (BM) plays a role in maintaining the alveolar epithelium,
and its disruption is important in lung fibrosis pathogenesis 320, as fibroblast and
317
myofibroblast migration into alveolar spaces occurs through disrupted BM . How
BM disruption occurs is unknown, though it has been suggested that myofibroblasts
may play a role 32\
As already inferred fibroblasts and myofibroblasts are crucial in the synthesis,
deposition, and remodelling of extracellular matrix (ECM). Excess deposition of
ECM including fibrillar collagens, fibronectin, elastic fibres, and proteoglycans is the
322 323
hallmark of the aberrant tissue remodelling in IPF
1.4.2.4 Cytokines in ELD
It has been suggested that an imbalance in cytokines, with a shift toward T helper2
(Th2) type, contributes to fibrogenesis. Thl and Th2 cytokines are not only produced
by their respective CD4+ T helper subsets; they are also released by other cell types
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such as fibroblasts, macrophages and mast cells. Type 1 cytokines include interferon
gamma (IFNy), TNF(3, and the interleukins, IL2, IL12 and IL18, while Type 2
cytokines include IL4, IL5, IL10, IL13 and monocyte chemoattractant proteinl
(MCP1). Several of these will be discussed further in Section 1.6.
IL4 has been shown to promote fibroblast proliferation, collagen gene expression and
collagen synthesis 324"326. IL13 and MCP1 increase in vitro type 1 procollagen
production, and IL10 is capable of suppressing type 1, thus favouring type 2
* 321 328
cytokines ' . In contrast the type 1 cytokine, IFNy, inhibits fibroblast proliferation
and collagen deposition as well as inhibiting TGFp synthesis and action 329"331. Other
type 1 cytokines appear to promote IFNy production 332.
These findings are further strengthened by animal studies. IL4 is raised in a rat model
of radiation-induced lung fibrosis, and both EL5 and MCP1 in a mouse bleomycin
333 335model " . Furthermore blocking either IL5 or MCP1 reduces inflammation and
* 336337fibrosis ' . Type 2 cytokines are not necessarily produced in isolation. In a mouse
model of silicosis lymphocyte IFNy production is increased consistent with a type 1
cytokine role in fibrosis 338. In human studies, expression of the type 2 cytokines IL4,
IL5, IL13 and MCP1 was increased in cells (including fibroblasts, alveolar
macrophages and lymphocytes), BAL and serum from patients with fibrotic disease
339-343. Proportionally more mononuclear cells in the lungs of patients with IPF
stained positively for IL4 and EL5 (>50%) than IFNy (<7%), as assessed by
immunohistochemistry 344. Therefore, evidence for predominant type 1 cytokine
activity in the granulomatous diseases, sarcoidosis and hypersensitivity pneumonitis,
goes against the grain somewhat though it serves to remind us that it is likely that
type 1 cytokines may also play some role in ILD 345"348.
Of the three TGFP isoforms, TGFPi has been most widely studied in the context of
fibrogenesis. TGFp is produced by T cells, monocytes/macrophages, platelets,
fibroblasts and epithelial cells, and influences both immune and structural cells. It is
capable of suppressing monocyte function and of inhibiting B and T cell proliferation
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349. Notably, TGFp and IFNy appear to be mutually antagonistic 350. TGFP is known
to be a strong stimulator of ECM production including collagen, proteoglycans and
fibronectin , and is capable of inducing a myofibroblast phenotype in fibroblasts in
352
vitro . In vivo, TGFp expression is increased in a variety of mouse models and in
353 35Vhuman ILD Using adenovirus vectors, it has been shown that transient
overexpression of the active form of TGFpi in rat lungs induces a myofibroblast
phenotype and a severe irreversible fibrogenesis in the pulmonary interstitium and
pleura. Moreover, similar overexpression of the full-length latent TGFp! protein does
not induce fibrosis, implying that the state of TGFP activation is crucial 358. How this
activation might occur in vivo is not fully understood.
In addition it seems that other profibotic molecules, such as TNFa and granulocyte -
macrophage colony-stimulating factor may mediate their fibrogenic effects through
TGFP upregulation 359.
1.4.2.5 CD40-CD40L
CD40 is a member of the TNFa receptor superfamily initially identified on B
lymphocytes and its ligand, CD40L, is found on activated T lymphocytes 360. CD40-
CD40L interactions are known to stimulate T lymphocyte cytokine production (IL4,
IL6, IFNy), B lymphocyte antibody production and fibroblast activation 361>362 CD40
is also expressed on macrophages, dendritic cells, fibroblasts, epithelial and
endothelial cells 363-366, and CD40L is also found on mast cells, eosinophils and
activated platelets 367.
Therefore following injury CD40-CD40L interaction promotes production of
proinflammatory cytokines and the profibrotic prostaglandin E2 3 , cell adhesion
molecule expression and fibroblast activation. Therapeutically blocking this
interaction, with an anti-CD40L antibody (MR1), has been shown to protect mice
369
from radiation-induced lung injury and fibrosis
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1.4.2.6 Lymphocytes
The number of T lymphocytes is increased in the BAL of patients with IPF when
compared with normal controls. T lymphocyte infiltration is also characteristic.
Although all subsets are represented, a relative increase in the number of CD8+ T
cells has been correlated with a poorer prognosis 370 The potential role of CD4+ T
cells in ILD pathogenesis with particular respect to Th2 cytokine production has
already been discussed.
The total number of B lymphocytes is also increased in IPF, and B-lymphocytic
follicles with germinal centres have been identified in biopsy sections371. IgG levels
are increased in the BAL of IPF patients, suggesting there is active local
immunoglobulin production 372,373, against an as yet unknown antigen(s). Wallace el
al did however identify a 70-90kDa cytoplasmic protein present in alveolar epithelial
lining cells, which is recognised by autoantibodies from the plasma of IPF patients
374,375
1.4.3 TREATMENT AND PROGNOSIS
1.4.3.1 Anti-inflammatory therapy
In early reports addressing the use of corticosteroids and cytotoxic agents in the
management of IPF response rates of 10-40% were noted 288'376>377 However, other
idiopathic interstitial pneumonias than UIP, which are generally more responsive to
steroid therapy, were not excluded in such studies. When they are, and UIP is looked
at in isolation, there is little evidence of a meaningful response to anti-inflammatory
drugs 378"380. Therefore current evidence does not support the use of anti¬
inflammatory drugs in IPF/UIP. However a trial of therapy is often attempted
particularly in cases in which features of other idiopathic interstitial pneumonias than
UIP are identified.
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Current British Thoracic Society Guidelines for the treatment of IPF 381 recommend
initial combined therapy with the corticosteroid, prednisolone, and azathioprine or
cyclophosphamide. If there is an objectively measurable response therapy should be
continued with steady reduction in prednisolone dose. If not, alternative therapies
such as colchicines should be considered. Referral for lung transplantation should be
considered shortly after failure of first line treatment. Lung transplantation has
emerged as a viable option for IPF patients over recent years 382.
1.4.3.2 Anti-fibrotic therapy
Therapies aimed at directly inhibiting fibrogenesis have also been applied to IPF.
Colchicine has been shown to increase expression of collagen-degrading enzymes
and suppress fibroblast growth factors in vitro 383. However, though initial studies
using colchicine therapy seemed promising 384, as with anti-inflammatory drugs it
appears to offer no benefit when given to patients with confirmed UIP 306,307 The
collagen cross-link inhibitor pencillamine is equally ineffective 306. Other potential
anti-fibrotic therapies include pirfenidone, a growth factor inhibitor shown to have
* 3S3 386 ■ *
some effect in animal studies and a preliminary IPF trial ' ; relaxin, which
inhibits fibrogenesis in mice and has improved lung function in patients with
systemic sclerosis 387,388; and suramin, which has shown some benefits in rabbit
models 389 Futhermore, inhibitors of fibroblast mitogenic peptides such as
endothelinl and angiotensin II have also been considered 390,391.
Consistent with the "emerging hypothesis" for the pathogenesis of IPF new therapies
392
aimed at enhancing reepithelialization are being tried, including N-Acetylcysteine
393
and Keratinocyte growth factor
1.4.3.3 Anti-cytokine therapy
In an attempt to manipulate the type 1-type 2 cytokine balance IFNy has been used to
treat fibrotic disease in mice, with some success 394. More recently IFNy-lb has been
shown to improve lung capacity and oxygenation, and reduce mRNA levels of the
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profibrotic cytokines TGFP and connective tissue growth factor, in patients with IPF
35°. IFNy therapy has also proved efficacious in patients with systemic sclerosis
induced pulmonary fibrosis 395. As a result of such success a multicentre trial of IFNy
in IPF treatment has been commenced. EL 12 therapy has also proved successful in
reducing the severity of bleomycin-induced fibrosis 396.
As a precautionary note, skewing the cytokine profile towards type 1 responses may
cause its own problems. Though not as yet encountered in human studies there is a
theoretical risk of inducing type 1 associated disease such as autoimmune disease.
There has been some preliminary work on anti-TGFP therapy for lung fibrosis in
animals, but none as yet in humans. In rodents, anti-TGFP antibodies and TGFP-
soluble receptors have been shown to reduce bleomycin-induced fibrosis 397>398.
Overexpression of decorin, a proteoglycan known to block TGFp activity 3", can
also inhibit fibrogenesis in the bleomycin model 400. As with anti-cytokine therapy
side-affects of generally blocking TGFP could potentially arise, particularly in view
of its many biological functions. In both cases targeted localised inhibition may be
preferable.
1.4.3.4 Prognosis
IPF is a progressive disease from which 40% of patients die with respiratory failure.
End-stage disease is characterized by severe pulmonary hypertension with cor
pulmonale (secondary right heart failure). The median survival is less than 3 years
40\ Poor prognostic factors include older age, poor lung function at presentation and
advanced fibrosis 402. There is also an, as yet unexplained, increase in the incidence
ofbronchogenic carcinoma in IPF patients 403.
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1 .4.4 FITC MODEL OF ILD
As discussed, most IPF patients have symptoms for more than 6 months, and the
average duration of symptoms is 24 months, before diagnosis 292. As a result of the
insidious onset and late presentation it is impossible to study the initial events in
human disease. It is in this respect that animal models have proved most useful.
There are presently a range of models of lung fibrosis, some ofwhich have already
been mentioned, including those induced by bleomycin, metals, reactive chemicals
and dusts 404 407 In one such rodent ILD model, a single intra-tracheal administration
of the fluorescent hapten fluorescein isothiocyanate (FITC) resulted in a patchy
fibrosis, which was localised to areas of FITC deposition (Roberts et al 408). Since
this model was used in the experiments reported in this thesis I will describe it in
detail.
Following FITC instillation rodents initially develop an acute inflammatory response
characterized, at 3 days, by a diffuse interstitial and alveolar mononuclear cell and
neutrophil infiltrate, significant airway epithelial cell hyperplasia and alveolar
oedema. By 5 months, a focal, patchy, peribronchial interstitial fibrosis and
predominantly mononuclear infiltrate are evident. FITC fluorescence can be co-
localized to areas of fibrosis by confocal microscopy (Figures illustrating this are
included in Chapter 3). The BAL differential cell counts from the original paper 408
confirmed a shift from a baseline control of predominantly macrophages/monocytes
to a marked relative increase in neutrophils by 24 hrs post-FITC. Lymphocytes
become apparent from day 7 and persist thereafter (Figure 1.4C). Specific anti-FITC
antibodies are detectable in the serum of treated rats from 7 days to 6 weeks
following FITC instillation. This fibrosis model was reproduced by Christensen et al
409, who also confirmed that the levels of hydroxyproline, a surrogate marker of
collagen deposition, in FITC treated mice were nearly double that of controls, a
similar relative increase as that found in bleomycin-induced fibrosis . They also
showed that FITC-induced fibrosis, as measured at 3 weeks, did not appear to be T
cell dependent. Data concerning the potential role of T cells in the bleomycin model
is conflicting 410"412.
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Roberts et al 408 proposed a mechanism in which intra-tracheal FITC is cytotoxic to
the airway epithelial cells, resulting in epithelial cell shedding, and a compensatory
hyperplasia. The FITC is then able to bind to exposed proteins such as elastin
through the breached epithelium, inducing chronic inflammation and fibrosis.
Both groups have suggested potential advantages of the FITC model of ILD over
other animal models 408'409. As FITC can be visualised by its fluorescence its
association with the observed pathology can be easily assessed. The patchy
distribution of the fibrosis in the FITC model is more reminiscent of the pattern seen
in IPF, though the peribronchial distribution is not. In addition, the chronic persistent
inflammation characteristic of FITC-induced fibrosis may allow further analysis of



















Time 0 FH C- FITC- FITC- FITC- F1TC- FTTC-
3hr 6hr 24hr 3days 7days 6wks
Time after treatment
Figure 1.4: Interstitial Lung Disease histology and BAL differential
Haematoxylin & Eosin stains of biopsy sections from a patient with Idiopathic
Pulmonary Fibrosis. A) Normal alveoli are seen adjacent to areas of fibrosis
with markedly thickened alveolar walls, inflammatory infiltrate and ECM
deposition. B) Note marked airway epithelial hyperplasia.
C) Differential bronchoalveolar lavage fluid (BALF) cell count in FITC treated
mice. As indicated, the blue bars represent the percentage of macrophages, the
maroon of lymphocytes and the yellow of granulocytes. Data represent mean
and standard error the mean; 4-7 mice at each time-point. Taken from original
FITC paper by Roberts et al.
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1.5 Human T Cell Activation
In this section it is not my intention to review T cell biology in its entirety, but to
discuss the areas that relate to the experimental work of this thesis.
T cell activation, clonal expansion and the induction of effector function are essential
events in the efficient response of the immune system. Optimal activation is
dependent on at least two signals following contact and adhesion between the APC
(antigen presenting cell) and T cell. The first signal is mediated through recognition
of antigenic peptide/MHC (major histocompatability complex) complexes on the cell
surface of APCs by the T cell receptor (TCR). The second signal(s) is provided by
ligation of co-stimulatory receptors (eg CD28) expressed on T cells and by ligands
expressed on APCs.
1.5 .1 T CELL RECEPTOR MEDIATED ACTIVATION
1.5.1.1 Antigen Presentation
Of the APCs, which include B cells and macrophages, dendritic cells (DCs) are
particularly important in activating primary naive T cells. DCs normally reside
throughout all non-lymphoid tissues in a resting, so-called immature state. In
response to inflammatory stimuli or pathogens, they migrate to the T cell areas of
secondary lymphoid organs where they switch from an antigen capturing to an
antigen presenting mode 413'414 During this so-called DC maturation they assemble
peptide-MHC complexes, upregulate co-stimulatory molecules such as B7.1 and
B7.2, and release cytokines such as IL12, IL18 and IL4 . Mature DCs have a
finite life span, surviving for only a few days after reaching lymph nodes and for up
to 48 hours after interacting with antigen-specific naive T cells
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Immature DCs efficiently capture exogenous antigens and, upon maturation, load the
antigenic peptides onto newly synthesized MHC class II molecules, which
accumulate on the cell surface for in excess of 100 hours thereby maximising
presentation 415>421"423 qcs process and present on MHC class I molecules viral
proteins that are either synthesized intracellularly or taken up from apoptotic cells
41 '424 These peptide-MHC class I complexes have only relatively short half-lives (~
10 hours) and therefore must be continually replenished using internal antigen
sources to facilitate presentation.
1.5.1.2 T Cell Receptor Mediated Activation
The TCR is a complex machine that allows the T cell to monitor and, when
appropriate, respond to the presentation of antigen. TCR signalling is sustained for as
long as the T cell is in contact with the APC, ceasing immediately after the antigen is
425 426removed ' . Variable TCR aP and y5 receptors are associated with the invariant
CD3 y, 5, s and C, proteins to from the TCR-CD3 complex. TCR mediated antigen
recognition results in downstream activation of a number of intracellular signalling
pathways, some associated with cytokine gene expression. The CD3 chains are
responsible for TCR associated signal transduction, though they do not in themselves
possess intrinsic enzymatic activity. They influence activation signals, including IL2
production, which is a key event in T cell activation, through cytoplasmic tail motifs,
ITAMs (immunoglobulin family tyrosine-based activation motif) 427"429. However,
binding of the TCR to the antigen-MHC complex is not sufficient in itself to induce
T cell activation. As discussed later, co-stimulation is also required.
CD4 and CD8, which are co-receptors on the T cell, appear to have both cell
adhesion and signalling functions 430. CD4+ T cells (T helper or Th cells) only
recognise antigen presented with MHC class II, and endogenous antigens complexed
with MHC class I molecules activate CD8+ (Tc) cytotoxic T cells. As MHC class I
molecules are expressed on almost all nucleated cells, any such cell infected with a
virus or intracellular pathogen can present the antigen with class I and thus be
removed by cytotoxic attack. In contrast to this specific CD8 cell targeting, CD4
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activation leads to production of cytokines, which activate a wide range of cells
around them. To keep this reaction in check MHC class II molecule expression is
therefore limited only to the APCs 43\
After the first round of mitosis, activated T cells divide every -10 hours. As they
divide, under continuous TCR and cytokine stimulation, they progressively
differentiate and acquire the ability to produce effector cytokines 432'433. Polarization
towards either Thl or Th2 is directed by IL12 and IL4 respectively 417>434"436j as well
as by the strength and duration ofTCR stimulation 437"439.
1.5.1.3 T Cell Synapse
T cell activation requires a long physical coupling between APCs and T cells. Two
adhesion pathways capable of maintaining this avidity are the CD2 pathway and the
lymphocyte function-associated antigen (LFA)-1/intercellular adhesion molecule
(ICAM) pathway. While the issue of the former remains controversial and poorly
understood, the role of the aLp2 integrin (LFA-1) pathway appears to be more
straightforward.
Activation of local LFA-1 integrins is one of the first consequences of TCR
activation. These integrins do not display significant affinity for their ICAM ligands
and have limited cytoskeleton contact in resting T cells. Upon TCR signalling, they
reveal a high-affinity binding site for ICAM and strengthen their linkage to the
cytoskeleton by actin fasciculation. They converge, forming focal contact areas,
thereby increasing their affinity and T cell avidity for the APC, and ensuring binding
of the two cellular partners. LFA-1 also delivers a strong co-activation signal within
the T cell, which appears to the initial 'second signal'. The area of cell contact, in




Co-stimulation occurs independently of antigen recognition. It is critical to allow full
T cell activation, sustain cell proliferation, prevent anergy, and induce effector
function and differentiation into memory cells. Co-stimulator receptors include
CD28, ICOS (inducible co-stimulator molecules, which are related to CD28 441), and
members of the TNFR (TNF receptor) family, including CD40L 442.
1.5.2.1 CD28
CD28 was the first co-stimulatory receptor characterized in resting T cells, and is the
best-understood 443. It is a homodimeric glycoprotein expressed on 95% ofCD4+ and
approximately 50% of CD8+ T cells 444, and its ligation has been shown to activate
PLCyl and [Ca2+]i mobilization 440. Upon interaction with its ligands B7.1 (CD80)
and B7.2 (CD86) expressed on APCs, CD28 increases EL2 production and T cell
proliferation 444'445. Generally CD28 engagement does not have a physiological effect
in the absence of TCR signalling. The importance of CD28-mediated co-stimulation
has been demonstrated in a variety of model systems in vitro and in vivo. Most
notably, the absence of CD28 function, either by blockade, CD28-deficiency or
deficiency of CD28 ligands, results in a greatly reduced ability to respond to protein
antigens, parasites and some viruses, and to generate germinal centres and mediate B
cell help. Blocking CD28-mediated co-stimulation can prevent systemic and tissue-
specific autoimmune disease, and graft rejection 446-448 However, some T cell
responses appear to be CD28 co-stimulation independent, which of course does not
exclude other routes of co-stimulation 438-442>449
1.5.2.2 Inducible co-stimulator molecules (ICOS)
CD28 does not account for all co-stimulatory function in T cells. One recently
discovered alternative co-stimulator is ICOS, which is structurally related to CD28
but does not bind to B7.1 or B7.2. The ligand for ICOS (ICOSL) is a novel B7
family member expressed on APCs 441. ICOS is either absent or expressed at very
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low levels in naive T cells, but is upregulated upon stimulation, implying that its co-
stimulatory role may be more important for memory and effector cells 450. Indeed, its
co-stimulation promotes production of effector cytokines (IFNy, TNFa, IL4, IL5,
IL10) but not so much JL2 451'452. APCs show differential regulation of B7.1, B7.2
and ICOSL, which may allow specificity in elicting responses from naive or memory
T cells 453"455. Significantly, the inflammatory agents LPS and TNFa can induce
ICOSL expression in vitro, whereas CD28 ligands are not induced 453. Therefore,
inflamed tissues may be able to stimulate antigen-experienced T cells, but not naive
cells, as a result of the differential regulation of the ligands for CD28 and ICOS.
1.5.2.3 Negative regulators of co-stimulation
There are also negative regulators of co-stimulation, which include the CTLA-4 and
PD-1 receptors, both ofwhich share homology with CD28 and ICOS. The interaction
between negative signals and positive signals, such as those described above, appears
to be a critical aspect of the regulation of T cell function. CTLA-4 is the best studied
inhibitory receptor and was the second member of the CD28 family to be identified.
Like CD28, it also binds to B7.1 and B7.2, though with significantly higher affinity.
Naive (resting) T cells express little surface CTLA-4, but levels are increased upon
activation. CTLA-4 inhibits T cell proliferation and IL2 synthesis in response to anti-
CD3 and anti-CD28 antibodies, suggesting a model in which the regulation of
CTLA-4 and B7 levels is responsible for setting the activation threshold of T cells.
CD28 co-stimulation upregulates CTLA-4 expression, such that co-stimulation itself
is a self-limiting process 456'457. CTLA-4 can interfere with T cell activation both by
outcompeting CD28 for B7 binding and by inducing its own inhibitory signals 458"460.
1.5.3 CYTOKINES
Cytokines are small molecular weight regulatory proteins, secreted by lymphocytes
and other cells associated with immune activity, with a variety of roles in regulating
the kinetics as well as qualitative and quantitative aspects of immune and
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inflammatory responses. They are often produced transiently and exert effects on
cells near to their source by binding to specific cell surface receptors. In 1986,
Mosmann et al461 first proposed a new paradigm in which T helper (Th, CD4+) cells
could be classed into two reciprocally inhibitory populations depending on their
cytokine profiles. The so-called Thl cytokines, including IFNy and EL2, stimulate
cytotoxic cells and macrophages leading to cell mediated immunity, protecting
against viruses and bacteria. Th2 cytokines, including IL4, IL5, IL10 and IL13,
stimulate B cells and antibody production, activating defence mechanisms against
parasites and allergic inflammation 461-462. However, this Thl/Th2 classification has
been challenged in recent years. It has been suggested that it represents an
oversimplification in that many immune responses can involve a combination of both
classes of cytokines 463. The cytokines applicable to this thesis are each discussed in
more detail below.
I.5.3.1 Interferon y (IFNy)
Interferons are a major class of cytokine that play a complex and central role in the
resistance of mammalian hosts to pathogens. There are type 1 (interferon a and P),
produced by virally infected cells, and type 2 (interferon y) interferons, produced by
T cells and by natural killer (NK) cells. The former bind to a common receptor and
increase MHC class I expression on the infected cells, thereby facilitating Tc (CD8+)
431
targeting
IFNy was first identified in PHA (phytohaemagglutinin)-activated lymphocyte
supernatants as a distinctive antiviral agent, although this is only part of the function
of this pleiotropic cytokine 464 This Thl cytokine also activates macrophage and
neutrophil intracellular killing, stimulates NK cell function and enhances MHC class
II, as well as MHC class I expression, on APCs 431.
In T cells the main inducer of IFNy is cross-linking of the TCR complex . Its
production is also induced by IL2, IL12, IL15, TNF, and by other interferons
IFNy binds to a different receptor to that of the type 1 interferons, most highly
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expressed outside the lymphoid system 469. Elucidation of the IFN-signalling
mechanism led to the discovery of the JAK-STAT (Janus kinase-signal transducers
and activators of transcription) pathway 470, which is also employed by more than 30
members of the cytokine superfamily 471. Upon receptor binding, JAK-1 and JAK-2
are phosphorylated and modulate signal-transducing peptides, with eventual target
gene activation due to binding of STAT-1 to DNA elements 472.
1.5.3.2 Interleukin 2 (IL2)
Originally described as T cell growth factor 473, the function of IL2 extends beyond
lymphocyte activation and population expansion, though T cells still appear to be its
major target. This Thl cytokine also stimulates growth of B cells, NK cells and
lymphokine-activated killer cells. IL2 knockout mice do not develop lymphopaenia
or immune deficiency, suggesting that IL2 is not required for lymphopoiesis.
However, these mice do develop a syndrome of generalized inflammatory disease
involving multiple organs, often with a severe colitis 474
T cell growth and clonal expansion is a tightly regulated process determined by the
concentration of IL2 available to the cell and the level of IL2 receptor (IL2R)
expression on the cell 465. Accordingly, a primary focus in T cell activation studies is
on the receptors and intracellular mechanisms that control expression of the IL2 gene
and genes encoding the IL2R. IL2 is a 15kDa glycoprotein encoded by a single gene
whose transcriptional activity is rapidly increased in activated T cells 475,476 A
transcriptional enhancer at the initiation site of this gene has been shown to interact
with transcriptional factors such as AP-1, NFkB and Oct-1 477 There are also binding
sites for a unique lymphocyte-specific transcriptional complex termed NFAT
(nuclear factor of activated T cells), which appears to determine the T cell specificity
478
and inducibility of expression ofIL2
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1.5.3.3 Interleukin 5 (IL5)
IL5 is a T cell derived Th2 cytokine involved in the pathogenesis of atopic diseases.
Though predominantly produced by CD4+ T cells, it is also expressed by mast cells
and CD8+ cells. IL5 specifically plays a role in the differentiation, recruitment and
survival of eosinophils, which are known to mediate allergic and asthmatic
symptoms 479>48°. it also increases basophil numbers and can prime them for
histamine release and leukotriene production. In addition, IL5 can augment IL2
dependent differentiation and proliferation of T cells themselves, though IL5
receptors have not been identified on T cells a yet481.
The IL5 receptor consists of a specific a subunit (IL5Ra) and a P subunit common to
IL13 and GM-CSF 482. The a subunit is restricted to eosinophils and basophils in
humans, and binds IL5 with low affinity in isolation, and high affinity in association
with the P subunit. IL5, IL3 and GM-CSF are associated with similar intracellular
signalling events, including activation of protein kinase C, ras, raf, and mitogen
activated kinase 48 *.
1.5.3.4 Interleukin 10 (IL10)
IL10 is a major regulatory cytokine of inflammatory responses, originally described
as a mouse Th2 cytokine, inhibiting Thl cytokine synthesis 483. Since then, however,
there has been increasing evidence that it acts as a general inhibitor of proliferative
and cytokine responses of both Thl and Th2 cells in vitro and in vivo. IL10 is
secreted by monocytes, NK cells, T cells (Thl and Th2 CD4+, and CD8 ), mast cells
and B cells 484"487. It has been shown to play a pivotal role in the establishment of
peripheral T cell anergy, a state of immune inactivation characterized by abolished
proliferative and cytokine responses, in mice, in which its administration before
allergen treatment induced antigen-specific T cell tolerance ' . In addition, IL10
derived regulatory (CD4+) T cells have been identified in humans and mice. These
cells produce IL10, but not IL2 nor IL4, which suppresses antigen-specific T cell
response in vitro and prevents antigen-induced colitis . Furthermore, IL10 inhibits
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DC maturation, characterized by a decreased expression ofMHC class II molecules,
and drives their function towards tolerance induction of both Thl and Th2 T cells
491,492
The IL10 receptor (ELIOR) is composed of at least two subunits, which are members
of the interferon receptor family 493. The best characterized intracellular signalling
pathway is the JAK-STAT system, in which the EL10/IL10R interaction engages
JAK-1 and Tyk2, and transcription is activated by STAT-1, STAT-3 and STAT-5 494~
497
1.5.4 T CELL SURFACE ACTIVATION MARKERS
The changes that occur on the T cell surface during an immune response are multiple
but it is particularly well characterized that activated T cells synthesize and express
new receptor molecules of which the best studied examples are CD69, transferrin
receptors, and receptors for cytokines such as EL2 (CD25). Those applicable to this
thesis are discussed.
1.5.4.1 CD69
CD69, also known as activation inducer molecule, is one of the earliest cell surface
antigens expressed by activated T cells, detectable within 1 hour of TCR-CD3
ligation. Furthermore, it is expressed in response to alternative modes of activation
mediated by either CD2 or CD28. CD69 exists as a cytoplasmic pool in non-
activated T cells, which can be mobilized upon activation. Once expressed, it acts as
a co-stimulatory molecule for T cell activation and proliferation. Its expression can
also be induced in vitro in B cells, NK cells, macrophages and granulocytes.
Although a specific ligand has not identified, its wide distribution and the induction
of intracellular signalling upon CD69 cross-linking imply a role in haematopoietic
cell functions 498"500.
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CD69 generated signals include Ca2+ influx and PLA2 activation, as well as
cooperation with lymphokine gene expression and cell division 501"506. Futhermore, it
has been shown that accumulation of GTP-bound ras plays a central role in TCR-
CD3 mediated CD69 expression 507>508
1.5.4.2 CD25 (IL2Ra)
The IL2 receptor (IL2R) consists of 2 signalling units, IL2RP (CD 122) and yc
(CD 132), and a variably expressed IL2Ra subunit (CD25), which regulates IL2
affinity 509. Although signalling can occur in the absence of CD25, it is necessary for
normal immune function, as demonstrated by the autoimmunity, colitis and
premature mortality in CD25"'" mice 51°, and by the severe combined
immunodeficiency in a patient with CD25 deficiency 511. The presence of CD25
appears to increase the binding affinity of the IL2R for IL2, thus allowing
responsiveness to the low IL2 concentrations physiologically produced in vivo. CD25
expression is induced by a range of stimuli, including antigens/mitogens and
cytokines, such as IL2 473. Its expression is not only important for maximal T cell
proliferation, but also seems to contribute to activation-induced cell death 51°.
The CD25 gene contains at least three regulatory regions. The first two (I and II) are
essential for mitogen-induced CD25 expression, but are insufficient for IL2
regulation of CD25 5I2. This is dependent on region III, which binds both STAT-5
and ELF-1 in this respect513'514 Upon IL2 binding, JAK-1 and JAK-3 phosphorylate
the IL2R chains with eventual activation of target genes by STAT-5 (A+B) 515.
STAT-5A is essential for IL2 induced CD25 expression but not for that induced by
anti-CD3. Furthermore, proliferation at physiological IL2 levels is dependent on IL2-
induced CD25 expression, and antigen-mediated CD25 induction in the absence of
IL2 induction is insufficient for normal T cell proliferation or clonal expansion in
vivo 516.
CD4+CD25+ expression has also been recently associated with a regulatory T cell (Tr
cell) phenotype. Increasing evidence suggests that Tr cells may be acting to down-
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regulate other T cell responses, including those that are directed against self, thereby
helping to maintain peripheral tolerance 517"519. Such CD4+CD25+ T cells are
unresponsive to stimulation with anti-CD3 antibody, anti-CD3 and anti-CD28
antibodies used together, high IL-2 concentration, and con A in the presence of T
cell-depleted spleen cells as a source of APCs. In addition they suppress proliferation
of CD4+CD25" cells cultured in vitro in the presence of APCs and soluble anti-CD3
antibody, and inhibit induction of IL-2 mRNA. This is mediated by a cytokine-
independent (neither IL-10 nor TGF-P), cell-cell contact-dependent mechanism 520.
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1.6 Adenoviral Gene Delivery
1.6.1 VECTORS USED FOR GENE DELIVERY AND GENE THERAPY
A variety of gene transfer vectors can be used to deliver the therapeutic gene to the
relevant target cell. They are traditionally classified as either viral or non-viral. Viral
vectors exploit the sophisticated and efficient cellular entry characteristics of the
viruses specifically to deliver DNA to host nuclei. There are a range of viral vectors
including retroviruses, adenoviruses, adeno-associated viruses and herpes simplex
virus. Most experience to date has been with retroviruses and adenoviruses.
Recombinant retroviruses are the most long-standing vectors used 521. Viral DNA is
integrated into the host genome facilitating stable expression thus circumventing the
need for re-administration 522. However large-scale retroviral production is
technically difficult and they can only achieve gene transfer to dividing cells, which
largely precludes their use in the terminally differentiated surface bronchial
epithelium 523.
Adenoviruses are ideal candidates for gene delivery to the lungs, in that they are
capable of efficiently transfecting non-dividing cells and they have a natural tropism
for respiratory epithelium. They have a higher, in vitro and in vivo, transfection
efficiency than many of the other vectors, including naked DNA (as used in this
thesis). They can also be concentrated to produce high titres; up to 1012 plaque
forming units (pfu)/ml compared with only 106 pfii/ml for retroviruses. As the
adenoviral DNA is episomal, thus not integrating into the host chromosome,
transgene expression is only transient making re-administration necessary for long-
term therapy. However, the resultant risk of insertional mutagenesis is much less of a
concern than it is for retroviral vectors. A major disadvantage of adenoviral vectors
is the induction of a significant host immune response. A T cell-mediated response
against adenoviral proteins causes a local inflammatory reaction that can result in
lysis of the transduced cells and a shorter duration of adenoviral-mediated transgene
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expression. Another concern is the development of virus-neutralizing antibodies,
which eliminate the virus upon repeated administration 524 Overcoming these
immune mechanisms has become a priority in adenoviral gene therapy.
Non-viral vectors include ligand-DNA conjugates, naked DNA and, ofmost interest,
liposomes. Cationic liposomes form artificial membranes that complex with DNA
and confer transfection ofDNA into cells by endocytosis. They are easy to produce
and administer and do not appear to induce immune responses, nor carry the risk of
mutagenesis associated with viral vectors. Liposome-mediated gene transfer is
limited by aggregation and destruction of a majority of the DNA in endosomes
during transfer from the cytoplasm to the nucleus. DNA reaching the nucleus is often
only transiently and weakly expressed 525.
Several approaches have been adopted to address some of the disadvantages of
present vectors. For example viral proteins used to evade endosomal ingestion have
been fused to liposomes to allow more efficient gene delivery 525. Cell and tissue
specific promoters facilitating specific targeting are now available 526>527; as are
528 529
inducible promoters allowing transgene expression to be controlled at will
fn an attempt to make adenoviruses less immunogenic, Ad vectors ('gutted viruses')
in which almost the entire viral genome has been deleted have been constructed 530
532. This also frees up to 30 kb for DNA insertion, allows longer transgene expression
and re-administration 533. Host immunity to Ad vectors has also been modulated by a
534-539
variety of agents resulting in increased and prolonged transgene expression
1.6.2 ADENOVIRUSES
1.6.2.1 Wild type Adenoviruses
Adenoviruses (Ad) are a frequent cause of acute upper respiratory tract infections.
They were first isolated in 1953 by investigators trying to establish cell-lines from
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adenoidal tissue of children removed during tonsillectomy and from military recruits
with febrile illnesses. Ad are non-enveloped, icosahedral particles with a diameter of
approximately 70-100nm (see Figure 1.5A). They are composed of a linear, double-
stranded DNA core surrounded by a protein shell composed of 252 subunits, called
caspsomeres. Fibres that extend from the 12 vertices of the outer capsid mediate
adenoviral attachment to cells. To date more than 49 serotypes of human Ad have
been identified and classified into six distinct subgroups (A-F). The most studied
adenoviruses are the group C serotypes 1, 2, 5, and 6. Ad types 2 and 5 have been
most commonly used to prepare recombinant Ad vectors. The latter was used in this
thesis.
Uptake of the adenovirus particle initially involves an interaction of the fibre protein
with a range of cellular receptors, which include the MHC class I molecule and the
coxsackievirus-adenovirus receptor 540>541. The penton base protein then binds to the
integrin family of cell surface heterodimers allowing internalisation via receptor-
mediated endocytosis 542-544 Most cells express primary receptors for the adenovirus
fibre coat protein, however internalisation is more selective. Penetration involves
phagocytosis into vacuoles, after which the toxic activity of the pentons is
responsible for rupture of the phagocytic membrane and release of the particle into
the cytoplasm. The core migrates to the nucleus where the DNA enters through
nuclear pores, whereupon it is converted into a virus DNA-cell histone complex (see
Figure 1.5B)
The adenoviral genome is approximately 36 kilobases (kb), conventionally
represented as 100 map units (1 map unit = 360 bp). Viral gene expression occurs in
a sequential cascade. Adenoviral genes are grouped as early (E) genes whose
expression precedes viral DNA replication and the transcription of the late (L) genes,
which takes place 6 to 8 hours after infection. The E genes encode regulatory
proteins for viral replication and the L genes encode structural proteins necessary for
. . 545
assembly of progeny virions
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1.6.2.2 Adenoviral Vector Construction
The ElA and E1B products of the El gene are the first viral proteins produced after
infection and are critical for adenoviral replication, which occurs in the nucleus of
the host cell. Their deletion results in replication-deficient viruses, which have been
used as adenoviral vectors 546. These viruses can be propagated in transformed helper
cell lines, such as the 293 line prepared from human embryonic cells, that express the
El gene products 547 The E3 gene product functions in abrogating the host immune
response to the virus. It is not required for viral growth in tissue culture, and E3-
deleted viruses appear to be fully infectious. Up to 3.2 and 3.1 kb of the El and E3
region, respectively, can be deleted 546, and -105% of the wild-type genome can be
effectively packaged into Ad virions 548, thus allowing for the insertion of a further
-2 kb of foreign DNA, without effecting viral growth rate or titre. Therefore E1/E3-
deleted Ad vectors allow packaging of-8.1-8.2 kb of foreign DNA 546.
A number of strategies of adenoviral vector construction have been employed. The
homologous recombination method, as relevant to this thesis, was developed by Bett
et al in 1994 546. This method uses two plasmids containing overlapping fragments
that recombine. The first plasmid contains most of the viral genome in circular form,
minus the DNA packaging signals and the El region. In this thesis pBHGlO, an
E1/E3-deleted Ad 5 plasmid, was used 549. The second plasmid contains the left 100
to 150 bp of repeated DNA sequence (inverted terminal repeat), packaging signal,
and sequence overlapping the first plasmid: pDK6, which contains the murine
cytomegalovirus promoter (MCMV), was used in the construction of Ad5-MCMV-
Dvll. MCMV is a particularly efficient promoter of adenoviral-mediated transgene
expression in rodent lungs 55°. After the gene of interest (Dvllin this case) has been
cloned into the second plasmid (pDK6), the two plasmids are co-transfected into the
El-transformed 293 cells (see Figure 1.5C). The resultant virus produced by
homologous recombination in 293 cells is then isolated through plaque purification.
This process is limited by the low frequency of the recombination event and the




Figure 1.5: Adenoviral Gene Therapy. A & B:Taken from University of
Leicester BS335 Virology (http://www-micro.msb.le.ac.uk/335/BS335.html)
A) Negatively-stained electron micrograph of adenoviral particles. The thin
fibres protruding from each vertex of the icosahedral particles are just visible
B) Uptake of the adenovirus particle initially involves interaction of the fibre
proteins with cellular receptors. The penton base protein then binds to integrins
allowing internalisation via receptor-mediated endocytosis. Penetration involves
phagocytosis, after which the toxic activity of the pentons is responsible for
rupture of the phagocytic membrane and release of the particle into the
cytoplasm. The core migrates to the nucleus where the DNA enters through
nuclear pores, whereupon it is converted into a virus DNA-cell histone complex
C) After the gene of interest (Dvl1 in this thesis) has been cloned into pDK6,
containing the MCMV promoter, this is co-transfected with pBHGIO, an E1/E3-
deleted Ad 5 plasmid, in the E1-transformed 293 cells The resultant virus







All reagents were purchased from Sigma (Poole, Dorset, U.K.) unless otherwise
stated.
Cell Culture Media for 293 Cells
50ml 10X MEM (Eagle w/o sodium bicarbonate) with 10% foetal calf serum (FCS)
(F-9665), lOOIU/ml penicillin/lOOpg/ml streptomycin (Gibco, Paisley, U.K. 15070-
071), 2mM L-Glutamine (Gibco, Paisley, U.K., 25033-010), 15ml 7.5% sodium
bicarbonate (Gibco) and 375ml autoclaved dH20. Kept at 4°C.
10X Citrate Saline
50gm KC1, 22gm Na-Citrate.2H20; made up to 500ml with dH20. Diluted 1/10 and
filter-sterilized (0.22p) for IX Citrate Saline.
10X HEBS Buffer
8gm NaCl, 5.46 gm HEPES (sodium salt), 0.36gm KC1, 0.2gm Na2FIP04; made up to
100ml with dH20. and filter-sterilized (0.22p). Diluted with dH20 to 2X HEBS and
pH adjusted to 7.1.
Agarose Overlay for DNA Co-transfection (adenovirus)
A) lgm agarose dissolved in 100ml dH20
B) 16.8ml 10X MEM (Eagle w/o sodium bicarbonate), 61.2ml dH20, 6ml 7.5%
sodium bicarbonate (Gibco), 10% foetal calf serum (FCS) (F-9665), 2ml 5%
yeast extract (Difco 0127-17), lOOIU/ml penicillin/streptomycin (Gibco,
Paisley, U.K. 15070-071), 2mM L-Glutamine (Gibco, Paisley, U.K., 25033-
010), 2|il/ml fungizone; filter-sterilized (0.22p).
A + B made freshly, mixed and incubated at 44°C before pouring.
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PBS2+ (adenovirus dilution)
A) 80gm NaCl, 2g KC1, 11.5 Na2HP04, 2g KH2P04/ litre of dH20
B) lgm CaC1.2H20 / 100ml dH20
C) lgm MgCl2.6H20 / 100ml dH20
For 1L ofPBS2+: 880ml dH20 + 100ml A + 10ml B + 10ml C.
Pronase
Pronase (Protease) dissolved at 5mg/ml in 0.01M Tris-HCl pH 7.5, 15 minute
incubation at 56°C and 60 minutes at 37°C
Pronase-SDS
0.5mg/ml Pronase (as above), 0.01M EDTA, 0.5% SDS, 8.3mM Tris-HCl pH 7.5;
freshly made.
Complete Human RPMI Culture Media
500ml RPMI 1640 (R-0883) with 5% human AB serum [heat inactivated] (H-1513),
lOOIU/ml penicillin/100p.g/ml streptomycin (Gibco, Paisley, U.K. 15070-071), 2mM
L-Glutamine (Gibco, Paisley, U.K., 25033-010). Kept at 4°C.
Complete DMEM Culture Media
500ml DMEM (D-5921) with 5-10% foetal calf serum (FCS) (F-9665), lOOIU/ml
penicillin/lOOpg/ml streptomycin (Gibco, Paisley, U.K. 15070-071), 2mM L-
Glutamine (Gibco, Paisley, U.K., 25033-010). Kept at 4°C.
Avertin (Tribromoethanol anaesthetic)
2.5gm 2,2,2-tribromoethanol (Aldrich T4840-2), 5ml 2 methyl-2-butanol (tertiary
amyl alcohol; Sigma A1685); made up to 200 ml with dH20.
LB Medium




Ten LB agar capsules (Sigma L-7025) in 500ml dH20; autoclaved. Ampicillin at
50pg/ml if required.
6X PCR Loading Buffer
0.25% weight/volume of bromophenol blue and 40% weight/volume of sucrose in
distilled water. Stored at 4°C.
TE Buffer
lOmM Tris-HCl (pH 8), ImMEDTA
8% SDS-PAGE Gel (200mls)
67.8ml dH20, 53.2ml 30% acrylamide/bis-acrylamide mix (A-3699), 75ml 1M
Trizma Base pH 8.8 (T-1503), 2ml 10% SDS (L-4509). Kept at 4°C. Polymerisation
of 5mls gel mixture catalysed by addition of 5pi TEMED (T-9281) and 50pl 10%
APS (A-3678).
15% SDS-PAGE Gel (200mls)
21ml dH20, 100ml 30% acrylamide/bis-acrylamide mix (A-3699), 75ml 1M Trizma
Base pH 8.8 (T-1503), 2ml 10% SDS (L-4509). Kept at 4°C. Polymerisation of 5mls
gel mixture catalysed by addition of 5gl TEMED (T-9281) and 50pl 10% APS (A-
3678).
5% Stacking Gel (lOOmls)
68ml dEl20, 17ml 30% acrylamide/bis-acrylamide mix (A-3699), 12.5ml 1M Trizma
Base pH 6.8 (T-1503), 1ml 10% SDS (L-4509). Kept at 4°C. Polymerisation of 5mls
gel mixture catalysed by addition of 5pl TEMED (T-9281) and 50pl 10% APS (A-
3678).
SDS-Tris Glycine Electrophoresis Buffer
25mM Trizma Base (T-1503), 250mM Glycine (G-7403), 0.1% SDS (L-4509). Kept
at room temperature.
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Methanol Based Transfer Buffer (1L)
14.4gm Glycine (G-7403), 3gm Trizma Base (T-1503), 200ml methanol (M-1770);
CIH2O to make up to 1L. Made fresh.
Western Blot Nitrocellulose Wash Buffer (TBS Tween)
0.5M Tris-HCl (pH7.6) made up to 2L with dH20. Diluted 1/10 in 0.85% NaCl with
0.05% Tween-20 (P-7949). Kept at room temperature.
Western Blot Blocking Buffer
Western blot nitrocellulose wash buffer with 5% 'Marvel' dried skimmed milk
powder.
Whole Organ Lysis Buffer
1% NP40 (BDH 56009) in PBS (D-8662); 1 protease inhibitor tablet (Roche
1836170)/ 10ml. Made fresh.
Cytoplasmic Lysis Buffer
50mM sodium fluoride, 5mM tetra sodium pyrophosphate, ImM sodium
orthovanadate (pH 10), lOmM P-glyceropyrophosphate, 0.5% NP40 (BDH 56009),
2mM EDTA, 20mM Na2HP04, 20mM NaH2P04; made up to 10ml with dH20 and 1
protease inhibitor tablet (Roche 1836170) added. Stored at -20°C.
Nuclear Lysis Buffer
50mM sodium fluoride, 5mM tetra sodium pyrophosphate, ImM sodium
orthovanadate (pH 10), lOmM P-glyceropyrophosphate, 0.5% NP40 (BDH 56009),
2mM EDTA, 20mM Na2HP04, 20mM NaH2P04, 300mM NaCl; made up to 10ml
with dH20 and 1 protease inhibitor tablet (Roche 1836170) added. Stored at-20°C.
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Physiological Buffer
lOmM Tris-HCl (pH 7.4), 140mM NaCl, 5mM EDTA, 2mM dithiothreitol, ImM
phenylmethylsulfonyl fluoride, lpg aprotonin/ml, 2ug leupeptin/ml, 2pg
pepstatin/ml. Stored at -20°C.
Recombinant Mouse Sonic Hedgehog Peptide
The recombinant mouse Sonic Hedgehog amino-terminal peptide (R&D Systems,
UK; 461-SH) was reconstituted in filter-sterilised PBS (D-8537) containing 0.2%
endotoxin free BSA (A-4919), to a final concentration of 50pg/ml. Aliquots were
prepared and stored at -20°C for up to 3 months.
Anti-Sonic Hedgehog Antibody
The neutralising anti-Sonic Hedgehog antibody 5E1 (Developmental Studies
Hybridoma Bank, USA) was purified from hybridoma supernatants using Protein G
columns (Amersham Pharmacia Biotech, UK) as per standard protocols.
Fluorescein Isothiocyanate (FITC)
FITC powder (Sigma F-7250) was resuspended at 2mg/ml in sterile PBS (D-8537)
and 50p.l was given intra-tracheally to each mouse. For latter experiments with the
larger Gli mutant mice FITC was given at 7ug/gm.
Red Blood Cell Lysis Buffer
ImM NH4HCO3 and 114mM NH4CI. Kept at 4°C.
MACS Buffer
0.5% BSA (A-2153) in PBS (D-8537). Kept at 4°C.
FACS Fixing Buffer
2% paraformaldehyde (P-6148) in PBS (D-8537). Kept at 4°C.
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FACS Wash
0.1% sodium azide, 0.2% BSA (A-2153) in PBS (D-8537). Kept at 4°C.
ELISA Binding Buffer
Carbonate-Bicarbonate buffer (C-3041). 1 capsule dissolved in 100ml of distilled
water yields a 50mM Carbonate-Bicarbonate buffer, pH 9.6. Kept at 4°C.
ELISA Wash Buffer
PBS tablets (Oxoid BR14) diluted in water (1 tablet/100ml distilled water)
containing 0.05% Tween-20 (P-7949). Kept at room temperature.
ELISA Blocking Buffer
ELISA washing buffer containing 1% BSA (A-9418). Freshly prepared.
ELISA Substrate Solution
ELISA ethanolamine buffer (Don Whitley Scientific, Shipton, U.K. E-016)




The construction and application of the recombinant adenovirus, Ad5-MCMV-Dvll
(Dishevelledl), is discussed below and presented in detail in Chapter 5. It is
important to note that the facilities for large scale virus production and purification
were not available locally. These steps were very kindly carried out by staff in
Professor Jack Gauldie's laboratory, Department ofPathology, McMaster University,
Ontario, Canada. All the protocols described were based on those used by Professor
Gauldie's lab.
2.2.1.1 DNA Co-transfection
Details of the construction of pDK6-Dvll are given below and in Chapter 5. This
new construct and pBHGlO were co-transfected into 293 cells [human embryonic
kidney cell line (European Collection of Cell Cultures [ECACC], Salisbury, UK)] to
rescue Dvll cDNA in the adenovirus genome. The co-transfections were carried out
in 60mm tissue culture dishes. 293 cells were grown to 70-80% confluence in these
dishes, media was removed and replaced with 5ml of fresh media per dish. The DNA
(10pg of both pDK6-Dvll and pBHGlO per dish) was added to 2X HEBS (500pl per
dish) in a 15ml Falcon tube and mixed well. 250mM CaCl2 (500pl per dish) was
added very slowly with gentle agitation, during which a cloudy precipitate was
noted. This mixture was incubated for 15 minutes at room temperature, 1ml was
added to each of the 293 cell dishes (containing 5ml of fresh medium) and gently
mixed. The dishes were then incubated overnight (-16 hours). Normally between 4
and 8 dishes were transfected at one time. The following day an agarose/media
overlay was freshly made and maintained at 44°C. The medium from each dish was
gently aspirated and 10ml of overlay was very slowly added to each. The dishes were
then returned to the humidified 37°C incubator with 5% C02. Culture dishes were
examined daily thereafter for the development of plaques (which took 1 to 2 weeks).
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Plaques were characterized by slowly increasing localised areas of cell clearing
beneath the overlay, due to the cytopathic effect of the replicating virus. Once
identified a plaque, was repeatedly 'stabbed' with a PI000 tip (Gilson) and the
samples were resuspended in PBS2+ before storage at -80°C.
2.2.1.2 Amplification
293 cells were grown to near confluence in 60mm culture dishes and the media
gently removed. Virus was released from the plaque 'stabs' by repeated freeze-
thawing between liquid nitrogen and a 37°C water bath. An aliquot was then added
to 293 cells (in a 60mm tissue culture dish) in a 500pl volume and the cells were
returned to the incubator for 45-60 minutes with gentle 'swirling' intermittently,
before fresh media was added. The viral associated cytopathic effect (CPE) was
observed within a few days, characterized by the cells rounding up and detaching
from the dish. Once complete CPE was evident (all cells rounded up) the contents of
each dish were transferred to a 15ml Falcon tube and centrifuged at 300g for 10
minutes at room temperature. The supernatant, which contained adenovirus, was
removed and stored at -80°C for later use. The cell debris/pellet and any remaining
cells in the dishes were resuspended in freshly prepared Pronase-SDS solution and
incubated overnight at 37°C. DNA was then extracted as follows. 500pl of the
overnight Pronase-SDS digestion was added to 500pl of water-saturated phenol and
mixed before centrifugation at 12,000g for 10 minutes at 4°C. The aqueous (top)
layer was removed and mixed with 1ml of 96% ethanol before a further
centrifugation at 12,000g for 10 minutes at 4°C. The pellet was washed twice in 96%
ethanol with repeat centrifugations, dried and resuspended in 50pi of TE, pEl 8. DNA
was quantified and analysed by Southern blotting as described.
A second plaque purification step, to minimise potential contaminating wild type
adenovirus, was performed once Dvll expression had been confirmed in the original
plaques. Essentially the protocol was the same as that used for titration, described
below. A single discrete plaque was identified and virus acquired, as above, was used
for large scale preparation.
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2.2.1.3 Titration
The adenovirus was titrated by a plaque assay giving the viral concentration in
plaque forming units per ml (pfu/ml). To do this, serial dilutions of the virus were
made in PBS2+ and 200|ul of each was added to near-confluent 293 cells in 60mm
dishes, with at least duplicate dishes of each dilution. These were incubated for 45-60
minutes with gentle 'swirling' at room temperature. 10ml of overlay (as in
cotransfection) were added slowly to each dish before being returned to the
incubator. The number of discrete plaques was counted after 5-7 and 10-14 days. The
optimal dilution at which discrete plaques were appreciable was chosen. The
concentration (in plaque forming units per ml or pfu/ml) was calculated as: the
number of plaques x 1/0.2 x dilution factor.
2.2.1.4 Large Scale Virus Production using Spinner Culture (in Canada)
To allow the adenovirus to be produced on a larger scale 293N3S (a variant of 293
cells which grow in suspension) cells were used in spinner cultures. The cells were
initially grown in 3-litre spinner flasks (Bellco Biotechnology) to a confluency of
2x105 cells/ml. They were then transferred to three 1-litre centrifuge bottles
(Nalgene) and centrifuged at 1500g for 45 minutes at room temperature (MSE
centrifuge). The supernatant was saved (as 'conditioned medium'), and the pellet
resuspended in 300ml of virus inoculum medium and transferred to a 1 litre spinner
flask. Viral supernatant, as taken during amplification, was added at a concentration
of 2 pfu/cell and incubated for 90 minutes in a 37°C 'warm room'. The whole
volume was then transferred to a 3-litre spinner flask along with 1500ml of
'conditioned medium' and 1200ml of fresh medium. Infection was allowed to
proceed until inclusion body staining was >90% (see below). Cells were harvested by
transferring to three 1-litre centrifuge bottles and centrifuging as before. The
supernatant was saved and the pellet resuspended in 15ml of 0.1M TrisHCl (pH 8),
ready for banding.
-95-
2.2.1.5 Purification (Banding) of Adenovirus using CsCi Gradient (in Canada)
The virus suspension, from spinner culture, was added to 5% sodium deoxycholate at
a ratio of 10:1 and incubated for 30 minutes at room temperature (RT), with
occasional mixing. l/100th volume of 2M MgCl2 and 1/200^ volume of lOmg/ml
DNase I were then added, and incubated for 45 minutes at 37°C, with gentle periodic
mixing. The virus was then ready for banding and fractionation. Briefly, the viral
suspension was mixed with saturated CsCl and centrifuged at 14,000g for 18 hours at
4°C. The band, containing the recombinant adenovirus, was collected and mixed
with 'top-up' solution before a second similar centrifugation. The viral band was
again collected and PD-10 column chromatography performed to remove the CsCl.
The purified adenovirus was then aliquoted, titred and stored at -80°C until use.
2.2.1.6 Inclusion Body Staining (in Canada)
Inclusion bodies are densely staining nuclear bodies resulting from accumulation of
large amounts of virus and viral products at late points in infection. They are used to
monitor adenoviral infection.
5ml aliquots of infected spinner culture were centrifuged (Beckman TJ-6 centrifuge)
at 1500g for 10 minutes at room temperature (RT). The pellet was resuspended in
0.5ml of 1% sodium citrate and incubated for 10 minutes at RT. 0.5ml of Carnoy s
fixative was added and fixed 10 minutes at RT. This was resuspended in 1ml of 1%
sodium citrate and centrifuged at 1500g for 10 minutes at RT, and the pellet
resuspended in 150pl of 1% sodium citrate. A drop of this suspension, containing
fixed cells, was placed on a microscope slide, dried for 60 minutes, a drop of orcein




In vitro transfections were carried out in all of the adherent cell lines listed below.
For each the quantity of virus added was expressed as a multiplicity of infection
(moi), which is the ratio of the number of pfu's of virus to the number of cells within
the well. The number of cells in a particular size ofwell/dish were pre-determined by
preliminary experiments, in which the cells were grown to the same confluency at
which transfection would be performed, trypsinized and counted; several counts were
averaged. Hence, an estimation of the cell number at transfection was obtained and a
specified moi calculated.
In transfections the cells were grown to 80-90% confluency in most cases (although
occasional transfections were carried out in less confluent cells eg 50%), media
removed and adenovirus added. The samples were then returned to the incubator for
45-60 minutes, with occasional swirling, before the cells were gently washed and
fresh media added. Cells were harvested at time-points from 6-72 hours for a variety
of assays as discussed in Chapter 5. In vivo, the adenoviruses were administered
intra-tracheally, as described (Section 2.2.3.2 below), at a range of pfu's.
2.2.1.8 Safety
All adenovirus work, including in vivo administration, was carried out in Class II
safety cabinets. Mice were always housed in isolators following adenoviral
treatment. All equipment in contact with adenovirus was thoroughly bleached (Mini-





The cell lines used included mouse Clara cells (mt-CCl-2, gift from Franco
DeMayo, Baylor College ofMedicine, Houston, USA), mouse Swiss 3T3 fibroblasts
and human A549 cells (ECACC), and rat-1 fibroblasts (American Type Culture
Collection [ATCC]). They were all maintained in DMEM based medium with 5-10%
foetal calf serum and cultured in a humidified incubator with 5% C02 at 37°C. As all
are adherent cell lines, trypsin-EDTA (Invitrogen, PL25300054, 0.5g/L Trypsin and
0.2g/L EDTA in Hanks' balanced salt solution) was required to dislodge them from
the culture flasks. 293 cells, as used for adenovirus rescue, were cultured in their own
media and displaced from culture flasks with IX citrate saline rather than trypsin-
EDTA.
2.2.2.2 Proliferation of Adherent Cells
Proliferation was measured by tritiated thymidine incorporation (3H-TdR-Amersham
Pharmacia Biotech, Amersham, UK, Cat # TRK61). Briefly, cells were cultured in
24 well plates. At a range of time-points O.lpCi/well tritiated thymidine was added.
24 hours later, the cells were washed twice with cold PBS (D-8662), twice with 5%
TCA and twice with 100% ethanol. 250pl of 0.3M sodium hydroxide was added and
the plates were incubated for 15 minutes at 4°C. The samples were then added to 1ml
of scintillation fluid (Packard) and read in a beta-counter (Packard Liquid
Scintillation Analyzer).
Alternatively, proliferation was assessed by the CellTiter AQueous One Solution Cell
Proliferation Assay (Promega, UK), following manufacturers guidelines. Briefly, the
cells were cultured lOOpl of medium in flat bottomed 96 well plates, to which 20pl
of One Solution Reagent (Promega, UK) was added. The plates were read 1-4 hours
later by a microplate reader (Dynatech Laboratories MRX) set to a wavelength of
490nm with a reference of 630nm.
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Cell counts were performed using haemocytometers and 0.4% trypan blue exclusion
(Sigma).
2.2.2.3 Hoechst Staining
To assess nuclear morphology and apoptosis, cells were stained with Hoechst stain
(Calbiochem H33258). Freshly made 3% paraformaldehyde solution was added to
fix cells and incubated for 20 minutes at room temperature. An equal volume of
50mM NH4/C1 in D-PBS (D-8537) was added and incubated for a further 10
minutes. The cells were then washed twice in D-PBS before 0.1% Triton X-100 (in
D-PBS) was added for 4 minutes. The cells were washed again and 2pg/ml of
Hoechst dye (in D-PBS) was then added before a final 10 minute incubation.
Following 3 final washes (in D-PBS) the cells were visualised with a fluorescent
microscope (Zeiss Axiovert SI00) using appropriate software (Openlab 3.0 on Apple
Mac).
2.2.2.4 Cytospins
Cells were spun onto Vectabond treated microscope slides (Vector Laboratories,
Peterborough, England) using a Cytospin 3 (Shandon Scientific Ltd, Runcorn,
Cheshire, UK) set at 300rpm for 3 minutes. Following air-drying and methanol
fixation cytospins were stained with Diffquick as per manufacturers instructions
(Gamidor Ltd, Abingdon, Oxon., UK), or used for immunohistochemistry. Cytospins
of purified CD4+ or CD8+ cells were made in the same way.
2.2.3 IN VIVO
2.2.3.1 Anaesthesia and Culling
Mice were anaesthetised with an intra-peritoneal injection of avertin
(tribromoethanol anaesthetic) at a dose of 0.2ml per lOgm body weight. Avertin was
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prewarmed to 37°C for at least 30 minutes before administration. Mice were culled
with a single 0.5ml intra-peritoneal injection of phenobarbitone sodium (Sagatal,
Merial Animal Health, UK).
2.2.3.2 Intra-tracheal Administration
Following anaesthesia the mice were placed in a holder in which their upper teeth
were suspended from a horizontal strip of wire. The jaw was held open by a light
weight suspended from the lower teeth and the pharynx was illuminated with a
strong focal cold light source, thus allowing the vocal cords to be visualised. 40-50pl
of the sample was instilled into the bevel of a blunted orange needle (Microlance
25G), into which a 1ml syringe barrel could be inserted without displacement. The
needle (with attached syringe barrel) was then inserted into the trachea through the
vocal cords and the plunger of the 1ml syringe reinserted into its barrel thus
expelling the sample into the mouse lungs. Samples administered in this manner
included FITC, PBS, adenovirus constructs and the SPC 'naked DNA' vectors. In all
cases the volume was made up to 40-50pl with sterile PBS (D-8537).
2.2.3.3 Screening Mice
Gli2+/" and Gli3+/" mutations were screened by PCR analysis (by Ms Susan Haley)
and phenotype, respectively, as described in chapter 3. Briefly, genomic DNA was
isolated from mouse tail tips using a commercial kit (Promega, UK; H4131), as per
manufacturer's instructions. DNA was then amplified in a 'touch-down' PCR
reaction with primers specific for the neo-cassette used in the original construction of
the Gli2+/~ phenotype, following the recommended protocol given in The Jackson
Laboratory (USA) website (www.jax.org). Products were analysed on 2% agarose
gels as described below.
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2.2.3.4 Bronchoalveolar Lavage (BAL)
Following culling, the mouse lungs and trachea were removed intact. A 2-3cm length
of plastic tubing was inserted into the trachea and the lungs were washed with 2
volumes of sterile PBS (D-8662); though wash volumes varied between 450pl
(250pl+200pl) and 1400pl (800,600) they were consistent within experiments.
Typical BAL yields were between 50-80% of instilled volume. Samples were stored
on ice before centrifugation at 600g for 7 minutes at 4°C. The supernatants were
centrifuged at 13,000g for 5 minutes at 4°C and the supernatants from this used for
cytokine analysis.
2.2.3.5 Lung Analysis
The lungs were often divided and used for immunohistochemistry (IHC), RNA and
protein analysis. For IHC lungs were reinflated slowly with, and fixed in, 4%
buffered formalin overnight and were then paraffin embedded. 3pm sections were
stained with Hematoxylin and Eosin (Sigma) for general morphology or mounted on
Vectabond treated slides (Vector Laboratories, Peterborough, England) for later IHC.
For RNA extraction the lungs were initially stored at 4°C in RNAlater (Ams
Biotechnology, Abingdon, UK) as per manufacturers instructions. They were then
homogenised (Polytron PT3100, Kinematica, Switzerland) in volumes of 1.4-2ml of
Trizol Reagent (Life Technologies); 20,000 rpm for 30 seconds with samples on ice.
RNA was extracted immediately from homogenised samples as described below. For
protein analysis the lung tissue was initially snap frozen in liquid nitrogen, before
homogenising as for RNA but in 250pl of lysis buffer. The homogenised samples
were then incubated for 30 minutes at 30°C and centrifuged at 13,000g for 20
minutes at 4°C. The supernatants were quantified and used for immunoblotting as
described below.
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2.2.3.6 Human Biopsy Sections
After ethical permission was obtained from Lothian Research Ethics Committee,
anonymised paraffin embedded open lung biopsy material from patients with Usual
Interstitial Pneumonia (UIP) was taken from the Department of Pathology archive.
As with mouse blocks, 3pm sections were cut and mounted on Vectabond treated
slides (Vector Laboratories, Peterborough, England) for IHC.
2.2.3.7 Assessment of lung fibrosis in the FITC model
This was based on the scoring system devised by Ashcroft et al in 1988, in which
human biopsies were examined at xlO magnification 551. Randomly selected fields
were scored on a scale of 0 to 8 (see Table 2), dependent upon the score applicable to
over 50% of the field. As proposed by Ashcroft et al, every effort was made to assign
fields to an odd number on the scale, only using even numbers if it was difficult to
decide between two odd numbers. Main airways, blood vessels and inflammatory
exudates in air spaces were all excluded.
FITC and PBS treated mice lung sections were examined microscopically at x40
magnification (adjusting for difference in size between human and murine acini) by
at least two observers, who agreed a consensus number for each field. To allow for
differences between FITC +ve and FITC -ve areas of the lung, lung sections stained
with the anti-FITC antibody were examined. A field was considered FITC +ve if
>50% of the tissue within the field stained and FITC -ve if <50% stained. PBS lung
sections were all FITC -ve, as would be expected. 36 FITC +ve and 36 FITC -ve
fields were assessed per section, as this was in the middle of the range of field
numbers proposed by Ashcroft et al, and also covered nearly the entirety of the
section proceeding from one outside edge in non-overlapping rows. Some areas
where there was poor or overinflation (usually at lobe margins) were ignored. After
examining the whole section the mean score of all the fields was taken as the fibrosis
score, again sub-divided into FITC +ve and FITC -ve where appropriate.
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2.2.4 MOLECULAR BIOLOGY
2.2.4.1 Transformation of Competent Cells
lOOpl of freshly thawed competent cells (E. coli XLl-Blue, Stratagene) and 0.9pl of
P-mercaptoethanol (in kit) were incubated in a transformation tube (Falcon 352059)
for 10 minutes on ice, swirling every 2 minutes, lpl (maximum of 50ng) of DNA
was added and the tube incubated for a further 30 minutes on ice, before a 45 second
incubation at 42°C and a further 2 minutes on ice. 900p.l of preheated (42°C) SOC
medium (GibcoBrl 15544-034) was added, and the tube incubated with shaking for
60 minutes at 37°C. The transformation mixture was then plated on agar plates, with
the appropriate antibiotic (eg. kanamycin, ampicillin). These were incubated
overnight at 37°C and colonies picked the following day. A control plasmid, such as
pUC18 (provided with competent cells), was transformed in parallel to confirm
transformation efficiency.
2.2.4.2 Analysis of Transformants by DNA Miniprep
DNA minipreps were performed with a commercially available kit (Promega, UK;
A1330) following manufacturer's instructions. Briefly, 5ml of LB medium (with
appropriate antibiotic) was inoculated with a single bacterial colony in a 50ml Falcon
tube, and incubated overnight, with shaking, at 37°C. 750pil was mixed with 750pl of
30% glycerol to make a stock, which was stored at -80°C. The remainder was
centrifuged at 12,000g for 5 minutes at room temperature (RT). The pellet was
resuspended in 250pl of ice cold cell resuspension solution and incubated for 5
minutes at RT. 250pl of cell lysis solution was added and the mixture incubated for a
further 5 minutes. lOp.1 of alkaline protease solution was added, followed by a final 5
minute incubation. 350pl of neutralization solution was then added and the sample
centrifuged at 13,000g for 10 minutes at RT. The cleared lysate was decanted into a
spin column and centrifuged at 13,000g for 1 minute at RT, discarding flowthrough.
The column was washed twice with the provided column wash (75Opil and 250pl)
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followed by centrifugation at 13,000g for 1 minute and 2 minutes respectively. The
spin column was then transferred to a fresh tube and the DNA eluted with nuclease-
free water (Sigma).
2.2.4.3 Quantification ofNucleic Acids
To determine the concentration of nucleic acids in solution, absorbance at 260 and
280 nanometers (nm) was measured, from which the concentration was
calculated, in a spectrophotometer (Ultrospec 200, Pharmacia Biotech). To
determine the purity of solutions of DNA and RNA, the ratio of absorbance at
260nm and 280nm (OD26o/28o) was taken. This value should ideally be about 1.8
for DNA and 2.0 for RNA.
2.2.4.5 Large Scale Plasmid Preparation
Large scale DNA preparation was performed using a commercial kit (Qiagen, UK;
12263), as per the manufacturer's instructions. Briefly, 5ml of inoculated LB
medium (as grown for minipreps) was used to inoculate a further 500-1000ml, which
was incubated overnight, with shaking, at 37°C. The cells were harvested by
centrifugation at 6000g for 15 minutes at 4°C. They were then resuspended, lysed,
filtered and precipitated as per the protocol provided. The final DNA pellet was
resuspended in dH20 and quantified as above.
2.2.4.6 Agarose gel electrophoresis
Agarose gels (0.8%-2%; SeaKem LE agarose, FMC) were prepared in lxTAE buffer
(GibcoBRL UK), containing lpl of ethidium bromide (10pg/|il, SIGMA) per 50ml
of agarose. The gel was transferred to a gel tank (Biorad) containing IxTAE buffer.
In general, 10pl of the DNA sample or PCR reaction were mixed with 2pl 6x loading
buffer and loaded into each well. A 50ml gel was run at 80 volts for approximately 1
hour. The UVGrab program connected to a white/ultraviolet transilluminator (UVP)
was used to visualise the nucleic acid bands and capture the gel image. SIGMA s
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PCR marker or Gibco s lkb (kilobase) DNA ladder were used as molecular weight
markers. The lkb ladder included fragment sizes ranging from 75 base pairs (bp) to
12kb pairs. The brightest central band on each gel (Figure 5.3) corresponded to
~1.6kb; the bands higher than this to ~2kb, 3kb, 4kb, 5kb, 6kb, 7kb, 8kb, 9kb, lOkb,
1 lkb and 12kb respectively. The bands lower than the brighter 1.6kb band
corresponded to ~500bp, 400bp, 350bp, 300pb, 220bp, 200bp, 150bp and 75bp,
respectively. Therefore, using this ladder, the size of a fragment of DNA run on an
agarose gel was estimated. In addition, the PCR ladder used (throughout the thesis)
represented the following sizes from the largest molecular weight band down: 2kb,
1.5kb, lkb, 750bp, 500bp, 300bp, 150bp and 50bp.
2.2.4.7 Restriction Enzyme Digestion
Restriction enzymes, buffers and BSA (Promega, UK) each made up 10% of the
digest reaction mixture, which also included nuclease free water and the DNA
sample itself. At least 1 unit of restriction enzyme was used per pg of DNA to be
digested. The samples were incubated at the recommended temperature
(manufacturer; generally 37°C) for 1-4 hours, followed by a 10 minute incubation at
65°C to inactivate the enzymes. For digests with two restriction enzymes an optimal
common buffer was used.
2.2.4.8 Purification of DNA from agarose
To extract DNA fragments from agarose gels the sample was initially run as usual
and the band of interest identified under ultraviolet light. Once visualised, the
agarose containing the band was cut out and placed in a 2ml Eppendorf tube with
300pl of binding buffer (Biorad 732-6022). This was incubated at 55°C, with
mixing, until the agarose had dissolved. 1ml ofDNA clean-up resin (Promega, UK,
Wizard DNA clean-up system A7280) was added and the mixture inserted into the
barrel of a 2ml syringe, which in turn was inserted into a filter (Promega, UK,
Wizard DNA clean-up system A7280). The syringe barrel was reinserted gently
discarding the filtrate. 2mls of 80% isopropanol were placed in the empty syringe
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and passed through the filter, which was then centrifuged at 600g for 2 minutes. To
elute the DNA, 50pl of prewarmed dH20 (65°C) was placed into the filter and
incubated for 1 minute before centrifugation at 600g for 30 seconds.
2.2.4.9 Ligation of Plasmid Vector and Insert DNA
After the vector and insert DNA were prepared for ligation, by restriction enzyme
digest and agarose gel extraction, they were quantified (as described) and included in
a ligation reaction in 1:1, 1:3 and 3:1 ratios of vector:insert. The ligation reaction
mixture also included T4 DNA ligase, ligase 10X buffer (Promega, UK) and dH20 to
a final volume of 10pl. The samples were incubated overnight at 16°C. The
following day 1 p.1 of each ligation reaction was transformed in competent cells and
colonies screened by DNA minipreps.
2.2.4.10 Phenol/Chloroform Extraction
Residual salts and nucleotides were removed from DNA and RNA samples by
phenol/chloroform extraction and ethanol precipitation. The DNA or RNA sample
was made up to a 400pl volume with dH20 and added to an equal volume of
phenol/chloroform (Sigma P-2069). The mixture was vortexed, centrifuged at
13,000g for 5 minutes at RT, the supernatant taken and added to 1ml of 100%
ethanol and 40pl of 3M sodium acetate (Sigma). The sample was incubated on dry
ice for 30 minutes, centrifuged at 13,000g for 30 minutes and the pellet resuspended
in 200pl of 70% ethanol. This was centrifuged at 13,000g for 15 minutes, the pellet
air dried and resuspended in nuclease free dH20.
2.2.4.11 Polymerase Chain Reaction (PCR) and Reverse Transcription PCR
(RT-PCR)
DNA sequences of interest were obtained from PubMed's DNA sequence programme
(BLAST), and primers were designed using Holyrood's gcg Prime program, or
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MacVector programme. They were tested for binding specificity using a DNA
Strider programme.
The reverse transcription of total RNA into first strand DNA, and the synthesis of
second strand complementary DNA (cDNA) and its amplification, was performed
using Promega's Access RT-PCR kit (A1280), which allows the two reactions to take
place in a single tube. The reaction was set up according to the manufacturer's
instructions. For simple PCR reactions the AMV reverse transcriptase was omitted.
Nuclease-free water was included as a negative control for each gene tested.
The thermocycler (Peltier Thermal Cycler-200 DNA engine, MJ Research) was
programmed as follows:
First strand synthesis:
1 cycle 48°C for 45 minutes (Reverse Transcription)
1 cycle 94°C for 2 minutes (Reverse Transcriptase inactivation and
RNA/cDNA/primer denaturation).
Second strand cDNA synthesis and PCR amplification:
35 cycles 94°C for 30 seconds (denaturation)
primer-specific Tm for 1 minute (annealing)
68°C for 2 minutes (extension)
1 cycle 68°C for 7 minutes (final extension)
Annealing temperatures (Tm) and number of cycles were optimised for each gene
(See Table 3).
2.2.4.12 RNA Isolation
Extraction of total RNA was performed using Trizol Reagent (GibcoBrl 15596-018)
as per the manufacturer's instructions. Briefly, cells or homogenised tissue was
suspended in Trizol and incubated for 5 minutes at RT, chloroform (Sigma C-2432)
was added (200pl per ml of Trizol), the tubes were shaken for 15 seconds and
incubated for 3 minutes at RT before centrifugation at 12,000g for 15 minutes at 4 C.
The aqueous phase was removed and added to isopropanol (500p.l per ml of Trizol),
incubated for 10 minutes at RT and centrifiiged at 12,000g for 10 minutes at 4 C.
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The RNA pellet was resuspended in 75% ethanol (1ml per ml of Trizol), vortexed
and centrifuged at 7,500g for 5 minutes at 4°C. The pellet was air dried and
resuspended in pre-warmed (55°C) nuclease free H20 (Promega, UK).
2.2.4.13 DNase Treatment of RNA
To remove any contaminating DNA the extracted RNA was DNase treated as per
manufacturers instructions (GibcoBRL DNase I, Amplification Grade). Briefly, lpg
of RNA was added to l|il of DNase I and lgl of 10X DNase I buffer; and DEPC
treated water added to a final reaction volume of lOpil. This was incubated for 15
minutes at RT, lpl of 25mM EDTA added and incubated for a further 10 minutes at
65°C.
2.2.4.14 Real-Time PCR
Higuchi et al 552 pioneered the analysis ofPCR kinetics by constructing a system that
detects PCR products as they accumulate in 'real time'. The reaction relies on the
5'nuclease activity of Taq DNA polymerase 553, which cleaves a probe that binds
specifically to its target DNA sequence. Only when the PCR product is amplified is
the probe cleaved, therefore the signal emitted by the probe corresponds to the
amount of product amplified in real-time.
Primers and probes were designed using Primer Express® software, supplied by PE
Biosystems (see Table 4). RNA samples for real-time PCR were reverse transcribed
into cDNA using TaqMan MultiScribe Reverse Transcriptase kit (PE Biosystems,
UK), as per the manufacturers instructions.
The thermocycler (Perkin Elmer) was programmed as follows:
1 cycle 25°C for 10 minutes, (incubation)
1 cycle 48°C for 30 minutes (reverse transcription)
1 cycle 95°C for 5 minutes (Reverse Transcriptase inactivation)
The fluorogenic probe, labelled with the fluorescent dye, fam (6-carboxy-
fluorescein), specifically annealed the template between the PCR primers. A
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sequence detector (ABI Prism 7700, PE Biosystems, USA) measured amplification
of the product, in direct proportion to the increase in fluorescence emitted by the
probe. Each sample was run in duplicates in 96-well optical reaction plates (PE
Biosystems). 25pl of the PCR reaction were added per well.
The thermal cycler conditions were standard for all the genes tested. These were:
40 cycles 50°C for 2 minutes
95°C for 10 minutes
95°C for 15 seconds
60°C for 1 minute
All the values obtained were normalised to 18S rRNA (labelled with the fluorescent
dye, 'vie'), which was included in the Multiplex PCR reaction (more than one primer
pair in the same tube) with its own set of primers and probe, as an internal
endogenous control. Furthermore, each sample was compared to a relevant positive
control, which was always given a value of 1. The data was plotted relative to the
positive control.
2.2.4.15 Northern Blotting
Before use the gel box, casting tray and combs were cleaned with mild detergent and
dH20. 2.89gm of agarose was added to 156ml of dH20 (1.4% agarose when poured)
and boiled until the agarose had melted, cooled to 60°C, 20ml of 20X MOPS and
34ml of 37% formaldehyde added and the gel gently poured, within a fume hood.
20(j.g of each RNA sample was resuspended in 5pl of TE and added to: lpl of 20X
MOPS (Sigma M-5755), lOpl of formamide (BDH 103266T), 3.5pl of 37%
formaldehyde (BDH 101135B), 0.15mg of ethidium bromide and 2(il of blue juice
(bromophenol blue/glycerol) dye. The samples were heat-denatured for 10-15
minutes at 60°C, loaded onto the gel next to an RNA ladder, and run at 60-70 volts
for 5-7 hours. The gel was visualised, next to a ruler, using the UVGrab program
connected to a white/ultraviolet transilluminator (UVP). The gel was then soaked in
dH20 for 30 minutes, in 20X SSC for 5 minutes, and transferred in 20X SSC
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(GibcoBrl 15557-028) to Hybond N+ (Amersham, UK) overnight. The Hybond N*
was baked for 3 hours at 68°C and a further image captured before hybridization.
The specific DNA probe (linearised DNA fragment for gene of interest,
normallyclkb) was then labelled with 32P-dCTP (Amersham Pharmacia Biotech,
UK) using the 'Ready-To-Go' DNA labelling beads (Amersham Pharmacia Biotech,
UK), as per the manufacturer's protocol. Briefly, 50ng of the DNA probe was
dissolved in TE to a final volume of 45pi, which was then denatured by incubation
for 2-3 minutes at 95-100°C and brief centrifugation. This and 5pl (50pCi) of the
32P-dCTP were added to the provided tube containing the Reaction Mix bead and
gently mixed; all with appropriate radioactivity shielding. Following an incubation
period of at least 30 minutes at 37°C, the unincorporated nucleotides were removed
using Nick Spin Columns (Amersham Pharmacia Biotech, UK) as instructed.
Hybridization was carried out using ExpressHyb Hybridization Solution (Clontech,
UK; 8015-1) following the manufacturer's protocol. Briefly, the ExpressHyb
Solution was warmed to 68°C, mixed well and 5ml added to the Hybond N+
membrane (wrapped in nylon), followed by a 30 minute incubation at 68°C with
continuous rotation in a Hybaid tube. The labelled probe was denatured as above,
chilled on ice and added to 5ml fresh pre-warmed (68°C) ExpressHyb Solution,
which replaced the original pre-hybridization solution for a further 60 minute
incubation at 68°C. This solution was then appropriately discarded, and the
membrane washed three times in solution 1 (2X SSC, 0.05%SDS) at RT, and twice
with solution 2 (0.1X SSC, 0.1%SDS) at 50°C; each wash lasting 40 minutes. The
labelled membrane was carefully mounted on Whatmann paper (Whatmann
International 1003917) and covered with plastic wrap. The membrane was finally
exposed to X-ray sensitive film between two intensifying screens at -70°C. Films
were processed through an X-ray developer (X-Ograph Imaging Systems, Wilts,
U.K.) at various exposure time points (1 hour, 6 hours, overnight and 4-7 days).
To remove a probe from a blot (to allow reprobing), the membrane was incubated for
20 minutes (with shaking) in preheated (95-100°C) H2O/0.5% SDS solution and air
dried. Membranes were stored at -20°C between use.
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2.2.4.16 Southern Blotting
Briefly, DNA samples were run on a 0.8% agarose gel at 20 volts overnight,
alongside a lkb ladder (Gibco). Similar to Northern blotting, the gel image was
captured next to a ruler and the gel transferred overnight (in 0.4M sodium hydroxide)
to a Hybond N (Amersham, UK) membrane. The membrane was then rinsed briefly
with 5X SSC, dried and UV cross-linked at 3000J (Hoefer UV cross-linker). DNA
probe preparation was as described above for Northern Blotting. Hybridization was
also as above apart from prehybridization and hybridisation steps taking place at
60°C rather than 68°C. Finally, the membrane was exposed to X-ray sensitive film
between two intensifying screens at -70°C and the films were processed through an
X-ray developer (X-Ograph Imaging Systems, Wilts, U.K.) at various exposure time
points (1 hour, 6 hours, and 1-3 days).
2.2.5 PROTEIN ANALYSIS
2.2.5.1 Lysis and Fractionization
Adherent cells were removed from the culture wells with trypsin-EDTA. The cells
were centrifuged at 300g for 5 minutes at 4°C and washed twice in ice cold PBS (D-
8662) with further centrifiigation 300g for 5 minutes at 4°C with each wash. They
were then resuspended in cytoplasmic lysis buffer and incubated on ice for 10
minutes. The samples were centrifuged at 4300g for 10 minutes at 4°C and the
supernatants (cytoplasmic extract) removed. The pellets were resuspended in nuclear
lysis buffer and incubated on ice for a further 10 minutes. These samples were spun
at 23,100g for 10 minutes at 4°C and the supernatants (nuclear protein) taken.
For subcellular fractionization (SCF), the cells were trysinized and washed as before.
They were then resuspended in a physiological buffer and homogenized by 10-20
strokes of a Dounce homogenizer (Uniform), and the lysate centrifuged at 500g for
10 minutes at 4°C. Membranous and cytosolic material was obtained by centrifgation
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at 500,000g (Optima TLX Ultracentrifuge) for 10 minutes at 4°C. The supernatant
was designated the cytosolic fraction, and pellets, resuspended in physiological
buffer (with 0.1% SDS), the membranous fraction.
2.2.5.2 Protein Quantification
The extracted protein was quantified by one of two methods. For most samples a
BCA Protein Assay Kit (Pierce, USA; 23225) was used as per the manufacturer's
instructions. Briefly, the provided standards and samples were aliquoted at
appropriate dilutions into a 96 well plate. Following a 30 minute incubation at 37°C
the plate was read by a microplate reader (Dynex Technologies MRX) set to a
wavelength of 560nm.
As the physiological buffer used for SCF was incompatible with the BCA kit,
protein extracts were quantified using a Bio-Rad Protein (Bradford) Assay (Bio-
Rad Laboratories,UK), as per the manufacturers instructions. Briefly, 800pl of
appropriately diluted standards and samples were added to 200pl of the provided
dye reagent concentrate, and mixed well. Following a 10 minute incubation, the
OD595 (against a reagent blank) was measured in a spectrophotometer (Ultrospec
200, Pharmacia Biotech).
2.2.5.3 Immunoblotting
8% or 15% mini SDS-poly acrylamide gel electrophesis (PAGE) gels were cast with
5% stacking gels. Quantified protein samples were added to 2X sample buffer
(Sigma S-3401) and electrophoresed at 200 Volts, in SDS-Tris-Glycine
Electrophoresis Buffer, for one hour beside pre-stained molecular weight markers
(Gibco BRL, Paisley, U.K.). They were then transferred to nitrocellulose (Amersham
Pharmacia Biotech, Amersham, U.K.) in Methanol Based Transfer Buffer at 400
milliAmps for 1 hour. The membranes were incubated in Ponceau S solution (Sigma
P7170, 0.1% Ponceau S in 0.5% acetic acid) for 5 minutes at room temperature and
rinsed briefly with distilled water to allow transferred protein to be visualized, thus
confirming equal protein loading between lanes. Non-specific protein binding sites
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on the nitrocellulose membrane were blocked by incubation of the membranes in
40ml of Western Blot Blocking Buffer for one hour at room temperature (RT) or
overnight at 4°C. Membranes were washed 3 times in 50 ml of Western Blot
Nitrocellulose Wash Buffer for 5 minutes. Appropriate primary antibodies were
diluted in 20ml of the blocking buffer and incubated for one hour at RT with constant
shaking. Membranes were washed 5 times with 50ml of the wash buffer at RT. For
detection, horseradish peroxidase (HRP) conjugated antibodies were diluted in 20ml
of the blocking buffer and incubated with the membranes for one hour at RT with
gentle shaking. Membranes were washed a further 5 times with 50ml of the wash
buffer before 5 minute incubation with ECL reagent (Amersham Pharmacia Biotech,
Amersham, U.K.). Excess ECL reagent was removed and the membrane placed
under BioMax MS-1 X-ray sensitive film. Films were processed through an X-ray
developer (X-Ograph Imaging Systems, Wilts, U.K.) at various exposure time points
(eg.lmin, 3min, 5 min and 10 minutes). Optimally exposed films were photographed
using a white trans-illuminator and gel documentation system (Ultra Violet Products,
Cambridge, U.K.).
For P-catenin detection the samples were run on an 8% SDS-PAGE gel. The primary
mouse IgGl anti-mouse P-catenin monoclonal antibody (Affiniti Research Products
Ltd, UK) was diluted 1:500, and the secondary HRP-Goat anti-mouse Ig antibody
(Dako Corporation, Carpinteria, CA, USA) was diluted 1:2000. For Dvll detection
the samples were run on an 8% SDS-PAGE gel. The primary rabbit anti-Dvll
polyclonal antibody (gift from Roel Nusse, Stanford University, California, USA)
was diluted 1:1000, and the secondary HRP-Donkey anti-rabbit Ig antibody
(Amersham Life Science) was diluted 1:5000. For Sonic hedgehog (Shh) detection
the samples were run on a 15% SDS-PAGE gel. The primary goat anti-N-Shh
polyclonal antibody (Santa Cruz Biotechnology, Insight Biotechnology Ltd.
Wembley, Middlesex, England) was diluted 1:200, and the secondary HRP-Rabbit
anti-goat Ig antibody (Dako Corporation, Carpinteria, CA, USA) was diluted 1:2000.




Immunohistochemistry was performed on a Bio-Genex automatic staining machine
(Menarini Diagnostics, Wokingham, Berkshire, UK) or using a Sequenza (Shandon).
Briefly, 3 pm sections of paraffin-embedded tissues were dewaxed in xylene,
followed by microwave antigen retrieval using Antigen Retrieval Buffer (Vector
Laboratories Ltd., Peterborough, UK) as per the manufacturers instructions. The
slides were then blocked with 3% hydrogen peroxide (Sigma H-1009), followed by
20% rabbit or goat serum. Avidin/biotin blocking (Avidin/Biotin blocking kit, Vector
Laboratories) was used as appropriate and slides were washed with PBS (D-8662)
between steps. Slides were incubated with the primary antibody diluted in
appropriate serum for 30-120 minutes at room temperature (RT) or overnight at 4°C,
washed with PBS and incubated with a biotinylated secondary antibody for 30
minutes at RT. They were washed again, Vector RTU ABC (Vector Laboratories
[binds to biotin]) applied and positive signal was visualised by the addition of
diaminobenzidine (DAKO). Sections were counterstained with haematoxylin.
The following secondary antibodies and blocking sera were used: biotinylated rabbit
anti-goat IgG (1:400 dilution, DAKO UK Ltd, Ely Cambridgeshire, UK);
biotinylated goat anti-chicken Ig (1:250 dilution, Vector Laboratories, Ltd.,
Peterborough, UK); biotinylated goat anti-rabbit Ig (1:300 dilution, DAKO, UK);
biotinylated rabbit anti-mouse IgG (1:300 dilution, DAKO UK); normal goat, rabbit,
mouse and chicken serum (Scottish Antibody Production Unit, Carluke, Scotland,
UK), normal human serum (Sigma-Aldrich Ltd, Poole road, Fancy, Dorset, UK).
Primary antibodies to the N-terminus of Shh (goat, 1:40 dilution), the C-terminus of
Ptc (goat, 1:30 dilution) [both Santa Cruz Biotechnology, Insight Biotechnology Ltd.
Wembley, Middlesex, England], TGF-pl (chicken, 1:50 dilution, R&D Systems
Europe, Abingdon, UK) and P-catenin (mouse monoclonal, 1:500 dilution, Affiniti
Research Products Ltd, UK) recognised murine and human proteins. Other primary
antibodies included anti-Dvll (rabbit, 1:200 dilution, gift from Roel Nusse, Stanford
University, USA), anti-Ki67 (mouse monoclonal, 1:200 dilution, Novocastra, UK)
and anti-FITC (rabbit, 1:1000 dilution, DAKO, UK).
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All primary antibodies were diluted in 20% normal human or mouse serum to block
background reactivity on human or mouse tissue sections respectively, and blocking
peptides (Santa Cruz Biotechnology, Insight Biotechnology Ltd. Wembley,
Middlesex, England) were used as additional controls in conjunction with Shh and
Ptc antibodies. Images were captured using a Progres 3012 camera (Kontron
Elektronik) through a Zeiss Axioskop microscope.
2.2.6 T CELL EXPERIMENTS
2.2.6.1 Human PBMC isolation
Human peripheral blood mononuclear cells (PBMC) were isolated by centrifugal
separation over Histopaque 1077 (Sigma H-8889). Briefly, single donor BufFy Coats,
obtained from the Blood Transfusion Centre (Royal Infirmary of Edinburgh, UK)
after viral screening, were made up to a volume of 200mls with D-PBS ((D-8537)),
roughly equivalent to a 1:1 ratio. This was then layered in 25ml aliquots onto 15ml
of Histopaque 1077 in eight 50ml falcon tubes and centrifuged at 800g for 25
minutes at room temperature. The mononuclear cell layer was gently aspirated and
washed 2 times with 2 volumes of D-PBS and centrifuged at 300g for 7 minutes at
room temperature. The pooled pellets were then resuspended in 50ml of PBS and
counted using a haemocytometer chamber with 0.4% trypan blue exclusion (Sigma).
Cells were resuspended at lxl08/ml in D-PBS, to which 4ml of red blood cell lysis
buffer was added per ml ofPBS. The suspension was incubated on ice for 10 minutes
before further centrifugation at 300g for 7 minutes at room temperature. The PBMC
were resuspended in D-PBS, recounted and purified using either MACS or T cell
columns as described below.
2.2.6.2 Cell Purifications
Human CD4+or CD8+expressing cells were separated from PBMC suspensions to
generate near pure populations. This was performed either using a magnetic cell
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separation method (MACS; Miltenyi Biotec, Surrey, UK) or human T cell subset
negative selection affinity columns (R&D Systems, UK) both according to the
manufacturer's instructions.
Briefly, for the former, single cell suspensions were generated as described above
with the final resuspension in MACS buffer prior to a 15 minute incubation with
antibody coated microbeads. Excess microbeads were removed by washing and
labelled cells were passed through a magnetised positive selection column (Miltenyi
Biotec, Germany). The selection column was washed with several volumes ofMACS
buffer, removing any unlabelled cells. The column was demagnetised and cells
bearing the antigen of interest (i.e. CD4 or CD8) were expelled from the column with
5ml MACS buffer.
For T cell negative selection, the PBMCs were resuspended in the sterile column
buffer provided to which the provided monoclonal antibody cocktail was added
followed by a 15 minute incubation at room temperature. The cells were washed
twice in column buffer and centrifuged at 300g for 10 minutes, then resuspended in
column buffer and added to the negative selection columns. Following a further 10
minute incubation the cells of interest were eluted with 12ml of column buffer.
After either of the above selection methods, cells were washed in complete human
RPMI culture media and counted using a haemocytometer with 0.4% trypan blue
exclusion. Using these methods of purification typically generated >93% pure
populations.
2.2.6.3 Polyclonal TCR stimulation using plate bound and soluble antibodies
Stimulation of purified T cell populations was performed using the combination of
monoclonal antibodies against CD3s and CD28 (Pharmingen, San Diego, CA, USA).
The anti-CD3s monoclonal antibody was immobilised onto plastic by diluting the
antibody to final concentrations of l-5pg/ml in D-PBS (D-8662) and dispensing 50pl
of the diluted monoclonal per well of a flat bottomed 96 well plate. The plates were
incubated for 16 hours at 4°C. Wells were washed three times with ice cold D-PBS
to remove excess unbound antibody. Purified cells were plated out at 1x10 per well
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in complete RPMI 1640 (106cells/ml). Anti-CD28 monoclonal antibodies were added
to the wells at a final concentration of 5pg/ml diluted in the appropriate cell culture
buffer. Addition of either exogenous soluble N-Shh peptide or 5E1 antibody was
performed prior to incubation at 37°C in a humidified incubator with 5% C02 for 72
hours. Proliferation was assessed by incorporation of tritiated methyl thymidine and
assayed as described below.
2.2.6.4 Proliferation
Proliferation was assessed by addition of excess (lpCi/well) tritiated methyl
thymidine (3H-TdR-Amersham Pharmacia Biotech, Amersham, UK). Plates were
harvested onto glass fibre filtermats (Wallac, Milton Keynes, U.K.) with an
automated 96 well plate harvester (Tomtec, Harborview, USA), dried and sealed in
plastic bags (Wallac, Milton Keynes, U.K.) with 10ml of scintillation fluid (Wallac,
Milton Keynes, U.K.). 3H-TdR incorporation was assessed using a liquid scintillation
counter Betaplate 1205 (Wallac, Milton Keynes, U.K.) and associated software.
Counts per minute (cpm) observed per sample were indicative of the extent of
proliferation. All samples were tested in triplicate or sextuplet and each experiment
repeated three times unless otherwise stated.
2.2.6.5 Apoptosis Assay (AnnexinV-FITC staining)
AnnexinV-FITC conjugate binds phospholipid phosphatidylserine (PS). PS is
translocated from the inner leaflet of the plasma membrane to the outer leaflet during
very early phases of apoptosis and can thus bind AnnexinV-FITC extracellularly. It
can therefore be used as an early indicator of programmed cell death in flow
cytometry. Propidium Iodide, used in conjunction with AnnexinV-FITC, detects
membrane integrity of the cells, thus distinguishing necrotic from apoptotic cells.
AnnexinV-FITC staining of cells was performed using an apoptosis detection kit
following the manufacturer's instructions (Pharmingen, BD, USA). Cells boiled for
2-3 minutes at 95°C were used as control "dead cells". Briefly, cells were washed
- 117-
twice in cold PBS (D-8537) and centrifiiged at 300g for 7mins at 4°C, resuspended
in the supplied lx binding buffer at 105 cells/lOOul, and added to flexible 96 round-
bottom well plates (Becton Dickinson). 5pi of AnnexinV-FITC and 2pl of PI were
added per 10 cells and incubated for 15 minutes in the dark at room temperature.
Cells were resuspended in 400pl lx Binding Buffer and analysed by flow cytometric
analysis using a Becton Dickinson FACSCalibur (BDIS, San Jose, CA, USA).
2.2.6.6 Flow Cytometry
All flow cytometry was performed on a Becton Dickinson FACSCalibur (BDIS, San
Jose, CA, USA) and experiments were repeated at least three times. Phenotypic
analysis of human cell surface markers was accomplished using Phycoerythrin (PE)
and Fluorescein isothiocyanate (FITC) conjugated monoclonal antibodies
(Pharmingen, San Diego, CA, USA) recognising the following cell surface proteins
(CD3, CD4, CD8, CD25, CD69). Appropriate isotype controls were also purchased
from Pharmingen. Briefly, cells of interest were washed in ice-cold D-PBS (D-8537)
and resuspended in FACS staining buffer at a maximum final concentration of 106
cells per lOOpl. lpg of relevant monoclonal antibody was added per 106 cells and
incubated in the dark at 4°C for 30 minutes. Samples were washed three times with
ice-cold D-PBS and resuspended in ice-cold FACS fixing solution. Fixed samples
were kept at 4°C and analysed as specified by Becton Dickinson within 48 hours of
staining and fixing.
2.2.6.7 Enzyme Linked ImmunoSorbant Assay (ELISA)
Cytokine secretion was analysed by detecting soluble protein in aliquots of
supernatants or bronchoalveolar lavage fluid as appropriate. Reagents for IL5
detection and standards were purchased from Pharmingen (San Diego, CA, USA).
Briefly, the anti-IL5 capture antibody was diluted to lpg/ml in ELISA binding
buffer. 50pl of diluted capture antibody was added to the wells of enhanced protein
binding ELISA plates (Corning, NY, USA). The plates were sealed and incubated
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overnight at 4°C. Capture antibody was removed, 200pl of ELISA blocking buffer
was added to each well and the plates incubated at 37°C for one hour. Wells were
washed 3 times with ELISA wash buffer and 50pi of standards and samples were
added to the wells (appropriately diluted in ELISA blocking buffer). Plates were
sealed and incubated overnight at 4°C. Wells were washed 4 times with 200pl
ELISA wash buffer and 50pl of lgg/ml biotinylated IL5 detection antibody diluted
in ELISA blocking buffer was added to each well. Plates were incubated for one hour
at room temperature, after which wells were washed 5 times with 200pl ELISA wash
buffer. 50pl of 1 in 2000 diluted (manufacturer's instructions) Streptavidin-alkaline
phosphatase conjugate (Amersham Life Sciences, Amersham, U.K.) was added to
the wells and incubated for 30 minutes at room temperature. Wells were washed 5
times with ELISA wash buffer to remove excess alkaline phosphatase and lOOpl of
substrate solution was added to wells. Plates were placed in the dark for colour
change to occur and assayed at 10 minute intervals on a Microplate Reader 450
(BioRad Laboratories, Hemel Hempstead, U.K.) and associated software.
IL2, IL10, IFNyand TGF(31 were measured using Duoset ELISA development
system kits (R&D systems, UK) following the manufacturer's protocols. As the
TGFpi kit only measured active TGFpi, latent TGFpi was activated as per the
manufacturers instructions to allow total TGFpi to be determined. The plates were
read by a microplate reader set (Dynatech Laboratories MRX) to a wavelength of
450nm with a reference of 550nm.
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Grade of fibrosis Histological Features
0 Normal lung
1 Minimal fibrous thickening of alveolar or bronchiolar
walls
2
3 Moderate thickening ofwalls without obvious damage to
lung architecture
4
5 Increased fibrosis with definite damage to lung structures
and formation of fibrous bands or small fibrous masses
6
7 Severe distortion of structure and large fibrous areas:
'honeycomb lung' is placed in this category
8 Total fibrous obliteration of field
Table 2: Ashcroft scoring system for lung fibrosis
Table lists scoring system used to grade fibrosis in the lungs of FITC-treated
lung mice. This is taken from the original paper by Ashcroft et al (see text for
reference)
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Human Ptc For: CCATGTTCCAGTTAATGACTC
Rev: ACATCATCCACACCAACA
462 58






Table 3: Primers used for PCR and RT-PCR
Table lists primers used for all PCR discussed in thesis, including length of
products and optimal annealing temperatures (Tm). Dvl1 A+B refers to 2
different primer pairs (see Chapter 5). For: Forward Primer, Rev: Reverse
Primer.
64*: Touchdown PCR reaction with Tm reducing by 0.5°C per cycle.
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Gene Primer Sequence (5'-3') and Probe
Human Ptc For: CGGCAGCCGCGATAAG
Rev: TTAATGATGCCATCTGCATCCA
Probe: ATCGACATCAGCCAGTT GACTAAACAGCGTC
Mouse Dvll For: AGCACCTCCTCTCGGCTAGTT
Rev: GGGACATGGTGGAGTCTGTGAT
Probe: AAGCACAAATGCCGTCGTCGGAA
Mouse Shh For: TGACCCCTTTAGCCTACAAGCA
Rev: TTCTTGTGATCTTCCCTTCATATCTG
Probe: TTTATTCCCAACGTAGCCGAGAAGACCC
Mouse Ptc For: CTCCAAGTGTCGTCCGGTTT
Rev: TGTACTCCGAGTCGGAGGAATC
Probe: CGTGCCTCCTGGTCACACGAACAA
Table 4: Primers and Probes used for Real-Time PCR
Table lists primers and probes used for all Real-time PCR discussed in thesis.
For: Forward Primer, Rev: Reverse Primer.
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Chapter 3




As discussed in Chapter 1 the Sonic hedgehog (Shh) signalling pathway plays an
important role in lung development55'94. In this respect it interacts with other genes
such as TGFP and FGFs ,01'102>104 Significantly, such genes are known to be
associated with the pathogenesis of interstitial lung disease (ILD) or lung fibrosis
353,358
Upregulation of the Shh pathway results in increased proliferation of many cell
types, including epithelial cells 116417 Indeed, as described in Chapter 4, the Shh
pathway is also involved in regulation of T lymphocytes. The pathway has been
reported to induce epithelial and mesenchymal hyperplasia when overexpressed in
vivo 56, both features of ILD 292>293.
The combination of the interactions with other genes important in fibrosis and the in
vitro and in vivo increased proliferation associated with overexpression of Shh
prompted this investigation into whether or not the Shh pathway was induced in ILD.
To address this question, a murine model of ILD 408, induced by intra-tracheal
instillation of fluorescein isothiocyanate (FITC), and archival human biopsy
specimens from patients with idiopathic pulmonary fibrosis (EPF) were used.
Expression of components of the Shh pathway and TGFpl were determined by
immunohistochemistry (IHC).
In this chapter the expression of these proteins is investigated, as are the effects of
FITC treatment in mice deficient of downstream genes in the Shh pathway. In
addition an attempt to upregulate Shh in lung epithelial cells in vivo using a naked
DNA vector is described.
- 124-
3.2 Reproducing the FITC Model
The FITC model of ELD is described in more detail in chapter 1. In the original paper
the trachea was exposed surgically and lOOp.1 of PBS or FITC resuspended in PBS
instilled, a procedure which resulted in a 5-10% mortality within 24 hours 408. An
alternative non-surgical approach has been developed as described below and in
chapter 2. The results presented in this chapter were verified in lung sections from
mice receiving FITC by both methods.
3.2.1 INTRA-TRACHEAL INSTILLATION OF FITC
PBS or FITC was instilled intra-tracheally as detailed in chapter 2. Briefly the
sample was instilled via an oral approach with no surgical intervention required. The
new approach offered the advantage of a reduced mortality (<1%). However, a
potential disadvantage was that the vocal cords were occasionally poorly visualised,
but, with experience, the trachea could still be accurately located in such
circumstances.
Mice were killed at time-points from 24hrs to 5 months following instillation. The
lungs were inflated, formalin fixed and 3 pm sections cut. In the first instance
sections were examined under a fluorescent microscope to ensure FITC had been
deposited in the lungs. This was followed by confocal microscopy. These methods
confirmed FITC deposition in a patchy distribution particularly localised around the
airways (Figure 3.1A).
FITC could also be detected by IHC using a specific anti-FITC antibody (Figure 3.1
B-F). At the earlier time-points (3 days) the staining was intense. Although noted
throughout the lungs it was often at its strongest within the airway epithelial cells
(Figure 3. IB), as one might expect as they present one of the first points of contact
for an antigen delivered by the an intra-tracheal route. Furthermore, alveolar
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macrophages were also strongly positive suggestive of uptake of the free FITC and
probable processing by the immune system (Figure 3.1C). The FITC could also be
detected at the 5 month time-point, though generally with a more localised
distribution. As before staining was notably patchy; some areas showed intense
staining and others no evidence of FITC at all (Figure 3. ID). This was in keeping
with the free FITC particles having been deposited in a random manner following
instillation, and with appearances previously observed in the model 408. Sites ofFITC
deposition corresponded to areas of scarring and fibrosis, and areas free of FITC
were often histologically normal. At this later time-point the staining was
predominantly peribronchial (Figure 3.1 E and F) as observed in the original paper,
in which it was suggested that the FITC may be binding to elastin fibres surrounding
., • 408the airways
A section from every mouse was stained with the anti-FITC antibody to ensure FITC
had been successfully delivered into the lungs. If the staining was negative the lung
was not used for further analysis.
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Figure 3.1: FITC deposition in mouse lungs
All sections are from FITC treated mice; magnifications are indicated in brackets
A) FITC fluorescence at day 3 post instillation as viewed by confocal
microscopy (x100). Patchy FITC deposition (bright green) against background
auto-fluorescence. Remaining pictures are sections stained with anti-FITC
antibody. B) Strong epithelial cell staining 3 days after FITC (x200). C) Positive
alveolar macrophages 3 days after FITC (x400). D) Patchy FITC staining 5
months after FITC (x100). E) Peribronchial staining 5 months after FITC (x200)
and F) x400.
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3 .2.2 LUNG MORPHOLOGY FOLLOWING FITC TREATMENT
Lung sections from FITC or PBS treated mice were stained with haematoxylin and
eosin to allow morphology to be assessed (Figure 3.2). PBS treated mice sections
were normal with no evidence of epithelial cell damage, cellular infiltration nor
fibrosis (Figure 3.2 A-C). Although only the day 7 time-point is shown appearances
were similar at all time-points.
The FITC treated mice sections were altogether different. At the earlier time-points
(days 3 and 7) there was a marked mononuclear cell and neutrophil infiltrate mainly
surrounding the airways and, in some cases, spreading throughout the interstitium
(Figure 3.2 D-F). As with FITC deposition this was often in a patchy distribution
(Figure 3.2D). There was evidence of damaged airway epithelial cells, which
appeared "peg-like", and of epithelial sloughing (Figure 3.2E).
By 5 months there was evidence of alveolar wall thickening and oedema (Figure
3.2G). A chronic, predominantly mononuclear inflammation was noted and areas of
established largely peribronchial fibrosis often corresponding with FITC deposition.
In many areas the normal lung architecture had been completely destroyed, replaced
by scar and fibrous tissue (Figure 3.2 H and I).
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Figure 3.2: Haematoxylin and Eosin (H&E) staining of FITC and PBS
treated mouse lungs
Magnifications are indicated in brackets
Normal lung architecture and morphology: A) 7 days after PBS (x100). B) 7
days after PBS (x200) C) 7 days after PBS (x400).
Patchy peribronchial cell infiltrate and evidence of epithelial cell damage: D) 3
days after FITC (x200). E) 3 days after FITC (x400). F) 7 days after FITC
(x400).
Evidence of alveolar wall thickening, persisting mononuclear cell infiltrate and
fibrosis: G) 5 months after FITC (x200). H) 5 months after FITC (x200). I) 5
months after FITC (x400)
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3.2.3 SCORING FIBROSIS IN THE FITC MODEL
Lung sections from FITC and PBS treated mice were each given a fibrosis score
based on a scoring system devised by Ashcroft et al551, as described in Chapter 2.
This was to allow comparison between different treatment groups and time-points.
For each time-point sections from six FITC treated mice and two PBS mice were
analysed, all treated by the new intra-tracheal approach discussed earlier. The FITC
sections were further subdivided into FITC +ve and FITC -ve fields, because of the
correlation noted between areas of FITC deposition and lung fibrosis in the original
paper by Roberts et al 408. The chosen time-points were 3 days, 1 week and 6 weeks
after a single instillation or following a second instillation (FITC or PBS),
administered 6 weeks after the first. Ashcroft scores for each group were averaged as
shown in table 5.
Ashcroft scores from the three groups (PBS, FITC +ve and FITC -ve) were then
statistically compared using the Mann-Whitney Test (Instat) as shown in table 6.
FITC -ve fields did not differ significantly from PBS treated mice at any time-point.
There was no significant difference between any of the groups following the first
instillation. However Ashcroft scores were significantly higher in the FITC +ve
fields when compared to both FITC -ve fields and PBS treated mice, following the
second instillation. These results show that there was significantly more fibrosis, as
assessed by Ashcroft scoring, in FITC treated mice, but only following a second
treatment and only in association with FITC +ve areas (Table 6).
Each of the three groups was then analysed longitudinally. Ashcroft scores from each
time-point were compared to the score at 3 days following the first instillation,
within the same group (Table 7). In the FITC +ve group, all scores following the
second FITC instillation were significantly higher than the 3 day time-point. There
was no significant difference in the FITC -ve or PBS groups between any of the
time-points, except 6 weeks following the second instillation. In both groups the
score at this time-point was significantly higher than the score at 3 days. This may
have been indicative of mice developing disease due to environmental exposure in
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the animal house. Importantly, as described above, there was no significant
difference between these two groups at this time-point, and the scores of both were
significantly lower than the FITC +ve group (Table 7). Taken together, these results
confirm significantly higher fibrosis scores in FITC +ve fields following a second
instillation ofFITC.
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Ashcroft Scores PBS FITC +ve IFITC -ve
3 days 0.0014 ±0.0014 0.0007 + 0.0007 0.0006 + 0.0006
1 week 0.0009 + 0.0009 0.0008 + 0.0008 0.0006 + 0.0006
6 weeks 0.0028 + 0.0028 0.0185 + 0.0185 0.0056 + 0.0056
6 weeks + 3 days 0.0009 + 0.0009 0.9928 + 0.06328 0.0226 + 0.0112
6 weeks + 1 week 0.0005 + 0.0005 1.746 + 0.1567 0.01852 + 0.0075
6 weeks + 6 weeks 0.337 + 0.0465 1.595 + 0.0749 0.3827 + 0.0398
Table 5: Mean Ashcroft scores in the FITC fibrosis model
Table lists mean Ashcroft scores (and standard errors) in PBS treated mice,
and in FITC +ve and -ve fields from FITC treated mice
p values PBS versus -ve PBS versus FITC+ve FITC+ve versus -ve
3 days ns ns ns
1 week ns ns ns
6 weeks ns ns ns
6 weeks + 3 days ns <0.001 <0.001
6 weeks + 1 week ns <0.001 <0.001
6 weeks + 6 weeks ns <0.001 <0.001
Table 6: Comparative Ashcroft scores in the FITC fibrosis model
Table lists statistical analysis of Ashcroft scores from table 5, comparing each of
the three groups. Results show statistical significance between FITC +ve fields
and both PBS and FITC -ve fields (p<0.001), but only at the time-points
following a second treatment (6 weeks+). There was no significant (ns)





3 days vs 6
weeks
3 days vs





3 days vs 6 weeks + 6
weeks
PBS ns ns ns ns <0.001
FITC+ve ns ns <0.001 <0.001 <0.001
FITC -ve ns ns ns ns <0.001
Table 7: Longitudinal Ashcroft scores in the FITC fibrosis model
Table lists statistical analysis comparing Ashcroft scores from each group with
the 3 day score from that group. Results show significant differences between 3
days and all of the second treatments (6 weeks+) within the FITC +ve group.
There were also statistical significance in the PBS and FITC -ve groups, in
relation to the final time-point, which may be related to mice developing disease
due to environmental exposure in the animal disease, (ns. not significan )
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3.3 Immunohistochemistry in the FITC Model
Lung sections from FITC or PBS treated mice were stained with antibodies against
Shh, Patched (Ptc) and TGFpi. IHC was performed on sections from 24hrs to 5
months, with at least six mice included for each treatment at every time-point. The
results shown are representative of features noted at all time-points.
3.3.1 SONIC HEDGEHOG EXPRESSION IN THE FITC MODEL
Expression of Shh protein was analysed using the goat polyclonal anti-Shh antibody
(Santa Cruz Biotechnology). The specificity of this antibody was demonstrated by
Western Blotting (Figure 5.16). This antibody was raised against the amino terminus
of Shh, which remains membrane bound. Shh IHC was carried out on lung sections
from FITC or PBS treated mice. The observed Shh staining was specifically blocked
when the associated Shh blocking peptide (Santa Cruz) was introduced (data not
shown).
Shh expression was markedly upregulated in the FITC treated mice when compared
with the corresponding PBS controls (Figure 3.3). This was noted at all time-points
from 3 days to 5 months. The staining, though particularly strong on the bronchial
and alveolar airway epithelial cells (Figure 3.3 B, D and F), was also present on
infiltrating mononuclear cells (Figure 3.3F). This latter feature is consistent with
findings presented in chapter 4 (Figure 4.1) where Shh expression is confirmed in
human T lymphocytes.
It would, therefore, appear that Shh protein expression is upregulated in the FITC
model of fibrosis.
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Figure 3.3: Shh expression in FITC and PBS treated mouse lungs
Magnifications are indicated in brackets
Shh IHC in mouse lungs A) 3 days after PBS (x400). B) 3 days after FITC
(x400). C) 7 days after PBS (x400). D) 7 days after FITC (x400). E) 5 months
after PBS (x400). F) 5 months after FITC (x400). At all time-points Shh
expression is notably upregulated in the FITC treated mice, particularly in the
airway epithelium
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3.3.2 PATCHED EXPRESSION IN THE FITC MODEL
Ptc, the Shh receptor, expression was then assessed by IHC on the same lung
sections.
Ptc was expressed in both PBS and FITC treated mice with no appreciable difference
between the intensity of staining between the treatment groups (Figure 3.4). As with
Shh, the bronchial and alveolar airway epithelium was strongly positive. Most
notably the alveolar and interstitial macrophages were also strongly positive for Ptc
throughout, as were the infiltrating mononuclear cells (Figure 3 .4 D and F). This was
more noticeable in the FITC treated mice as many more of these immune cells were
present in the lungs. The presence of Ptc and Shh on these immune cells is in
accordance with data presented in chapter 4 (Figure 4.1) in which expression of both
of these proteins on human T lymphocytes is demonstrated. Ptc staining was
specifically blocked when the associated Ptc blocking peptide (Santa Cruz) was
introduced (data not shown).
Using IHC there is no evidence of Ptc upregulation in the FITC model of fibrosis.
Unlike Shh, there appears to be constitutive Ptc expression in mouse lungs. Its
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Figure 3.4: Ptc expression in F1TC and PBS treated mouse lungs
Magnifications are indicated in brackets
Ptc IHC in mouse lungs A) 3 days after PBS (x400). B) 3 days after F1TC
(x400). C) 7 days after PBS (x400). D) 7 days after FITC (x400). E> 5 months
after PBS (x200). F) 5 months after FITC (x400). Throughout the time-points Ptc
expression is very similar in the airway epithelium in FITC and PBS treated
sections. Notably Ptc is expressed in the alveolar macrophages and cell
infiltrates
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3.3.3 TRANSFORMING GROWTH FACTOR-BETA EXPRESSION IN THE FITC
MODEL
TGFP already has a proven role in the pathogenesis of ILD 358. However its
expression has not been analysed in the FITC model. TGFpi IHC was therefore
carried out on lung sections from FITC and PBS treated mice.
TGFpi expression was markedly upregulated in the FITC treated mice when
compared with the corresponding PBS controls (Figure 3.5). The bronchial airway
epithelial cells stained particularly strongly (Figure 3.5 D and F). In addition alveolar
and interstitial macrophages, and infiltrating mononuclear cells were also positive
(Figure 3.5 D+F). These findings are in keeping with published work on TGFpi
353-357
expression in other animal models and lung fibrosis in humans
As would be expected TGFpi is upregulated in the FITC model of lung fibrosis.
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Figure 3.5: TGFpi expression in FITC and PBS treated mouse lungs
Magnifications are indicated in brackets
TGFpl IHC in mouse lungs A) 3 days after PBS (x200). B) 3 days after FITC
(x200). C) 7 days after PBS (x400). D) 7 days after FITC (x400). E) 5 months
after PBS (x400). F) 5 months after FITC (x400). As with Shh, TGFpi
expression is notably upregulated in the FITC treated mice throughout the time-
points, both in the airway epithelium and the cell infiltrates.
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3.4 Immunohistochemistry in Idiopathic Pulmonary Fibrosis
(IPF)
Having demonstrated the expression of Shh, Ptc and TGF(31 in the FITC model of
lung fibrosis the next objective was to stain for these same proteins in archival
human biopsies taken from patients with IPF, also known as Cryptogenic Fibrosing
Alveolitis (CFA) and more recently classified as usual interstitial pneumonia (UIP).
The pathology of IPF is discussed in more detail in chapter 1. However, to reiterate,
the features include a patchy distal lung fibrosis, a mononuclear interstitial cell
infiltrate, type II epithelial cell hyperplasia and metaplasia, and smooth muscle
proliferation. The data is representative of staining of biopsy material from six
patients with IPF. Histologically normal areas from these sections were used as
controls.
Shh was expressed in the remodelling type II epithelial cells and ciliated metaplastic
respiratory epithelial cells at diseased sites but not in histologically normal areas
(Figure 3.6 A, B, C and E). The protein was present in the cytoplasm and on the cell
surface and, at higher magnifications, it was evident that Shh positive and negative
cells lay in juxtaposition (Figure 3.6 C). The characteristic hypertrophic smooth
muscle also stained positively for Shh (Figure 3.6 B [arrow] and D). As in the FITC
model Ptc was uniformly expressed in the bronchial airway (type II) epithelial cells
(Figure 3.6 G). In IPF sections expression was notable both in diseased and normal
sites, consistent with significant constitutive Ptc expression (Figure 3.6 F and G). Ptc
was also notably present on the mononuclear cell infiltrates and alveolar
macrophages (Figure 3.6 F and H). As both the Shh and Ptc antibodies were raised in
goat, normal goat serum was used as a negative control. This confirmed no
background non-specific staining (Figure 3.6 L).
TGFpi expression was detected in both hyperplastic type II epithelial cells and
metaplastic bronchial epithelial cells at sites of remodelling (Figure 3.6 J and K). It
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was also present in alveolar macrophages and in the interstitial infiltrate (Figure 3.6
K). It was not, however, expressed in histologically normal alveoli (Figure 3.6 I).
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Figure 3.6: Shh, Ptc and TGFpi expression in Idiopathic Pulmonary
Fibrosis (IPF)
All IHC in human IPF sections: comparing histologically normal areas (A, F + I)
with fibrotic lung (remaining sections). Magnifications are indicated in brackets
A) Shh IHC (x400) Shh is not expressed in histologically normal areas B) Shh
IHC (x100) Hypertrophic smooth muscle is arrowed and boxed area is shown in
C) Shh IHC (x400). Staining of metaplastic epithelial cells. Shh positive and
negative epithelial cells are seen in close proximity. D) Shh IHC (x400) Positive
hypertrophic smooth muscle shown at greater magnification. E) Shh IHC (x600).
Staining of type II epithelial cells.
F) Ptc IHC (x400) Ptc is constitutively expressed in histologically normal lung G)
Ptc IHC (x600) Ptc expression is noted in type II epithelial cells H) Ptc IHC
(x600). Ptc present in interstitial infiltrate.
I) TGFpi IHC (x400) is not expressed in histologically normal alveoli J) TGFpi
IHC (x100) and K) TGFpi IHC (x600) TGFpi is noted in the airway type II
epithelial cells and interstitial infiltrate of fibrotic lung.
L) Normal Goat Serum control (x100) Negative control showing no background
staining.
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3.5 The FITC Model in Gli gene deficient mice
As described in chapter 1 the Gli genes are downstream targets of Shh signalling.
There are 3 G/z's in mammals: Glil, Gli2 and Gli3. Gli2 and Gli3 are known to play
a role in tracheal and lung development 86in which it is thought they are required for
the transduction of the Shh signal. Mice with Gli2 null mutations display phenotypic
features similar to Shh mutant mice 85'86 in keeping with a downregulation of the Shh
pathway. Mice with Gli3 null mutations have phenotypic features more in keeping
with upregulation of the Shh pathway 78,83. GU2/GU3 double mutants have more
marked phenotypic abnormalities than either homozygote implying common
functions of the two genes 85'86.
In the following experiments the aim was to introduce FITC into Gli gene deficient
mice to determine if the fibrotic response was altered in mice in which the Shh
pathway was dysregulated. Having observed that Shh is upregulated in ILD the
hypothesis was that the Shh pathway might be helping to "drive" the disease process.
If this were true one might predict that the response to intra-tracheal FITC would be
altered in Gli knockouts. It should be pointed out from the outset that lungs taken
from these mice, without treatment, appeared morphologically normal, as assessed
by haematoxylin and eosin staining.
3 .5.1 SCREENING THE GLI GENE DEFICIENT MICE
The response to FITC was investigated in Gli2+/~ (gift from C.C.Hui, Program in
Developmental Biology, University of Toronto, Canada), Gli3 / (gift from Prof
A.Joyner, Skirball Institute ofBiomolecular Medicine, NYU, New York) and Gli2
/Gli3+/" mice and compared with wild type control mice. They were all maintained in
a mixed 129 and CD1 background. Gli2"A and Gli3v" mice could not be used as mice
with these phenotypes died either before or shortly after birth ' .
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The Gli2+/" mice contain a targeted deletion of the DNA-binding zinc-fingers motif
of the gene 85. They were screened by PCR analysis ofDNA extracted from tail tips.
Primers specific for the neo-cassette utilised in the construction of the Gli2+/~
phenotype were used (Figure 3.7A). The Gli3+/" mice genotypes were screened by
their characteristic limb phenotype in the form of Polydactyly 90 as shown in Figure
3.7B. Both the Gli2+/7Gli3+/" double mutants and the wild type mice were thus
discriminated by these characteristics.
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Figure 3.7: Screening the G//'2+/" and Gli3+/~ mice
A) Gli2+/~ screening by genotype. PCR reaction with primers specific for the neo
cassette: 280 base pair (bp) product (arrow C). 2% agarose gel with 1: PCR
ladder with sizes (in bp) indicated in white numbering, 2+5: mice not containing
neo cassette and therefore no G//2 mutation, 3,4+6: mice containing neo
cassette and therefore Gli2+/~, 7: positive control from mouse known to contain
neo cassette, 8: negative (water) control for PCR reaction. B) Gli3+/~ screening
by phenotype. Pictures of wild type (left) and Gli3+/~ mutant (right) paw
phenotypes. Extra digit (Polydactyly) indicated by arrow E; absent in wild type
(arrow D)
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3 .5 2 LUNG MORPHOLOGY FOLLOWING FITC TREATMENT
FITC was instilled intra-tracheally as before. Initially a single dose of lOOgg in 50gl
ofPBS was given to each mouse. However many of the mice receiving this treatment
did not develop fibrosis. This may have been due to a number of factors as discussed
later. Each mouse was therefore given 2 doses ofFITC 6 weeks apart.
The Gli mutant (and wild type) mice were considerably larger than the BALB/c used
above (up to 50g compared with weights of ~20g). Thus the lOOpg dose was also
adjusted. Each mouse was given 7pg per g body weight at each treatment 408. The
mice (at least 6 per treatment group per time-point) were then killed up to 6 months
after the second FITC administration. The lungs were inflated and formalin fixed
before sectioning and staining. As before each was stained with the anti-FITC
antibody to confirm delivery before H&E staining to examine morphology.
With this modified method ofFITC instillation the pathology was similar to that seen
with the BALB/c mice. As always the degree of severity of fibrosis varied from
mouse to mouse even within grouped animals. Most importantly there appeared to be
no consistent differences between any of the Gli mutants and the control wild type
mice (Figure 3.8). In all groups the lungs of the PBS treated mice appeared normal
while those of the FITC treated bore all the hallmarks of FITC induced lung fibrosis,
including cellular infiltration, alveolar wall thickening and a patchy peribronchial
fibrosis (Figure 3.8).
It would therefore appear that, as assessed morphologically, the presence of these Gli




Figure 3.8: Haematoxylin and Eosin (H&E) staining of FITC and PBS
treated Glimutant mice lungs
Magnifications are indicated in brackets
Gli2+/~ mice 3 months after 2nd dose of A) PBS (x200) B) FITC (x200) Note the
marked perivascular cell infitrate and replacement of normal alveoli with fibrous
tissue.
Gli2+/~ Gli3+/~ mice 3 months after 2nd dose of C) PBS (x100) D) FITC (x100)
Note destruction of normal alveoli and central granuloma
Gli3+/~ mice 3 months after 2nd dose of E) PBS (x100) F) FITC (x100) G) FITC
(x200) Note the prominent peribronchial infiltrate and significant alveolar wall
thickening
Wild type control mice 3 months after 2nd dose of H) PBS (x200) I) FITC (x200)
Note peribronchial infiltration and scar (fibrous) tissue
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3.6 The effects of intra-tracheal SPC-mouse Shh DNA
Having demonstrated that Shh is upregulated in ILD, the potential role of Shh
signalling in pulmonary fibrosis was further investigated by attempting to upregulate
the Shh pathway in mouse lungs. Overexpression of Shh in the lungs of mouse
embryos results in epithelial and mesenchymal hyperplasia as discussed 56. The
working hypothesis was that upregulation in the adult mouse would lead to lung
fibrosis.
Various ways of overexpressing Shh in vivo were considered. The method of choice
was to rescue a replication deficient adenovirus expressing murine Shh, as
successfully achieved with murine Dvll (Chapter 5). Unfortunately, despite
numerous attempts by a colleague (Dr Susannah Lindey), an adenovirus expressing
Shh was not produced. Attempts to make inducible Shh transgenic mice were also
unsuccessful. The method presented below was therefore attempted.
The protocol was derived from a combination of sources. In a paper published by
Meyer et al 554 the chloramphenicol acetyltransferase (CAT) gene, under the control
of the cytomegalovirus (CMV) promoter, was successfully delivered intra-tracheally
as "naked" DNA into mouse airways. CAT expression was confirmed in the lungs
and trachea of treated mice; peak between 1 and 3 days and was detected up to 28
days after DNA administration. Thus, this method of gene delivery was feasible.
Furthermore, Shh overexpression has been driven in mouse embryonic lung by
insertion of murine Shh cDNA under the control of the surfactant protein-C (SPC)
promoter, by Bellusci et al 56. SPC is expressed at high levels early on in the
primitive embryonic epithelium, and eventually becomes restricted to the type 2
alveolar epithelial cell lineage. This specifically allows high levels of expression in
the distal respiratory epithelium. It was plausible that the SPC-mouse Shh cDNA
vector, a kind gift from Dr Bellusci (Department of Cell Biology, Vanderbilt
University Medical Center, Nashville, Tennessee, USA), might also be capable of
driving Shh expression in the airway epithelial cells ofmature mice.
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Based on the above observations, the aim was to combine these two protocols, in an
attempt to overexpress murine Shh in the respiratory epithelium ofBALB/c mice by
instilling the SPC-mouse Shh vector as naked DNA intra-tracheally. SPC alone was
used as a control plasmid.
In the first instance 20pg (quantity based on the CAT expression data 554) of either
SPC-mouse Shh or SPC DNA was resuspended in 50pl of sterile PBS and inserted
intra-tracheally as described in chapter 2. This was repeated 1 week later and six
mice per treatment group killed at time-points from 1 week to 5 months following
the second instillation. The lungs were inflated and formalin fixed for IHC. In
addition, after 5 months, 6 mice from each treatment arm (SPC-mouse Shh or SPC)
were each given 6 further 20pg treatments (2/week), before being killed 4 days after
the final treatment.
Lung sections were made and stained as described below. The results shown are
from the mice 4 days after the 6 additional doses, the rationale being that any
pathology and /or expression would be most marked following such intensive
treatment. Notably, histological appearances were similar throughout the time-
course.
3 .6.1 LUNG MORPHOLOGY AND CELL PROLIFERATION
Sections from mice treated with both SPC-Shh and SPC were stained with H&E to
allow analysis of the lung morphology.
In some of the sections the epithelial cells appeared to be a little "damaged" with
evidence of epithelial sloughing, denudation and "peg-like' morphology. This was
evident in both treatment arms suggesting that any abnormalities were not confined
to the presence of Shh, but were more likely to be due to a non-specific plasmid
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effect. For the most part, however, the lungs appearances were entirely normal
(Figure 3.9 A and B).
As Shh upregulation is associated with increased cell proliferation, the sections were
also stained with Ki67 to assess the degree of epithelial cell proliferation. Very few,
if any, airway cells were positive in any of the sections, regardless of the treatment or
time-point (Figure 3.9 C and D). These appearances were similar to untreated or PBS
treated mice, and differed markedly from those following adenoviral instillation
(Figure 5.23).
It would appear that SPC-Shh does not affect lung morphology or epithelial cell
proliferation when instilled as naked DNA into adult mouse lungs.
3 .6.2 THE SHH PATHWAY AMD SPC-SHH
The sections were also stained immunohistochemically for Shh and Ptc to determine
whether or not the SPC-Shh DNA instillation had driven upregulation of Shh, and
hence the Shh pathway, in the treated mouse lungs.
Shh expression was no different between the SPC-Shh and SPC DNA treated mice
(Figure 3.10 A and B). Neither was greater than control PBS treatment. Ptc
expression was also unaffected by the presence of SPC-Shh (Figure 3.10 C and D).
As before Ptc expression was equivalent in the epithelial cells in both treatment
groups.
As assessed by IHC, SPC-mouse Shh DNA delivered intra-tracheally as naked DNA
does not increase the expression of either Shh or Ptc at protein level.
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Figure 3.9: Haematoxylin and Eosin (H&E), and Ki67 staining of mouse
lungs treated with SPC plasmids
Magnifications are indicated in brackets
H&E staining of A) SPC treated (x200) and B) SPC-Shh treated (x200) mice
Ki67 staining of C) SPC treated (x200) and D) SPC-Shh treated (x200) mice
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Figure 3.10: Shh and Ptc expression in mouse lungs treated with SPC
plasmids
Magnifications are indicated in brackets
Shh staining of A) SPC treated (x200) and B) SPC-Shh treated (x200) mice
Ptc staining of C) SPC treated (x400) and D) SPC-Shh treated (x400) mice
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3.8 Discussion
The aim of the work presented in this chapter was to determine the role of the Shh
signalling pathway in ILD. To address this question, the expression of key
components of the pathway were analysed both in the FITC model of ILD and in
biopsy specimens from patients with IPF. Expression of the pro-fibrotic protein,
TGFpi, was also examined in similar sections.
In addition, FITC was given to mice with heterozygous mutations in Gli 2 and 3,
downstream targets of Shh signalling, to determine if such defects in the Shh
pathway would alter the pathology. Finally an attempt was made to upregulate Shh in
vivo by instilling the Shh gene into mouse lungs as "naked" DNA under control of a
SPC promoter.
The Modified FITC Model
The IHC findings presented were consistent on both archival sections from mice
given FITC/PBS via the original surgical approach 408 and those receiving treatment
via the modified method described, in which the trachea was accessed through the
mouth. However some of the mice receiving a single dose ofFITC via the oral route
did not develop fibrosis. There may be several reasons for this.
Whereas in the original method of FITC instillation used there could be little doubt
that all of the FITC had been delivered to the lungs, this was not always the case with
the new method. Though all cases were checked with the anti-FITC antibody this
information would not reveal how much of the lOOpg was present. If a smaller dose
were to be delivered, this may be insufficient to induce fibrosis. Importantly, in test
instillations using trypan blue, the lungs were well infiltrated and there was little
evidence of dye elsewhere such as in the oesophagus or stomach. In addition, the
original method involved a surgical procedure as the trachea was exposed and
incised. This was not the case with the new oral approach. It may be that the
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associated stress on the mice during the surgical delivery in some way contributed to
the development of fibrosis. For example, the immune response to FITC may be
more pronounced in this context.
Regardless of the reason such inconsistency was unacceptable. In an effort to address
this, the treatment (FITC or PBS) was given twice to each mouse at an interval of 6
weeks; this interval was chosen to allow the mouse to sufficiently recover from the
initial dose. On each occasion a standard dose of lOOpg in 50pl of PBS was given.
Encouragingly the PBS mice were unaffected by this additional dose. More
importantly the FITC treated mice developed significant lung fibrosis as intended.
In addition all mouse sections were stained with the anti-FITC antibody to confirm
successful delivery into the lungs (Figure 3.1). Only those lungs with positive FITC
staining were used for IHC.
It would therefore appear that although this new method of intra-tracheal instillation,
via an oral approach has its advantages in terms of practicality and a reduced
mortality, it may be less efficient at inducing fibrosis. Should this be as a result of a
less reliable delivery this would obviously have implications on other in vivo
experiments employing the same method; as in SPC mouse-Shh in this chapter and
later adenoviral work.
Furthermore, lung sections from mice treated with this modified intra-tracheal
instillation technique were given fibrosis scores using a system devised by Ashcroft
etal551. This revealed significantly higher scores, and thus more fibrosis, in areas of
lung with FITC deposition, though only following a second administration of FITC.
The former finding supports the observation that fibrosis is localised to areas ofFITC
scarring, originally made by Roberts et al 408. The fact that this was only notable
following a second treatment may be due to those factors discussed above. However,
mice given a second treatment were also killed at later time-points than those given a
single treatment, thus allowing more time for potential lung fibrosis to develop. A
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further control, assessing Ashcroft scores in mice treated only once and killed at
time-points corresponding to those treated twice, would be needed to clarify this.
Immunohistochemistry in the FITC model
Shh expression was upregulated in the bronchial and alveolar epithelial cells ofFITC
treated mice and detected in the infiltrating immune cells (Figure 3.3). Ptc epithelial
expression was appreciable even in PBS treated mice and was not clearly changed in
the FITC treated lungs. It was also expressed in the infiltrating mononuclear cells
(Figure 3.4).
Shh upregulation would imply that the Shh pathway was also upregulated. The
pattern of Ptc expression is less clear. Normally Ptc is upregulated when the Shh
pathway is induced 14'27. Therefore one would expect Ptc and Shh expression to be
increased if this were to be the case. There are several possible explanations to
explain why Ptc expression is not increased.
As basal Ptc expression is already fairly high, any changes may be difficult to
appreciate especially using IHC. It may well be that Ptc is upregulated in the
epithelial cells but that the chosen method of analysis (IHC) is not sensitive enough
to detect this. If this were true, changes in Ptc expression as analysed throughout the
thesis (IHC) may also be too subtle to appreciate. As Ptc antagonises Shh signalling,
by sequestering Shh 28 and inhibiting Smo, it is possible that its constitutive
expression in the lung epithelial cells is a means by which they attempt to block
pathway activation, possibly as a protective mechanism. It may also be that, for some
reason, the observed Shh upregulation results predominantly in increases in Ptc
expression elsewhere (eg. immune cells) and not in the airway epithelial cells.
Shh and Ptc were both expressed in the infiltrating immune cells, seen most clearly
in the FITC mice in which more of these cells were present. This correlates with
findings in T lymphocytes presented in chapter 4. Of particular relevance to ILD, it
raises the possibility that the Shh signalling pathway enables communication
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between the epithelial cells and the infiltrating immune cells including lymphocytes
and macrophages in the disease process. The roles played by these infiltrating cells in
the pathogenesis of ILD may be, at least in part, related to Shh signalling.
TGFpi expression was also upregulated in FITC treated lungs as assessed by IF1C.
As described previously 353"357j this was noted particularly in the airway epithelial
cells and the infiltrating immune cells (Figure 3.5). These findings imply that, as in
several other models of ILD, pulmonary fibrosis in FITC treated mice is associated
with increased TGFpi expression.
Immunohistochemistry in EPF Patient Biopsies
The same proteins displayed similar expression patterns in archival human biopsy
sections from patients with IPF.
Shh was notably expressed in remodelling type II epithelial cells, metaplastic
respiratory epithelial cells and in hypertrophic smooth muscle (Figure 3.6).
Interestingly Shh positive and negative cells were interspersed throughout the
respiratory epithelium. It is possible that this pattern of staining is due to the dynamic
nature of Shh signalling i.e. adjacent cells signalling to their neighbours and
increasing Shh expression before downregulating expression themselves. It would
also appear that Shh is produced by hypertrophic muscle in IPF patients, and may
contribute to this hypertrophy. It is certainly associated with mesenchymal
proliferation in vivo 56. Significantly Shh staining was limited to diseased areas,
suggestive of a specific role in the fibrotic process.
Ptc and TGF(31 were also expressed in remodelling epithelium and in infiltrating
mononuclear cells (Figure 3.6). These findings are consistent with the FITC data
discussed.
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The FITC model in Gli gene deficient mice
The Gli gene deficient mice were chosen as models of dysregulated Shh signalling.
They were treated with FITC in an attempt to provide further, if indirect, evidence of
the role of Shh in the pathogenesis of ILD. As described Gli2+/~, Gli3+/~ and Gh2+/~
/Gli3+/~ double mutants were compared with their littermate wild type controls. There
were no clear differences in morphology or degree of lung fibrosis between the Gli
gene deficient mice, their littermate controls or conventional BALB/c mice in
response to intra-tracheal FITC (Figures 3.2 and 3.8).
For several reasons these findings were difficult to interpret. The extent of fibrosis
was assessed morphologically, but perhaps a more accurate, objective and sensitive
test would have been to measure tissue hydroxyproline levels. This method has been
commonly used in fibrosis models including the FITC model 409. These sections were
not formally given fibrosis (Ashcroft) scores 551 as there were clearly no consistent
differences on H&E staining. In addition, the function of the different Glis has not
been fully resolved. Though features of the Gli2 mutants are in keeping with
downregulation, and Gli3 with upregulation of Shh signalling, these features are not
absolute. They are largely based on observed phenotypic characteristics. Both are
capable of either activating or repressing Shh signalling in different contexts, as
discussed in detail in Chapter 1. Furthermore, there is a degree of redundancy and
overlap of the different Glis; as observed where Glil and Gli2 compensate for each
other 8I'84,88, and in the phenotype of the GU2/3 double mutants 85,86. Therefore even
the double mutations still have preserved Glil expression, which could be
compensating for the other Glis. The extent to which Shh signalling has been altered
in these mice is thus not clearly established, making any further interpretations of
responses to FITC in different genotypes more difficult to dissect. Finally, as
homozygous mutations of these mice result in an embryonic lethal phenotype ' ,
heterozygotes were used. Therefore absolute expression of the genes would not be
lost, limiting the effect of the mutation on Shh signalling and phenotype.
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Although these gene deficient animals with dysregulated Shh signalling did not
provide any further evidence to implicate the pathway in ILD, they were far from
ideal experimental tools. In light of the complex phenotype of the Gli mutant mice, it
would be difficult to make any firm conclusions regarding the role of the Shh
pathway in ILD based on data derived from their analysis.
Intra-tracheal SPC-mouse Shh delivery
The immunohistochemical findings discussed above prompted an attempt to
overexpress Shh in vivo to determine if Shh upregulation in vivo resulted in lung
fibrosis. Shh was introduced intra-tracheally as "naked" DNA in the form of SPC-
mouse Shh.
In the parameters investigated there was no difference between mice receiving Shh
and control mice, receiving either SPC alone or PBS. Neither a prolonged time-
course nor multiple treatments resulted in any significant changes in lung
morphology (Figure 3.9). Cell proliferation was also unaffected (Figure 3.9). Most
significantly there was no evidence ofupregulation of either Shh or Ptc in the treated
lungs as assessed by IHC (Figure 3.10).
The delivery of Shh by this method would appear to have been unsuccessful. There
are several possible contributing factors. The delivery of genes intra-tracheally as
plasmid DNA is uncommon largely because the efficiency and level of expression
are relatively poor, especially when compared with alternative methods such as
adenoviruses and liposomes 555. In addition, the SPC promoter, whilst extensively
used in utero 56, may not be the ideal choice to allow maximal gene expression when
given intra-tracheally into fully developed lungs. There is no published work in
which the SPC promoter has been used for gene delivery intra-tracheally, as
attempted in this thesis. Any Shh expression might be expected to be evident in the
type II epithelial cells as they express SPC. In the paper quoted in the text (Meyer et
al 554) the pCMV (cytomegalovirus) promoter was used and not an SPC promoter.
Perhaps delivery of Shh under control of the pCMV promoter would have been more
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efficient. Finally, the IHC data implies that neither Shh nor Ptc were upregulated.
The relatively poor sensitivity of IHC could be a contributing factor. Meyer et al
measured CAT expression by a luciferase reporter assay of whole lung homogenate.
In their discussion the authors suggest that IHC, and indeed in situ hybridisation, can
be unrewarding in assessing naked DNA delivery. Ideally in these experiments it
would have been informative to measure Shh and/or Ptc at mRNA level from whole
lungs (as described in later adenovirus experiments in chapter 5). It is possible that
such analysis may have shown that either or both were increased following SPC-
mouse Shh instillation.
It is not clear therefore whether or not the observed effects were due to poor delivery
and low Shh expression in the lungs, or because Shh upregulation has no effect on
lung morphology or cell proliferation. As there is no evidence of Shh upregulation
this would certainly have to be addressed in the first instance, either by repeating the
plasmid DNA experiments incorporating more sensitive indicators of Shh expression
or, preferably, using more reliable methods of gene delivery. This should be possible
in the future, particularly as an adenovirus expressing Shh has already been rescued
by Sato et al120, and successfully used to drive expression of Shh in the skin.
Summary
The work detailed in this chapter provides the first report of a link between the Shh
signalling pathway and ILD, in both an experimental model (FITC induced fibrosis)
and in human biopsy sections from patients with IPF. The FITC model was
reproduced with an alternative, non-surgical method of intra-tracheal instillation. Shh
is upregulated in the remodelling airway epithelium of FITC treated mice when
compared with control mice, and is also expressed in the infiltrating mononuclear
cells. The Shh receptor, Ptc, is constitutively expressed in murine airway epithelium
and infiltrating mononuclear cells, with particularly strong expression in the alveolar
macrophages. Ptc expression does not appear to change in FITC treated mice, at least
as assessed by immunohistochemistry (IHC). These features were paralleled in
staining of sections from patients with IPF, in which Shh expression was increased
- 158-
only in the remodelling epithelium in fibrotic areas and Ptc expression was uniform
throughout, with positive infiltrates. Expression of TGFpi was also increased in
remodelling airway epithelium and notable in cell infiltrates in both FITC treated
mice and human IPF sections, by IHC.
The fibrotic response to intra-tracheal FITC was no different in mice with Gli
(Gli2+/'and/or Gli3+/) heterozygous mutations though, as discussed, this does not
prove that Shh signalling has no role in the pathogenesis of ILD. An attempt to
upregulate Shh in vivo, using intra-tracheal naked DNA, was unsuccessful in that it
produced no evidence of increased Shh expression, and there were no discernible
differences in either morphology or cell proliferation when compared with controls.
More efficient Shh expression, as facilitated by a recombinant adenovirus, is likely to
be more informative.
Therefore the Shh pathway appears to be upregulated in ILD. Whether or not Shh
signalling enhances the fibrotic response or is expressed by the lungs in an attempt to
control repair remains unclear. Notably, the emerging hypothesis of IPF aetiology is
based on a model of abnormal wound healing/repair (Chapter 1 292). It may be that
inappropriate Shh expression contributes to this. In addition, TGFP is known to
inhibit112413 and Shh to promote94 branching morphogenesis in the developing lung,
suggesting that they have antagonistic functions. Translating this to ILD, it may well
be the case that, as TGFP is profibrotic, Shh signalling is anti-fibrotic and promotes
epithelial repair. These questions would be best addressed by overexpression of Shh,
as intended, and Shh antagonists, such as Hedgehog-interacting protein (Hip), in both
untreated mouse lungs and in models of fibrosis such as the FITC model.
Finally, although not addressed in this thesis, in collaborative work with Dr Elizabeth
Jarman, Shh signalling and TGFpl expression were not upregulated in a murine
allergic model of lung inflammation 556 Thus implying that the observed
upregulation of the Shh pathway may be specifically associated with lung fibrosis,
and not with general lung inflammation as such.
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Chapter 4
The Sonic Hedgehog Pathway in human
CD4+ T cell activation
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4.1 Introduction
The Sonic Hedgehog (Shh) pathway has never previously been studied with respect
to the mature human T cell. However, as discussed in Chapter 1, related work in
murine thymocytes 121 and human haemotopoietic stem cells 125has recently been
published. The work described below uses similar strategies to ascertain what role
the pathway plays in human CD4+ T cell activation.
For all of the experiments described, human peripheral blood mononuclear cells
(PBMCs) were isolated by centrifugal separation over Histopaque 1077. CD4+ or
CD8+ T cell subsets were then obtained using either positive or negative selection
techniques. Cell purity for the desired subset, as assessed by flow cytometry, was
consistently at least 93% with either method. The method of isolation did not appear
to affect the activity of the cells.
4.2 The Sonic Hedgehog Signalling Pathway is present in
Human T Cells
4.2.1 SONIC HEDGEHOG AND PATCHED ARE EXPRESSED IN HUMAN T
CELLS
These initial experiments were designed to determine if the Shh pathway was present
in human T cells. To address this issue two important pathway genes were chosen:
the Shh ligand and its receptor Patched (Ptc).
A proportion of each purified T cell subset was used to make cytospins, and RNA
was extracted from a further fraction.
Immunocytochemistry for Shh and Ptc proteins was carried out using commercial
primary antibodies (Santa Cruz). Cells stained with no primary antibodies were used
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as negative controls. The results showed that both Shh and its receptor, Ptc, are
expressed in human T cells (brown positive staining against the blue haematoxylin
counterstain). Both proteins were detected on the cell surface membrane as would be
expected. The cytospins illustrated are of human CD4+ T cells (Figure 4.1). Similar
staining was noted on CD8+ cells.
RNA from purified lymphocyte populations was incorporated into reverse
transcription PCR reactions, in the presence of primers specific for human Shh or Ptc
mRNA (Table 2). Specific mRNAs for both were detected, thus confirming the
presence of Shh and Ptc in human CD4+and CD8+ T cells As shown, Ptc was also
present in human B cells, although this area was not explored further in the context
of this thesis. RNA extracted from the human A549 epithelial cell line was used as a
positive control in the Shh reaction shown (Figure 4.1).
These experiments proved that Shh and Ptc are expressed at both protein and RNA













Figure 4.1: Sonic Hedgehog (Shh) and Patched (Ptc) are expressed in
human T cells.
Expression of A) Ptc and B) Shh in cytospins of purified CD4+ T cells
(immunocytochemistry with haematoxylin counterstain)
C) Ptc mRNA expression in purified human CD4+, CD8+ and B cells; by rtPCR.
Product size 462bp
D) Shh mRNA expression in purified human CD4+ and CD8+ T cells; by rtPCR.
Positive control (+VE) is mRNA from human A549 cells. Product size 335bp
- 163 -
4.2.2 PATCHED EXPRESSION INCREASES UPON ADDITION OF SHH
PEPTIDE TO ACTIVATED HUMAN CD4+ T CELLS.
It has previously been shown that upregulation of the Shh pathway paradoxically
leads to an increase in expression of its receptor Ptc H27'55. it follows that an increase
in Ptc expression would be indicative of an associated upregulation of the pathway.
These experiments were aimed at determining the expression of Ptc mRNA as a
marker of Shh signalling.
Purified human CD4+ T cells were cultured in the presence of a commercially
available murine Shh peptide (R&D Systems) at a range of concentrations. Murine
Shh is produced as a precursor protein, which undergoes autoproteolysis to yield a 19
kDa amino-terminal domain (N-Shh) and a 27 kDa carboxy-terminal domain (C-
Shh). The N-Shh portion remains membrane associated and is known to contain the
active region. The C-Shh portion is secreted and is responsible for cleavage of the
precursor Shh 10,57 The peptide used throughout this thesis (hereafter referred to as
N-Shh peptide) was produced as a fusion protein from the DNA sequence encoding
amino acid (AA) residues 25-198 ofmouse Shh. This sequence is identical to human
Shh with the exception of one AA. The recombinant mouse N-Shh peptide has a
predicted molecular mass of ~20kDa. As in similar experiments in the developing
immune system, in which human and murine reagents were used interchangeably in
121 123
either species, the murine peptide was used in a human system
The N-Shh peptide was added to human CD4+ cells and RNA extracted at time-
points from 0-72 hours. The range of concentrations chosen were based on those
previously used by others working with similar Shh peptides 117. The T cells were
either "resting" or "activated"; the former referring to cells cultured in the presence
of culture medium and peptide alone, and the latter to the inclusion of anti-CD3s
(lpg/ml) and anti-CD28 (5pg/ml) antibodies.
Extracted RNA was analysed by real time PCR using a primer/probe mix specific to
human Ptc, with an internal 18S control. Each sample was run in duplicate wells and.
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and experiments were repeated with consistent results (n=3). Values were expressed
as a ratio of the concentration of Ptc mRNA relative to T cells cultured in the
absence of the N-Shh peptide, which were given a value of 1.
Peak expression ofPtc mRNA was found to be maximal after 24 hours in culture in
both resting and activated cells.
In "resting" (non-activated) human CD4+ T cells (Figure 4.2A) Ptc expression was
greater upon the addition ofN-Shh peptide with a peak expression at lOOng/ml; 1.7-
fold > control expression. The 48 hour time-point has been included to illustrate that:
a) Expression of Ptc was less than at 24 hours. All values were compared to Ptc
expression in the untreated (Ong/ml) cells at 24 hrs to allow this comparison to be
made.
b) Ptc expression at 48 hours also peaked at the lOOng/ml concentration of N-Shh
peptide.
In "activated" human CD4+ T cells (Figure 4.2B) Ptc expression was again greater
upon the addition of N-Shh peptide with a peak expression, as before, at lOOng/ml.
The difference was greater in activated than resting T cells with a 4.7-fold greater Ptc
expression at lOOng/ml than the Ong/ml control.
These experiments show that Ptc mRNA is upregulated in the human CD4+ T cells in
the presence of N-Shh peptide. The biological relevance of these differences is less
clear. In similar work comparing RNA expression in the context of gene microarrays
only differences of >2-fold were considered significant 557'558. Applying these same
principles, only the differences in Ptc expression in the "activated" T cells were
significant. Therefore, at least in activated human CD4+ T cells, the N-Shh peptide
appears to trigger Shh signalling, as assessed by Ptc mRNA expression.
- 165-
A) Patched mRNA expression in resting
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Figure 4.2: Patched mRNA expression increases upon addition of N-Shh
peptide to human CD4+ T cells.
Graphs are representative of mRNA concentrations as calculated following real
time PCR reactions specific for human Ptc compared with an 18S control. In
both graphs values are compared with the baseline Ptc expression seen in the
untreated (Ong/ml) cells at 24hrs, which has been given a value of 1. Results
are representative of triplicate experiments. (A) Relative Ptc mRNA expression
in purified resting (not activated) human CD4+ T cells after 24 and 48 hrs in
culture. (B) Relative Pfc mRNA expression in purified activated human CD4+ T
cells after 24hrs in culture, in which cells were activated with a combination of
plate-bound anti-CD3 (1pg/ml) and soluble anti-CD28 (5pg/ml) antibodies.
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4.3 Sonic Hedgehog Signalling amplifies T cell receptor
mediated activation in human T cells
In the following series of experiments the recombinant murine N-Shh peptide was
added to purified human CD4+ T cells. In all cases the T cells were activated using
plate-bound anti-CD3s (lpg/ml) and soluble anti-CD28 (5pg/ml) antibodies.
Preliminary proliferation experiments omitting the anti-CD28 antibody were also
carried out with similar results to below (data not shown).
4.3 .1 N-SHH PEPTIDE AUGMENTS HUMAN T CELL PROLIFERATION
The N-Shh peptide was added at a range of concentrations to purified, activated
human CD4+ and CD8+ T cell sub-populations. Following 72 hrs in culture sample
wells were pulsed with tritiated thymidine and read 16-24 hrs later.
In the illustrated experiment, CD4+ proliferation increased in a dose dependent
manner with a peak in the range of 1 -lOOng/ml (p< 0.001) ofN-Shh peptide (Figure
4.3A). In subsequent experiments lOOng/ml was identified as the optimal
concentration giving maximal proliferation, the same concentration that induced
maximal Pic mRNA expression. At higher concentrations of peptide, such as
500ng/ml, CD4+ proliferation fell towards control levels again. The control
('resting') wells contained T cells cultured in medium alone.
CD8+ cell proliferation also increased with N-Shh peptide concentration.
Proliferation was optimal at a concentration of lOOng/ml (p< 0.001) and, as with the
CD4+ cells, began to tail offwith higher doses such as 500ng/ml (Figure 4.3B).
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Activated samples with peptide were statistically compared with activated samples







These experiments demonstrated that N-Shh peptide augments proliferation of both
CD4+ and CD8+ T cells in a dose dependent manner (Figure 4.3). The CD8+
experiments were discussed at this point to illustrate that N-Shh peptide is capable of
enhancing proliferation of both T cell subsets. However, the remaining work
presented throughout this chapter is focussed on human CD4+ cell activation.
It should be stressed at this point that not all donor CD4+ T cells responded in the
same manner to the addition of the N-Shh peptide. From the many donors tested
(n>20), increased proliferation was observed in approximately 50%. These are
hereafter referred to as 'responders'.
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A) Human CD4+ T cell proliferation in the
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Figure 4.3: N-Shh peptide augments human T cell activation.
Graphs are representative of proliferation (samples in at least triplicate) of T
cells activated in the presence of plate-bound anti-CD3 (1 jag/ml) and soluble
anti-CD28 (5pg/ml) antibodies. Each well was pulsed with tritiated thymidine
after 72hrs in culture and read 16-24hrs later. Results are representative of at
least 3 experiments, showing means and standard deviations. Statistically all
activated samples are compared with those wells containing no peptide: Ong/ml.
Control cells (also represented by "C") were cultured in the absence of anti-CD3
and anti-CD28. Proliferation of purified (A) human CD4+ and (B) human CD8+ T
cells in the presence of N-Shh peptide.
*







4.3.2 N-SHH PEPTIDE ENHANCES CYTOKINE RELEASE FROM ACTIVATED
HUMAN CD4+ T CELLS
Supernatants from the 'responded donors, in whom N-Shh had enhanced CD4+
proliferation, were taken at 24, 48 and 72 hrs. Levels of the human cytokines
interleukin (IL) 2, 5 and 10, and interferon gamma (IFNy) were then measured.
IL2 was detectable from 24hrs in most cases and the concentration progressively
increased up to the 72 hr time-point. IL2 levels were elevated by the addition ofN-
Shh peptide in a dose dependent manner (Figure 4.4A), suggesting that IL2
production may be one method by which the peptide increases proliferation. Of note,
the levels of the cytokine continue to rise with higher concentrations of the peptide
such as lOOOng/ml (p< 0.001). This contrasted with the proliferation data in which
such concentrations resulted in a fall in counts towards control levels (Figure 4.3).
IFNy was optimally detected from 48 hrs onward. As with IL2 levels of IFNy
increased with N-Shh peptide dose and were highest at peptide concentrations of
lOOOng/ml (p< 0.001)(Figure 4.4B).
IL10 was optimally detected from 48hrs. Rises in IL10 followed the same pattern as
that observed with IL2 and IFNy (p< 0.001)(Figure 4.5A).
IL5 was difficult to detect in many experiments, even when other cytokines were
detectable at high concentrations. This may have been in part due to a difference in
sensitivity between the different cytokine analysis kits, as IL5 was measured using a
different method to the others (see methods). When detectable, there was no
appreciable difference in IL-5 levels in the presence of N-Shh peptide at a range of
concentrations (Figure 4.5B).
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A) IL 2 production by human CD4+ T cells
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Figure 4.4: N-Shh peptide increases IL2 and IFNy release from human
CD4+ T cells.
Graphs are representative of cytokine levels, as measured by ELISA, in
supernatants (triplicate wells) taken from CD4+ T cells activated in the presence
of plate-bound anti-CD3 (1 jig/ml) and soluble anti-CD28 (5pg/ml) antibodies.
Statistically samples are compared with those wells containing no peptide at the
equivalent time-point. (A) IL2 levels measured at 24 and 48hrs. (B) IFNy levels
measured at 48 and 72hrs. Results are representative of at least 3 experiments,
showing means and standard deviations.
*
p < 0.05; ** p < 0.01; *** p < 0.001
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A) IL 10 production by human CD4+ T cells
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Figure 4.5: N-Shh peptide increases IL10 but not IL5 release from human
CD4+ T cells.
Graphs are representative of cytokine levels, as measured by ELISA, in
supernatants (triplicate wells) taken from CD4+ T cells activated in the presence
of plate-bound anti-CD3 (Ipg/ml) and soluble anti-CD28 (5pg/ml) antibodies.
Statistically samples are compared with those wells containing no peptide at the
equivalent time-point. (A) IL10 levels measured at 48 and 72hrs. (B) IL5 levels
measured at 24 and 48hrs. Results are representative of at least 3 experiments,
showing means and standard deviations.
*
p < 0.05; ** p < 0.01; *** p < 0.001
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4.3.3 N-SHH PEPTIDE INCREASES THE EXPRESSION OF CD25 AND CD69
IN ACTIVATED HUMAN CD4+ T CELLS
As in experiments to date, the N-Shh peptide was added at a range of concentrations
to purified, activated human CD4+ T cells. Cells from responder donors were stained
for the presence ofCD25 and CD69 after 24, 48 and 72hrs in culture and analysed by
flow cytometry. Both of these proteins are upregulated on the surface of human
CD4+ T cells upon activation through the T cell receptor (TCR) 498'499>517>5i8 in each
case the cells were also stained with appropriate isotype-matched control antibodies.
In general CD25 expression was low at 24hrs (not shown), higher at 48hrs and
maximal at the 72hr time-point. CD69 expression was detectable from 24hrs (not
shown), maximal at 48 hrs and beginning to drop at 72 hrs. The data shown
represents expression of both CD25 (Figures 4.6 and 4.7) and CD69 (Figures 4.8 and
4.9) at 48 and 72hrs. Data shown is representative of at least three repeated
experiments.
The T cells were gated on viable cell populations shown as either R1 or R2 (Figures
4.6A, 4.7A, 4.8A and 4.9A). Expression of the relevant markers was examined in the
gated sub-populations. The isotype-matched controls were used to allow
discrimination between positive and negative staining, with the region of positive
staining (CD25 or CD69) labelled as Ml (Figures 4.6B, 4.7B, 4.8B and 4.9B).
In the representative experiment shown, the percentage of CD25 positive cells at
48hrs was greater in those cells cultured in the presence of the N-Shh peptide
(lOOOng/ml) than in control activated cells: 61% (Figure 4.6D) against 22% (Figure
4.6C), as listed in the corresponding tables. The CD25 mean fluorescent intensity
was also greater in the presence of the peptide (74 against 53). At 72 hrs the same
pattern was observed (Figure 4.7), with both the percentage of CD25 +ve cells and
their mean fluorescent intensity increasing in a dose dependant manner, maximal at
the lOOOng/ml concentration ofN-Shh peptide (Figure 4.7C-F). This correlates with
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Figure 4.6: N-Shh peptide increases C025 expression in human CD4+ T
cells at 48hrs.
(A) Dot plot representing all T cells after 48hrs in culture. Further histograms
are of the gated R1 population. (B) Isotype control histogram. Positive
population gated as M1 based on this control. Remaining histograms represent
CD25 expression in cells cultured in the presence of (C) no peptide (Ong/ml)
and (D) N-Shh peptide at a concentration of 1000ng/ml. Corresponding tables
represent the percentage cells (% Gated) staining for CD25 and their mean
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Figure 4.7: N-Shh peptide increases CD25 expression in human CD4+ T
cells at 72hrs.
(A) Dot plot of CD4+ T cells after 72hrs in culture. Further histograms are gated
on the R2 population. (B) Isotype control histogram. Remaining histograms
show cells cultured with (C) Ong/ml (D) 10ng/ml (E) 100ng/ml and (F) 1000ng/ml
of N-Shh peptide. CD25 positive cells fall within the M1 region.
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In the representative experiment shown, the percentage of CD69 positive cells at
48hrs was also greater in those cells cultured in the presence of the N-Shh peptide
than in activated control cells (Figure 4.8C-F), with the CD69 mean fluorescent
intensities essentially following suit (Figure 4.8D). CD69 expression was greatest at
the lOOng/ml, and lOOOng/ml peptide concentrations (Figure 4.8E). At 72hrs the
same pattern was observed (Figure 4.9), with peak expression at the lOOng/ml
peptide concentration. In contrast to CD25, CD69 levels were less at 72hrs than at
48hrs.
Therefore, addition of the N-Shh peptide increases expression of both CD25 and
CD69 in activated CD4+ T cells, in a dose-dependent manner. These increases are
significant, as determined by a paired T test using a one-tailed p value, in repeated
experiments. The presence of N-Shh at a concentration of lOOOng/ml increased the
number of CD25 positive cells significantly at both 48hrs (p=0.026, n=6) and 72hrs
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Figure 4.8: N-Shh peptide increases CD69 expression in human CD4* T
cells at 48hrs.
(A) Dot plot of CD4+ T cells after 48hrs in culture. Further histograms are gated
on the R1 population. (B) Isotype control histogram. Remaining histograms
show cells cultured with (C) Ong/ml (D) 10ng/ml (E) 100ng/ml and (F) 1000ng/ml
of N-Shh peptide. CD69 positive cells fall within the M1 region.
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Figure 4.9: N-Shh peptide increases CD69 expression in human CD4+ T
cells at 72hrs.
(A) Dot plot of CD4+ T cells after 72hrs in culture. Further histograms are gated
on the R2 population. (B) Isotype control histogram. Remaining histograms
show cells cultured with (C) Ong/ml (D) 10ng/ml (E) 100ng/ml and (F) 1000ng/ml
of N-Shh peptide. CD69 positive ceils fall within the M1 region.
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4.3.4 N-SHH PEPTIDE DOES NOT AFFECT CELL SURVIVAL IN ACTIVATED
HUMAN CD4+T CELLS
Shh is known to have anti-apoptotic properties in organogenesis 559'560and to induce
expression of the anti-apoptotic factor, bcl-2 561. Therefore, as the N-Shh peptide
enhances T cell proliferation, it was important to determine if this was related to
increased cell survival. In order to assess the effect of the N-Shh peptide on cellular
apoptosis and/or survival the peptide was added at the usual range of concentrations
to activated human CD4+ T cells. After 24hrs, 48hrs and 72hrs in culture the cells
were stained with AnnexinV and Propidium Iodide (PI). In each experiment the cells
were analysed without gating. The individual quadrants were set with unstained
control cells, cells stained with AnnexinV-FITC alone and cells stained with PI alone
(Figure 4.10 and 4.11 B-D). Experimental samples were stained with both
AnnexinV-FITC and PI. Data shown is representative of at least three repeated
experiments.
In the presented data, cells in the lower left (LL) quadrant do not stain for either
AnnexinV or PI and are, therefore, considered to be viable cells. Cells in the lower
right (LR) quadrant stain positively for AnnexinV-FITC indicating the cell
membrane has lost symmetry and PS has translocated to the outer leaflet of the
plasma membrane. These cells are actively undergoing early apoptosis. The upper
right quadrant (UR) cells are at advanced stages of apoptosis, since these cells stain
positively for AnnexinV and are also Propidium Iodide (PI) positive due to increased
plasma membrane permeability. Events acquired in the upper left quandrants (UL)
indicate necrotic cells which stain positively for PI, but not for AnnexinV-FITC as
the membranes are no longer capable ofbinding AnnexinV (Figure 4.10 and 4.11).
In the representative experiments shown the percentage ofT cells, at each time-point,
in each quadrant remained the same regardless of the concentration ofN-Shh peptide
in the system (Figure 4.10 and 4.11 F-I). Therefore, there was no increase in cell
survival associated with the addition of the peptide at either the 24hr or 72hr time-
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points, thus implying that the measured increases in proliferation shown before were
not related to an improved T cell survival.
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Figure 4.10: N-Shh peptide does not affect cell survival in activated human
CD4+ T cells at 24hrs.
Control samples: (A) All cells (FSC/SSC) (B) Cells unstained (C) AnnexinV
single stain (D) PI single and (E) "Dead cells" control. Thereafter, activated cells
cultured in the presence of (F) Ong/ml (G) 10ng/ml (H) 100ng/ml and (I)
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Figure 4.11: N-Shh peptide does not affect ceil survival in activated human
CD4+ T cells at 72hrs.
Control samples: (A) All cells (FSC/SSC) (B) Cells unstained (C) AnnexinV
single stain (D) PI single and (E) "Dead cells" control. Thereafter, activated cells
cultured in the presence of (F) Ong/ml (G) 10ng/ml (H) 100ng/ml and (I)
1000ng/ml of N-Shh peptide for 72hrs and stained for AnnexinV and PI.
Anne>dn YFITC
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4.4 Blocking Sonic Hedgehog Signalling inhibits T cell
receptor mediated activation in human CD4+ T cells
In the following series of experiments a neutralizing anti-Shh antibody
(Developmental Studies Hybridoma bank: 5E1) was added to purified human CD4+
T lymphocytes. This antibody has been shown to inhibit the function of Shh and thus
Shh signalling 121-125 jn ap cases the T cells were activated using plate-bound anti-
CD3 (lp.g/ml) and soluble anti-CD28 (5pg/ml) antibodies, and the 5E1
concentrations used were in the same range as those used previously by other groups
121,125 Resuits are 0f representative experiments, which were repeated at least three
times.
4.4.1 ANTI-SHH NEUTRALIZING ANTIBODY INHIBITS HUMAN CD4+ T
CELL PROLIFERATION
The 5E1 antibody was added at a range of concentrations to purified, activated
human CD4+ T cells. The same time course was used as in the N-Shh peptide
proliferation experiments. Following 72 hrs in culture, sample wells were pulsed
with tritiated thymidine and read 16-24 hrs later.
The 5E1 antibody inhibited proliferation of the activated human CD4+ T cells when
used at concentrations of 20qg/ml and above (Figure 4.12). Unactivated ("resting") T
cells were included as a further negative control (Figure 4.12B). Significantly, as
discussed in the recently published paper 556, an isotype control antibody for 5E1
used at equivalent concentrations had no inhibitory effects on T cell activation (work
completed by Dr Sonia Wakelin).
As noted in the parallel N-Shh peptide experiments, the 5E1 antibody had no effect
on proliferation in approximately 50% of donor CD4+ T cells. The remaining
analysis presented is focussed on the 'responder' donors.
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A) Human CD4+ T cell proliferation in the
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Figure 4.12: 5E1 antibody inhibits proliferation of human CD4+ T cells.
Graphs are representative of proliferation (samples in triplicate at least) of T
cells activated in the presence of plate-bound anti-CD3 (1pg/ml) and soluble
anti-CD28 (5pg/ml) antibodies. Each well was pulsed with tritiated thymidine
after 72hrs in culture and read 16-24hrs later. Statistically all activated samples
are compared with those wells containing no antibody (Opg/rnl). Control cells
were cultured in the absence of anti-CD3 and anti-CD28. The graphs show
proliferation of purified human CD4+ T cells (means and standard deviations) in
the presence 5E1 antibody in concentrations up to (A) 20pg/ml and (B)
50pg/ml.
*
p < 0.05; ** p < 0.01; *** p < 0.001
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4.4.2 ANTI-SHH NEUTRALIZING ANTIBODY REDUCES CYTOKINE
RELEASE FROM ACTIVATED HUMAN CD4^ T CELLS
Supernatants from responder donors, in whom the 5E1 antibody inhibited CD4+ T
cells proliferation, were taken from 24 to 72 hrs. Levels of interleukin (IL) 2, 5 and
10, and interferon gamma (EFNy) were then measured.
IL2 was detectable from 24hrs onwards, increasing up to 72hrs. The addition of the
5E1 antibody resulted in a reduction in IL2 levels in a dose dependant manner with
maximum effect at a concentration of 20pg/ml (p< 0.001)(Figure 4.13A).
IFNy was optimally detected from 48 hrs onward. As with IL2, IFNy levels were
reduced in the presence of the 5E1 antibody at concentrations of 10p.g/ml and
20pg/ml (p< 0.001)(Figure 4.13B).
IL10 and IL5 were most easily detected at 72hrs. However, as before IL5 was often
difficult to detect in many experiments. In addition, there was consistently no
appreciable difference in either IL10 or IL5 levels in the presence of the 5E1
antibody (Figure 4.14).
Therefore, addition of the neutralizing anti-Shh antibody (5E1) to activated T cells
reduces the release of IL2 and IFNy in a dose dependent manner, but does not affect
IL10 or IL5. An isotype control antibody for 5E1, used at equivalent concentrations,
had no inhibitory effect on cytokine secretion 556.
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A) IL 2 production by human CD4+ T cells
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Figure 4.13: 5E1 antibody decreases IL2 and IFNy release from human
CD4+ T cells.
Graphs are representative of cytokine measurements of supernatants (triplicate
wells) taken from CD4+ T cells activated in the presence of plate-bound anti-
CD3 (1pg/ml) and soluble anti-CD28 (5pg/ml) antibodies, showing means and
standard deviations. Statistically samples are compared with those wells
containing no antibody (0p.g/ml) at the equivalent time-point. (A) IL2 levels
measured at 24 and 72hrs. (B) IFNy levels measured at 72hrs.
*
p < 0.05; ** p < 0.01; *** p < 0.001
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A) IL 10 production by human CD4+ T cells
in the presence of 5E1 antibody
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B) IL 5 production by human CD4+ T cells
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Figure 4.14: 5E1 antibody does not alter IL10 or IL5 release from human
CD4+ T cells.
Graphs are representative of cytokine measurements of supernatants (triplicate
wells) taken from CD4+ T cells activated in the presence of plate-bound anti-
CD3 (l^g/ml) and soluble anti-CD28 (5pg/ml) antibodies, showing means and
standard deviations. Statistically samples are compared with those wells
containing no antibody (0jig/ml) at the equivalent time-point. (A) IL10 levels
measured at 72hrs. Error bars at the 5pg/ml and 20pg/ml concentrations are
included, but are too narrow to appreciate (B) IL5 levels measured at 72hrs in 2
separate experiments (Exp 1 and 2).
*
p < 0.05; ** p < 0.01; *** p < 0.001
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4.4.3 ANTI-SHH NEUTRALIZING ANTIBODY REDUCES THE EXPRESSION
OF CD25 AND CD69 IN ACTIVATED HUMAN CD4+T CELLS
The 5E1 antibody was added at a range of concentrations to purified, activated
human CD4+ T cells and the expression of the activation markers CD25 and CD69,
in responder donors, measured by flow cytometry. As with the parallel experiments
using the N-Shh peptide, the viable cell populations gated as R1 or R2 were
analysed. Suitable isotype matched antibody controls were again used to allow
discrimination between positive (Ml) and negative staining (Figures 4.15 and 4.16
B). The optimal time-points for peak CD25 (72hrs) and CD69 (48hrs) expression, as
discussed earlier, are shown (Figures 4.15 and 4.16).
In the representative experiment shown, the percentage of CD25 +ve cells was
marginally reduced from 56% (without) to 53% in the presence of the 5E1 (20pg/ml)
antibody. In the same experiment, the associated reduction in mean fluorescent
intensity was more notable falling from 347 to 278 (Figure 4.15 C-D; Experiment 1).
The final two histograms (Figure 4.15 E-F; Experiment 2) were from a separate
experiment, with a different isotype control (not shown) and hence Ml region, in
which a dose of 50pg/ml of 5E1 antibody was used. They show a more pronounced
reduction in both the percentage +ve cells (from 51% to 35%) and mean fluorescent
intensity (from 154 to 114), with this higher concentration. Even at the 20pg/ml dose
the percentage of CD25 positive cells, in a series of donor experiments, was
significantly reduced at both 48hrs (p=0.014, n=4) and 72hrs (p=0.033, n=4). These
findings correlate with the proliferation data (Figure 4.12).
The expression of CD69, as measured by the percentage of +ve cells (from 36% to
18%) and their mean fluorescent intensity (from 151 to 127), was also reduced in the
presence of the 5E1 neutralizing antibody (Figure 4.16). As with CD25 expression,
the effect was most notable at the 50pg/ml concentration (Figure 4.16F).
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Figure 4.15: 5E1 antibody reduces CD25 expression in human CD4+ T cells
at 72hrs.
Experiment 1:(A) Dot plot of CD4+ T cells after 72hrs in culture. Further
histograms gated on the R1 population. (B) Isotype control histogram.
Remaining histograms show cells cultured with (C) Ojig/ml and (D) 20pg/ml
Experiment 2:CD4+ T ceils after 72hrs in culture with (E) O^g/ml and (F)
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Figure 4.16: 5E1 antibody reduces CD69 expression in human CD4+ T
cells at 48hrs.
(A) Dot plot of CD4+ T cells after 48hrs in culture. Further histograms gated on
the R2 population. (B) Isotype control histogram. Remaining histograms show
cells cultured with (C) 0|ig/ml (D) 5(xg/ml (E) 20pg/ml and (F) 50pg/ml of 5E1
antibody. CD69 positive cells fall within the M1 region.
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4.4.4 ANTI-SHH NEUTRALIZING ANTIBODY DOES NOT AFFECT CELL
SURVIVAL IN ACTIVATED HUMAN CD4+T CELLS
As the 5E1 neutralizing antibody inhibits T cell proliferation, it was important to
determine if this was related to reduced cell survival, particularly in view of the links
between Shh signalling and apoptosis 559"561. To assess the effect of 5E1 on cellular
apoptosis and/or survival, the antibody was added to purified, activated human CD4+
T cells, as before. As in the peptide experiments the cells were stained with
AnnexinV-FITC and Propidium Iodide (PI) at 24hrs and 72 hrs, before flow
cytometry analysis (see Section 4.3.4). Data shown is representative of at least
repeated experiments.
In the experiments shown, there was no detectable difference in cell
survival/apoptosis between T cells cultured in the presence or absence of the 5E1
antibody, at either time-point (Figures 4.17 and 4.18). This would imply that
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Figure 4.17: 5E1 antibody does not affect cell survival in activated human
CD4+ T cells at 24hrs.
Control samples: (A) All cells (FSC/SSC) (B) cells unstained (C) AnnexinV
single stain (D) PI single stain and (E) "Dead cells" control. Thereafter, activated
cells cultured in the presence of (F) 0pg/ml (G) 10ng/ml (H) 20pg/ml of 5E1
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Figure 4.18: 5E1 antibody does not affect cell survival in activated human
CD4+ T cells at 72hrs.
Control samples: (A) All cells (FSC/SSC) (B) cells unstained (C) AnnexinV
single stain (D) PI single stain and (E) "Dead cells" control. Thereafter, activated
cells cultured in the presence of (F) 0pg/mi (G) 10fig/ml (H) 20pg/ml of 5E1
antibody for 72hrs and stained for AnnexinV and PI.
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4.5 Sonic Hedgehog signalling does not induce proliferation
of non-activated ('resting') human CD4+ T cells
The experiments outlined above have concentrated almost exclusively on purified
human CD4+ T cells activated using anti-CD3 and anti-CD28 antibodies. It was of
interest to determine whether Shh had any effect on unstimulated cells. Thus, similar
experiments using non-activated ('resting') T cells were carried out, using both the
N-Shh peptide and 5E1 antibody.
4.5.1 SONIC HEDGEHOG SIGNALLING DOES NOT INFLUENCE
PROLIFERATION OF RESTING T CELLS
Purified human CD4+ T cells were cultured in the presence of either the N-Shh
peptide (Figure 4.19A) or the 5E1 anti-Shh blocking antibody (Figure 4.19B). These
resting T cells were cultured for 72hrs before pulsing with tritiated thymidine. As
before readings were taken 16-24 hrs later.
The counts were generally very low, as would be expected in the absence of
activation. In addition, neither the N-Shh peptide nor the 5E1 antibody altered cell
proliferation, from any of the donors, when used at concentrations equivalent to
those proven to affect activated T cells. Notably, 'activated' and resting CD4+ cells
from the same donor were often analysed simultaneously. Even in 'responder'
donors, the resting T cells appeared to be unaffected by either the peptide or the
antibody. Similar results were seen with resting human CD8+ T cells as shown earlier
(Figure 4.3B).
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A) Human CD4+ T cell proliferation in the
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Figure 4.19: Neither the N-Shh peptide nor the 5E1 antibody affect
proliferation of resting CD4+ T cells.
Graphs are representative of proliferation (samples in triplicate at least) of T
cells cultured without activation. Each well was pulsed with tritiated thymidine
after 72hrs in culture and read 16-24hrs later. Proliferation of purified human
CD4+ T cells (showing means and standard deviations) in the presence of (A)
N-Shh peptide and (B) 5E1 antibody. Results are representative of at least 3
experiments.
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4.5.2 SONIC HEDGEHOG SIGNALLING DOES NOT AFFECT RESTING T
CELL SURVIVAL
Purified human CD4+ T cells were cultured in the presence of either the N-Shh
peptide or the 5E1 anti-Shh blocking antibody without activation. To assess whether
or not either of these compounds affected survival and/or apoptosis in a "resting"
population, the T cells were stained, for AnnexinV-FITC and PI and analysed by
flow cytometry.
Neither the N-Shh peptide nor the 5E1 antibody affected resting CD4+ T cell survival
or apoptosis (Figures 4.20,4.21 and 4.22). These findings correlate with the parallel
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Figure 4.20: N-Shh peptide does not affect cell survival in resting human
CD4+ T cells at 24hrs.
Control samples: (A) All cells (FSC/SSC) (B) cells unstained (C) AnnexinV
single stain (D) PI single and (E) "Dead cells" control. Thereafter, resting cells
cultured in the presence of (F) Ong/ml (G) 10ng/ml (H) 100ng/ml and (I)
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Figure 4.21: N-Shh peptide does not affect cell survival in resting human
CD4+ T cells at 72hrs.
Control samples: (A) All cells (FSC/SSC) (B) cells unstained (C) AnnexinV
single stain and (D) PI single. "Dead cells" control was as for Figure 4.11 (not
shown here). Thereafter, activated cells cultured in the presence of (E) Ong/ml
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Figure 4.22: 5E1 blocking antibody does not affect ceil survival in resting
human CD4+ T cells.
Control samples: (A) All cells (FSC/SSC) (B) cells unstained (C) AnnexinV
single stain (D) PI single and (E) "Dead cells" control. Thereafter, activated cells
cultured in the presence of (F) Opg/ml (G) 5pg/ml and (H) 20pg/ml of 5E1
antibody for 24hrs and stained for AnnexinV and PI.
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4.6 Discussion
As mentioned in the introduction to this chapter the Shh signalling pathway has
never previously been studied with respect to the mature immune system, and indeed
has only very recently identified in the developing immune system of humans and
Sonic Hedgehog Pathway expression in Human T cells
The findings reported here importantly confirm the presence of the ligand (Shh) and
the receptor (Ptc) of the Shh pathway, at both RNA and protein level, in human T
cells. The presence of Ptc is interesting in that it implies that human T cells could
respond to a Shh signal from other cell types, such as epithelial cells, in vivo. The
presence ofShh in these T cells suggests a potential for this pathway to play a role in
T cell autocrine signalling, and to allow T cells to send signals to other cells. As
described in chapter 3, both Shh and Ptc are also present in macrophages. Shh
signalling may also play a role in their function and activation, and possibly in T
cell-macrophage interactions.
Upregulation of the Shh pathway leads to a paradoxical increase in Ptc expression
itself. Therefore, an increase in Ptc expression has been used as an indicator of Shh
signalling 14>27'55. The data presented showed that Ptc mRNA expression is indeed
increased in both resting and activated human CD4+ T cells upon addition of the N-
Shh peptide. From this, one can postulate that the Shh pathway is functional in
human CD4+ T cells and that the N-Shh peptide is a suitable ligand. However, these
results were obtained using real time PCR analysis, as discussed in chapter 2.
Briefly, this is a relatively new technique in which the levels of the gene of interest
are compared to an internal positive control such as 18S, thereby allowing expression
of a particular gene to be quantitatively compared between samples. A potential
problem in data interpretation is determining what constitutes a significant relative
difference in RNA expression between two samples. In published work, comparing
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RNA expression in the context of gene microarrays 557>558) it was concluded that a 2-
fold difference (or greater) in RNA expression could be considered significant.
Therefore, the 4.7-fold increase in Ptc in activated T cells would be considered
significant, but the 1.7-fold difference in 'resting' T cells would not (Figure 4.2). In
addition, the relevance of any increase in mRNA alone could also be questioned.
Increased RNA expression does not necessarily equate with increased expression of
the associated protein, as other factors may be required for protein translation, or
indeed post-translational modification. However, in these experiments, Ptc protein
upregulation was difficult to evaluate, because the Ptc antibody proved incompatible
with either Western blotting or flow cytometry, and appreciation of increased Ptc
expression by immunocytochemistry against strong basal staining in untreated cells
(Figure 4.1) was not possible. Therefore relative Ptc expression could only be
assessed at the RNA level in this system.
Shh signalling and T cell receptor (TCR) mediated T cell activation
Addition of the N-Shh peptide to human T cells activated by anti-CD3/CD28
antibody treatment resulted in a dose dependant increase in proliferation, with peak
levels noted at a concentration of lOOng/ml. As the N-Shh peptide has been shown to
upregulate the Shh pathway, these findings imply that Shh signalling results in
augmentation of T cell receptor mediated activation. Shh signalling, as induced by
similar Shh peptides, has already been shown to increase proliferation in a range of
cell types 116'117'120, including haematopoietic stem cells 125. It would appear that the
pathway behaves in a similar manner in human T lymphocytes. The optimal
concentration for peak proliferation (lOOng/ml) was the same at which peak Ptc
mRNA expression was noted in previous experiments. Thus maximal Ptc expression,
suggestive of optimal Shh pathway activity, is associated with the greatest
proliferation.
Notably, as described, the proliferation of approximately 50% of donor CD4+ T cells
was unaffected by the addition of exogenous Shh. The reason for such 'responders'
and 'non-responders' is not clear. Bearing in mind that mutations in Ptc and Smo are
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known to result in constitutive Shh signalling activation 68'132'1333 it is possible that
there may be also polymorphisms which bring about the loss or modulation of
function of the pathway. Thus such polymorphisms may have rendered the donors
unresponsive to the N-Shh peptide.
Analysis of cytokine production followed similar trends to proliferation. Of most
significance, secretion of 3 of the 4 cytokines (IL2, IFNy and EL 10 but not IL5)
measured was increased in the presence of the N-Shh peptide, in a dose dependent
manner. The observed increase in IL2 secretion was in accordance with the increase
in T cell proliferation, since IL2 release is proportional to the amount of activation of
CD4+ T cells 562. It is possible that the IL5 results may have been affected by the
sensitivity of the assay used for this cytokine; a different system to the other
measured ELISAs. Indeed IL5 was often difficult to detect even in the presence of
high levels of the other cytokines. As discussed in Chapter 1, IL2 and IFNy are
associated with Thl T cells, and IL5 and to a lesser extent EL 10 with Th2 461'462. As
the pattern of cytokine secretion observed in the presence of the N-Shh peptide does
not appear to conform to either phenotype, it would therefore appear that Shh
signalling results in a polyclonal increase in cytokine secretion.
Furthermore, the highest levels of IL2, IFNy and EL 10 were associated N-Shh peptide
concentrations of lOOOng/ml. This differed slightly from the mRNA and proliferation
experiments in which lOOng/ml was found to be the peak concentration, above which
levels ofPtc transcript and proliferation diminished.
The presence of N-Shh also increased the proportion of cells staining positively for
both CD25 (IL2 receptor a chain) and CD69 (Activation Inducer Molecule or AIM),
in a dose dependent manner. These cell surface markers are themselves upregulated
upon activation of T lymphocytes. CD25 expression is maintained on the surface of
T lymphocytes by activated STAT5 (A and B) although initial expression of CD25 is
regulated by T cell receptor (TCR) activation 5I6. Maintenance of CD25 expression
on T cells works in a cyclic pattern whereby ligation of IL2 to the IL2 receptor
(IL2R) initiates STAT5 activation, which in turn induces expression of IL2R.
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Expression of CD69, however, is regulated by activated Ras 507, which plays an
integral role in TCR mediated signalling 508>563. it may be that Shh signalling
modifies STAT5 and Ras activation, thus leading to upregulation of CD25 and
CD69.
CD25 expression increased in a dose dependant manner with maximal expression in
the presence of the higher lOOOng/ml concentration of the N-Shh peptide. It is
encouraging to note that this matches the pattern observed in IL2 secretion. CD69
expression was most marked at the intermediate dose of lOOng/ml. This correlates
more closely with the proliferation and real time data and less so with cytokine
secretion. Therefore, it would appear that optimal N-Shh peptide concentrations vary
with different aspects of T cell function, including proliferation, cytokine secretion
and surface activation marker expression. Of course, there is a large body of
evidence, which demonstrates that proliferation can be dissociated from other T cell
effector functions, such as cytotoxic activity and cytokine production 564.
As described, Shh signalling has been previously linked with apoptosis 559-561. To
determine whether the observed increases in T cell proliferation with the N-Shh
peptide were influenced by improved cell survival, flow cytometric analysis, using
AnnexinV-FITC and PI, was carried out. Neither AnnexinV binding nor PI staining
was altered in the presence ofN-Shh, demonstrating that enhanced proliferation was
not due to increased cellular survival. Therefore, Shh signalling augments TCR
mediated T cell activation without affecting cell survival or apoptosis. These
observations bear similarities to those presented by Outram et al 121 who showed
that, whilst Shh signalling affects thymocyte differentiation and proliferation, it does
not affect thymocyte survival.
The effects of blocking endogenous Shh signalling on (TCR) mediated T cell
activation
5E1 has been established as an anti-Shh neutralizing antibody in several systems
121'125. In effect, it has been used to inhibit Shh signalling by preventing binding of
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endogenous Shh protein to the Ptc receptor. As both Shh and Ptc are present in
human T cells it would be logical to assume that autocrine signalling may take place.
As one might predict, 5E1 inhibited proliferation of human CD4+ T cells, at
concentrations of 20pg/ml and above, in keeping with observed affects in human
haematopoietic stem cells at similar concentrations 125. Therefore, it would appear
that endogenous Shh maintains proliferation in the CD4+ T cell culture, and blocking
of this endogenous Shh thus decreases proliferation. As with the N-Shh peptide, the
5E1 antibody had no effect on the CD4+ proliferation in approximately 50% of
donors, presumably for the same reason.
The presence of the 5E1 antibody resulted in a reduction in both IL2 and
IFNy secretion from activated human CD4+ T cells, but did not affect either IL5 or
IL10 production. Their reduction was in accordance with the decrease in
proliferation; as were increases with the N-Shh peptide with enhanced proliferation.
IL5 appears to be unaffected by either enhancing or inhibiting Shh signalling.
However, as discussed earlier, these findings may be related to the sensitivity of the
IL5 ELISA. In addition, it is not clear why exogenous Shh (N-Shh) increases IL10
secretion, whilst blocking endogenous Shh does not reduce it. It may be that IL10
production can be regulated by TCR signalling independently of Shh activation.
It is also notable that the concentrations of 5E1 as low as 5pg/ml significantly
lowered cytokine production, whereas only levels of 20pg/ml and above affected
proliferation. As in the peptide experiments, different concentrations of 5E1 affect T
cell proliferation and cytokine production.
Consistent with these findings, expression of the surface activation markers CD25
and CD69 was also reduced in the presence of the 5E1 neutralizing antibody. This
effect was most pronounced at the highest 50pg/ml dose. Considering these
observations, and the effects of the antibody on proliferation and IL2 secretion, it is
plausible that the induction of Shh signalling is a physiological component of T cell
activation following the ligation of TCR and co-stimulatory receptors.
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As with N-Shh, AnnexinV and PI analysis was performed to determine if the
decrease in T cell proliferation seen with 5E1 was in any way due to cellular
apoptosis or necrosis. The staining of both was unchanged confirming that these
processes were not responsible and that 5E1 was not affecting T cell survival.
Shh signalling in unstimulated ('resting') T Cells
Similar experiments using both the N-Shh peptide and the 5E1 antibody were carried
out in "resting" T cells i.e. purified human CD4+ T cells cultured in the absence of
the anti-CD3 and anti-CD28 antibodies. The aim was to see if the observed effects
described could occur in the absence of T cell activation.
As already discussed, relative Ptc mRNA expression in 'resting' T cells, in the
presence of the N-Shh peptide, was only 1.7-fold greater than with no peptide,
compared with up to 4.7-fold in activated cells. Accepting 2-fold differences as the
cut-off for biological significance 557-558j exogenous Shh does not appear to stimulate
Shh signalling in 'resting' T cells populations.
Neither the N-Shh peptide nor the 5E1 antibody altered proliferation in resting T
cells, even from donors in whom these agents significantly affected activated T cell
proliferation. AnnexinV/PI analysis confirmed that neither the peptide nor the
antibody affected cellular apoptosis or necrosis in resting T cells. Cytokine secretion
was measured in resting T cells but, as would be expected, levels were invariably
undetectable. The same was true for surface activation marker (CD25 and CD69)
expression (data not shown).
Therefore, it would appear that the Shh pathway is not functional in resting T cells.
This correlates with published work, in which Shh was unable to recruit quiescent




The work detailed in this chapter confirms that the Shh pathway is present and
functional in purified human CD4+ T cells. Increased pathway activity, by addition
of exogenous Shh, enhances T cell receptor mediated T cell activation as
demonstrated by proliferation, cytokine secretion and surface marker expression.
Blocking the endogenous Shh pathway inhibits activation as determined by the same
assays. Taken together these features suggest that the induction of Shh signalling is a
physiological component of peripheral CD4+ T cell responses. However, the pathway
does not appear to have any affect on T cell survival, nor does it induce proliferation
in non-activated ('resting') T cells. This latter feature suggests that Shh may act as a
cofactor, which potentiates TCR mediated signalling and amplifies clonal expansion.
Although not shown in this thesis, similar experiments carried out using purified
murine CD4+ T cells (collaborative work with Dr Jacqueline Lowry) suggest that the
pathway functions in a similar manner in mice. As the Shh (and hedgehog) pathway
is highly conserved throughout species, so may be the biological effects
demonstrated in the human system reported here and in this related mouse work.
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Chapter 5




The Wnt Signalling Pathway, like the Shh Pathway, is highly conserved throughout
species (see Chapter 1), and the two pathways are known to interact with one another
3 238 239' '
. As discussed in chapter 1, dysregulated Wnt signalling has been implicated
in several diseases in mature mammals, and particularly in tumourigenesis.
Upregulation of the Wnt pathway can result in an increase in epithelial cell
948 9SO
proliferation " . Furthermore, it has been recently reported that Wnt signalling is
associated with increased fibronectin expression and with TGF(3 signalling
203,240,241,566^ wj1icj1 have ciose associations with fibrosis. These features
together prompted the proposed hypothesis that the Wnt pathway may play a role in
the pathogenesis of Interstitial Lung Disease (ILD). More specifically, the aim of the
work presented in this chapter was to upregulate Wnt signalling in mouse lungs to
determine whether or not this lead to lung fibrosis.
It has been shown that overexpression of dishevelled (dsh) upregulates Wnt
signalling 187"189. The main objective, therefore, was to overexpress the mammalian
homolog, Dvll, in vitro and in vivo in mammalian systems in an attempt to induce
Wnt signalling. This was to be achieved by constructing a replication deficient
adenovirus expressing Dvll. The particular advantages of adenovirus vectors are
discussed in Chapter 1.
The work in this chapter addresses the expression ofWnt pathway members in ILD,
and the construction of a Dvll adenovirus with its use in vitro and in vivo. It is
important to point out that the experiments were not all carried out in the order in
which they have been discussed in this chapter. In particular, due largely to a paucity
of available reagents, much of the initial immunohistochemistry (IHC) presented
(Section 5.2) was not performed until later in the project. Hence, the adenoviral
experiments were not biased by these negative IHC findings.
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5.2 The Wnt Signalling Pathway in the FITC Model of ILD
The FITC model was used as a tool to investigate the Wnt pathway in the context of
lung fibrosis. Lungs sections taken from both PBS and FITC treated mice were
stained by IHC for two components (Dvll and (3-catenin) of the pathway. Results are
representative of at least six mice per treatment per time-point.
5.2.1 DVL1 EXPRESSION IS UNALTERED IN THE FITC MODEL OF ILD
Several Dvll antibodies, obtained commercially or as gifts, were tested and found to
have no specificity for Dvll protein. A polyclonal antibody kindly provided by Dr
Roel Nusse 567 was found to be particularly useful for Western blotting. However this
antibody also recognises Dvl2; its cross-reactivity on Dvl3 is not known (personal
correspondence with Dr Karl Willert, Howard Hughes Medical Institute, Stanford
University School ofMedicine). The antibody had not been previously used for IHC.
To establish if Dvll expression varied in lung fibrosis, lung sections from BALB/c
mice treated intra-tracheally with either FITC or PBS were stained with the
polyclonal anti-Dvll antibody. The airway epithelial cells were strongly positive
(brown staining) and the alveolar epithelium less so, whilst the remaining lung tissue
- including endothelium and cell infiltrates - was negative (Figure 5.1). The same
pattern and intensity of staining was noted in both PBS and FITC treated mice at all
time-points from 24hrs to 5 months (Figure 5.1). Therefore, based on the results of
stains with this antibody, expression of Dvll did not appear to change in the FITC
model of lung fibrosis.
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Figure 5.1: Dvl1 expression in the FITC model of lung fibrosis
Dvl1 expression by immunohistochemistry in BALB/c mouse lungs
A) Day 7 after PBS instillation (x 400 magnification)
B) Day 7 after FITC instillation (x 400 magnification)
C) 5 months after PBS instillation (x 400 magnification)
D) 5 months after FITC instillation (x 400 magnification)
- 210 -
5.2.2 BETA-CATENIN EXPRESSION, AS ANALYSED BY IHC, IS
UNALTERED IN THE FITC MODEL OF ILD
Further lung sections from FITC and PBS treated mice where stained for the
presence of (3-Catenin. Samples from time-points from 24hrs to 5 months post
instillation were analysed.
There was no discernible difference in (3-Catenin expression between the treatment
groups at any of the time-points (Figure 5.2). Predominantly membrane staining was
observed, which was most apparent on the airway epithelial cells and less so on the
alveoli (Figure 5.2). Since (3-Catenin is predominantly localised to the cell
membrane, where it interacts with cadherins in cellular adhesion, this distribution is
as would be expected. Interestingly, the staining was largely confined to areas of the
cell membrane in contact with adjacent cells as seen most clearly in Figure 5.2 C and
D.
It has been shown that upregulation of the Wnt pathway results in increased cytosolic
(3-Catenin levels. There was no evidence of increased cytoplasmic staining in
sections either from the FITC or PBS treated mice (Figure 5.2).
Therefore, as assessed by IHC, (3-Catenin expression in mouse lungs is unaffected by
FITC treatment. Most importantly, there is no evidence from the data presented that
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Figure 5.2: (3-Catenin expression in the FITC model of lung fibrosis
p-Catenin expression by immunohistochemistry in BALB/c mouse lungs
A) Day 3 after PBS instillation (x 400 magnification)
B) Day 3 after FITC instillation (x 400 magnification)
C) 5 months after PBS instillation (x 400 magnification)
D) 5 months after FITC instillation (x 400 magnification)
E) Day 3 after FITC instillation (x 200 magnification)
F) Negative control: Day 3 after FITC instillation (x 400 magnification)
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5.3 Adenovirus Construction
5 .3 .1 CLONING OF DVL1 INTO PDK6
The murine Dvll cDNA was a kind gift from Dr Daniel Sussman, provided as pSK+-
Dvll (Figure 5.3D). The initial aim was to clone this into a shuttle vector (pDK6),
containing the MCMV (murine cytomegalovirus) promoter, a polyadenylation signal
and essentially the "left side" of the adenovirus genome: Ad-5 sequences from 0 to 1
and 9.8 to 15.8 map units (mu), with the El region, which is essential for adenovirus
replication, deleted.
The pSK+-Dvll and pDK6 cDNAs were initially amplified using a commercially
available kit as detailed in chapter 2. 10pg of each was then digested overnight at
37°C. The pSK+-Dvll was initially digested with the restriction enzymes EcoR I and
Xho I in the presence of Buffer H (Promega), and the pDK6 with EcoR I and Sal I
with Buffer D. The cut Dvll fragment would later be inserted into the cut pDK6
using these sites. This was possible because digests with Xho I and Sal I have
compatible ends; therefore an EcoR I/Xho I fragment can be inserted into an EcoR
ESal I site.
Following these initial digests samples were analysed by agarose gel electrophoresis.
As described in chapter 2, with the lkb ladder, the brighter central band on each gel
(Figure 5.3) corresponds to ~1.6kb; the bands higher than this to ~2kb, 3kb, 4kb,
5kb, 6kb, 7kb, 8kb, 9kb, lOkb, 1 lkb and 12kb respectively, and the lower bands to
~500bp, 400bp, 350bp, 300pb, 220bp, 200bp, 150bp and 75bp, respectively. The
PCR ladder used represents: 2kb, 1.5kb, lkb, 750bp, 500bp, 300bp, 150bp and 50bp,
from the largest molecular weight band down. Cutting pSK+-Dvll with EcoR I/Xho I
resulted in 2 fragments: Dvll (3.29kb) and pSK+ (2.96kb). This is not obvious in the
gel shown, as they are so similar in size (Figure 5.3A). However 2 bands were
consistently observed when the gel was run for longer allowing greater band
separation (not shown). The EcoR I/Sal I cut was within the multiple cloning site of
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the pDK6, and resulted in a large (~7.9kb) fragment and a very small fragment
consisting of < 50bp. Only the former was visible on the agarose gel (Figure 5.3A).
The pDK6 was cut in 10 separate, identical restriction enzyme digests, and the final
digests pooled before purification.
The cut pSK+-Dvll and pDK6 (pooled) were then purified by phenol/chloroform
extraction and ethanol precipitation. Because of the closeness in size of the Dvll and
pSK+ bands, the latter was cut into 2 smaller fragments using Pvu I in the presence of
Buffer D (Promega). Importantly this enzyme does not cut Dvll. A check gel
confirmed an intact Dvll fragment (3.29kb) and 2 smaller fragments of pSK+ (Figure
5.3B). The upper (Dvll) band was excised, and the extracted DNA was run on a
further gel confirming a single Dvll band of the correct size (Figure5.3C)
The cut and purified pDK6 was also run on a fresh gel and the large single band
excised. As with Dvll the DNA was extracted and a final check gel confirmed a
single pure band of pDK6 of the correct size (Figure 5.3C). These Dvll and pDK6












EcoR 1 (5 )
Figure 5.3: Cloning of Dvl1 into pDK6
A) 1% agarose gel with samples of pSK+-Dvl1 (EcoR I and Xho I) and pDK6
(EcoR I and Sal I) following initial digests; Dvl1 being 3.29kb,pSK+ 2.96kb and
pDK6 7.9kb.The two Dvl1 and pSK+ bands appear as one on this gel. B) 1%
agarose gel showing Dvl1 following additional digest with Pvu I This has cut the
pSK+ into 2 smaller fragments (lower 2 bands) whilst leaving the 3.29Kb Dvl1
intact (top bands). C) 1% agarose gel with the gel extracted Dvl1 and pDK6
fragments; ready for ligation. D) Plasmid map of pSK+-Dvl1 showing the Dvl1
fragment (thicker segment) between the chosen restriction enzyme sites
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5.3.2 THE PDK6-DVL1 LIGATION
It was necessary to confirm the ligation of Dvll into pDK6. As already mentioned
the former was cut using EcoR I/Xho I and the latter using EcoR ESal I. The ligation
was possible because Xho I and Sal I leave compatible ends. However this restriction
site would be destroyed in a successful ligation reaction. There were few other
available compatible enzymes that would allow the insert to be cleanly cut, without
also cutting either the insert or plasmid (pDK6) in other regions. Therefore
successful ligations could not be simply verified by cutting out the (Dvll) insert.
This problem was dealt with in two ways.
The ligation product was cut with only the EcoR I enzyme. This only cut in one site
and effectively "linearised" the DNA. Both pDK6 alone and the candidate pDK6-
Dvll ligations were cut with EcoR I. Linearised pDK6 was ~7.9kb in size and
pDK6-Dvll ~11.2kb (7.9+3.29kb) as shown in Figure 5.4A. As this was a rather
crude estimate further evidence was required. To confirm this finding 2 sets of
primer pairs (A and B) were designed specifically for murine Dvll cDNA. DNA
from the pDK6-Dvllligation and control Dvll DNA were incorporated in PCRs with
these primer pairs. Dvll cDNA was used as a positive control. The PCR products,
run on a 1% agarose gel, were of the correct predicted size, confirming successful
pDK6- Dvll ligation (Figure 5.4A).
5.3 .3 DVL1 IS PRESENT WITHIN THE ADENOVIRUS PLAQUES
Following the pDK6-Dvll ligation, the next stage was to co-transfect this product
with the remainder of the adenovirus genome. The co-transfection was carried out
with the plasmid pBHGlO (which contains the entire adenovirus genome apart from
0.5-3.7 mu and 78-85.6 mu) in the presence of 293 cells (human embryonic, kidney
epithelial cells). Homologous recombination gave rise to an El-deleted (replication
deficient) adenovirus containing murine Dvll cDNA under the control of the MCMV
promoter (Ad5-MCMV-Dvll).
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The 293 cells provided the El region in trans allowing replication and amplification
of the adenovirus to be facilitated. The rescue of a replicating recombinant
adenovirus resulted in the development of slowly expanding areas of dying cells seen
beneath an agarose overlay, referred to as "plaques". Details of adenovirus
construction are discussed in greater detail in Chapter 2.
Following a number of co-transfection attempts, 2 plaques developed simultaneously
in one of the culture plates (plaques 1 and 2). DNA originating from these plaques
was then analysed for Dvll expression.
As with the pDK6-Dvl 1 ligation PCR reactions were carried out using both sets of
Dvll primer pairs (A and B). These confirmed the presence of Dvll cDNA in both
plaques (Figure 5.4B), demonstrating that Ad-5-MCMV-Dvll had been successfully
rescued.
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Figure 5.4: Confirming Dvl1 DNA expression
A) 1% agarose gel. EcoR1 digests of 1, pDK6, and 2, pDK6-Dvl1. 3 1 kb ladder.
PCR using Dvl1 primer set A (4+5) and B (6+7); former giving a PCR product of
894bp and latter of 521 bp. 4 and 6 represent products of PCR reactions using
Dvl1 as a positive control. 5 and 7 are of PCR reactions containing ligation
products. B) Further PCR reactions analysing DNA extracted from adenovirus
plaques; 2-5 primer set A and 6-9 primer set B. 1 and 10 PCR ladders. Within
each reaction: 2+6 DNA from plaque 1, 3+7 from plaque 2, 4+8 using pSK+-
Dvl1 as a positive control and 5+9 using water only in the PCR reactions as a
negative control.
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To confirm Dvll expression in these plaques, the extracted DNA was also used in
Southern Blots. Initially the DNA was digested with the restriction enzyme Hind III
in the presence ofBuffer E (Promega). Both 5pi and lOpl of each plaque digest were
loaded onto the gel (Figure 5.5 lanes 4 to 7). The plasmid pBHGlO was digested in
the same manner and run on the same agarose gel (Figure5.5 lane 3). Finally
linearised (Xho I single digest) pSK+-Dvllwas added as a positive control (lane 2).
Hind III is known to cut pBHGlO into 10 fragments of sizes: 8010bp, 5324bp,
4597bp, 3790bp, 3437bp, 3012bp, 2937bp, 208lbp, 1539bp and 75bp. These are
visible in lane 3 (Figure 5.5). All are visible except the smallest 75bp band, and the
3012bp and 2937bp bands are probably seen merged as the brighter band just below
arrow A. Once homologous recombination has taken place, and the shuttle vector has
become integrated into the pBHGlO backbone, a number of the Hind III sites are
moved or lost. This leads to an altered restriction digest pattern. In the case of pDK6-
Dvll one would predict the 3790bp, 3437bp and 1539bp bands would be lost with an
additional band at ~8kb. This was indeed observed. Arrow A indicates the presence
of the 3790bp and 3437bp bands in the pBHGlO digest (Figure 5.5 lane 3) and their
absence in the plaque digests (lanes 4-7). In addition, the 1539bp band (lowest seen
in lane 3) was absent in the plaque DNA lanes. Any additional ~8kb band would be
difficult to distinguish from the preserved 8010bp band. These digests were
consistent with a successful homologous recombination leading to the formation of
the observed adenoviral plaques (The streaking observed in the plaque DNA lanes is
due to the presence of genomic DNA).
Following blotting the membrane, containing the transferred DNA, was hybridised
with a 32P-labelled probe specific to murine Dvll. The probe was made by digesting
DVL-1 with Kpn I: producing a 574bp Dvll cDNA probe (not shown). This
fragment was gel excised before labelling and hybridisation. In Figure 5.5, the
bottom panel shows a radiograph of the same blot as the top gel picture. The probe
recognised the linearised +ve control (pSK+-Dvll) at the expected size of 6.2kb
(+ve)[Arrow C], Additionally it did not cross-react with the digested pBHGlO,
which should not contain Dvll, therefore acting as a suitable -ve control. Most
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importantly the probe recognised ~8kb bands within all of the plaque DNA lanes
[Arrow B], From the predicted Hind III digest the additional ~8kb band would be
expected to contain the Dvll cDNA, and therefore bind to the Dvll probe. In lanes 4
to 7, the lOp.1 samples are outer (4+7) and the 5pl innermost (5+6) for plaques 1 and
2, which correlates with the strength of signal observed in each lane.
The Southern Blot and digest therefore confirmed that the recombinant adenovirus
present in plaques 1 and 2 did indeed express Dvll cDNA. Ad5-MCMV-Dvll had
been successfully rescued.
Further details of large scale preparation and purification to produce the banded Ad5-
MCMV-Dvll (for experimental use) are described in Chapter 2. Control
adenoviruses used included a Lac Z expressing virus (gift from Dr Jean-Michel
Sallenave) and dl70-3 (gift from Prof Jack Gauldie). The dl70-3 adenovirus contains
no insert eg. pDK6 co-transfected with no Dvll. Both of these control viruses were





Figure 5.5: Southern Blot of Ad5-MCMV-Dvl1
The upper panel illustrates the 0.8% agarose gel with 1 and 8 being 1kb ladder,
2 the +ve control (linearised pSK+-Dvl1), 3 digested pBHGIO control, and 4+5
(plaque 1) and 6+7 (plaque 2) digests of plaque DNA. Arrow A indicates where
bands present in the pBHGIO digest are lost in the plaque DNA digests.
The lower panel is a radiograph of the same blot following hybridisation with a
32P labelled probe specific to murine Dvl1. Arrow B indicates the +ve bands
noted within the plaque DNA samples: ~8kb. Arrow C indicates the +ve control
band (linearised pSK+-Dvl1): ~6.2kb
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5.4 Effects of the Dvl1 Adenovirus in vitro
In the following series of experiments the purified, banded Ad5-MCMV-Dvll was
added to different cell types and a variety of effects analysed. The Lac Z and dl70-3
adenoviruses were used as controls in each transfection. In order to ensure equivalent
concentrations of these different viruses were used the titre of each was calculated, as
described in chapter 2. Each titre was expressed as plaque forming units per ml
(pfii/ml). The titre of the Dvll adenovirus was 1.6xl010pfu/ml, Lac Z was
1.8xl010pfu/ml and dl70-3 was 2.7xl010pfu/ml.
Knowing the titre, the amount of virus added to each culture dish or well can be
calculated. The quantity of virus added in vitro is expressed as a multiplicity of
infection (moi), which is the ratio of pfu's of virus to the number of cells within the
well (eg. moi of 10 signifies that 10 pfu's of adenovirus are added per cell).
5.4.1 AD5-MCMV-DVL1 RAISES DVL1 RNA EXPRESSION IN VITRO
The Ad5-MCMV-Dvll was added to A549 cells (human epithelial lung carcinoma
cell line) and Rat 1 fibroblasts at a range of moi's. These cells were harvested at
time-points from 24 to 72 hrs post-transfection. RNA was extracted, quantified and
run on formaldehyde gels (Figure 5.7A) for Northern Blotting.
The radiographs in Figure 5.6 show the expression of Dvll and GAPDH mRNA
following adenoviral transfection. The top radiograph is representative of the blot
following hybridisation with a 32P labelled probe specific to murine Dvll. This was
the same probe as that used for the Southern Blot described (Figure 5.5). In the A549
cells Dvll expression was negligible in untreated cells (moi 0). Dvll levels rose with
increasing moi of Ad5-MCMV-Dvll; from moi 1 to 100. This was evident at both
48hrs and 72hrs post-transfection. In the case of the Rat 1 fibroblasts Dvll was
detectable even in untreated cells and increased with increasing moi; though not to
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the same extent as in A549 cells. In both cell types the Dvl 1 signal was present as a
doublet at ~4kb. This was slightly larger than Dvll cDNA (3286bp). This larger size
was most likely as a result of the additional poly-A tail associated with mRNA and
not cDNA. The reason for the doublet was less clear. It is possible that the probe also
picked up a spliced variant of Dvll, though time constraints meant this was not
investigated further during this thesis.
The lower radiograph in Figure 5.5 shows the same blot following stripping of the
Dvll probe and hybridisation with a second 32P labelled probe specific to GAPDH
(~500bp). This "house-keeping gene" was used to assess whether or not the same
amount of RNA had been loaded in each lane, thereby validating the data presented
above. The observed increases in Dvll were therefore real. Although less than A549
cells, the level of GAPDH expression was equal between the Rat 1 fibroblast lanes,
confirming that the observed increases in Dvll in these cells were also genuine
As mentioned, Dvll expression appeared to increase to a greater extent in A549 than
Rat 1 cells with equivalent moi's of Ad5-MCMV-Dvll. This may have been as a
result of a relatively more efficient transfection of the A549 cells and/or related to
the baseline expression of Dvll in the two cell types. Notably, neither cell is of
mouse origin (inserting murine Dvll)\ though the strong homology of the Wnt
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Figure 5.6: Northern 1 of Ad5-MCMV-Dvl1 in vitro
The samples in both radiographs are human A549 cells and Rat 1 fibroblasts
treated with different concentrations of Ad5-MCMV-Dvl1. The numbering
indicates the concentration, referred to as the multiplicity of infection (MOI) of
adenovirus; ranging from 0 (no virus added) to 100. The first bracketed A549
cells were harvested (for RNA extraction) at 72hrs, as were the Rat 1
fibroblasts. The final three A549 lanes contained cells harvested at 48hrs.
The top caption is a radiograph following hybridisation with a 32P labelled probe
specific to murine Dvl1.The faint band in the marker lane immediately adjacent
to the Dvl1 arrow (extreme left) is ~4kb.
The lower radiograph is of the same blot following stripping of the Dvl1 probe
and hybridisation with a second 32P labelled probe specific to GAPDH.
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Northern blot data confirmed that Dvll mRNA is upregulated in vitro upon
transfection with Ad5-MCMV-Dvll. Since a control adenovirus had not been
included in these preliminary experiments, it was necessary to repeat the
transfections incorporating matched controls.
As before, the Ad5-MCMV-Dvllwas added at a range of moi's to A549 cells and
Rat 1 fibroblasts. The extracted RNA (48hr time-point) was run on a formaldehyde
gel (Figure 5.7A). This was then blotted overnight onto nitrocellulose membrane
(Figure 5.7B) before hybridisation.
In Figure 5.8 (as in Figure 5.6) the two radiographs are of the same blot; the upper
probed with murine Dvll and the lower with GAPDH. As before Dvll expression
increased with the moi of Ad5-MCMV-Dvll. Additionally adding the control
adenovirus (Lac Z) at equivalent moi's to Ad5-MCMV-Dvll did not increase Dvll
levels. The effect therefore was specific to the Dvll virus. The GAPDH radiograph
again confirmed equal RNA loading of both the A549 cells and Rat 1 fibroblasts;
validating the Dvll data.
A sample ofmouse brain RNA was also included in this northern blot (Figure 5.8) as
a positive control; Dvll is highly expressed in neural tissue. The Dvll expression in
this control was similar to that in the in vitro transfections. Significantly, a doublet
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Figure 5.7: Northern 2 of Ad5-MCMV-Dvl1 in vitro: gel and membrane
A) Formaldehyde gel of RNA from A549 cells and Rat 1 fibroblasts treated with
either Ad5-MCMV-Dvl1 or a control adenovirus expressing Lac Z. All cells were
harvested at 48hrs. In lanes 2-13 the upper bands are 28S (4718bp) and the
lower 18S (1874bp). Lane 1: RNA ladder. Lanes 2-7: A549 cells. Lanes 8-12:
Rat 1 fibroblasts. Lane 13: RNA from mouse brain as a +ve control. (The lines
across the gel are due to the cling film it was wrapped in for protection from any
RNases)
B) Nitrocellulose membrane containing the same RNA samples as above,
following blotting. This membrane was later hybridised with the specific probes
before exposure to film (Figure 5.8).
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Figure 5.8: Northern 2 of Ad5-MCMV-Dvl1 in vitro: radiographs
The radiographs above are of the same samples shown in Figure 5.7. As in
Figure 5.6 the numbering refers to the multiplicity of infection (MOI) of
adenovirus used. These are also colour coded. The black numbering refers to
cells not treated with adenovirus (0 moi) or to the positive control sample
(mouse brain RNA). As in the key the yellow numbering refers to cells treated
with the Dvl1 expressing adenovirus and the red to the Lac Z (control virus)
virus.
As in Figure 5.6, the top caption is a radiograph following hybridisation with a
32P labelled probe specific to murine Dvl1. The lower radiograph is of the same
blot following stripping of the Dvl1 probe and hybridisation with a second 32P
labelled probe specific to GAPDH.
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Dvll mRNA expression was thus confirmed by Northern blotting. For comparison,
samples transfected with adenovirus were also analysed by real time PCR. This has
the advantage of being quicker and more easily performed than Northern blotting, as
well as yielding immediate quantitative data.
Using real time PCR, an increase in the expression of murine Dvll was observed in
the presence of Ad5-MCMV-Dvll, in a dose dependant manner in A549 cells
(Figure 5.9A), mouse Swiss 3T3 fibroblasts (Figure 5.9B) and in a mouse Clara cell
line (Figure 5.10).
In A549 cells murine Dvll was undetectable in those cells treated with the control
adenovirus (dl70-3) and in untreated cells. As they are human cells this is not
unexpected, though one would not have been surprised should the primers have
picked up endogenous human Dvll (full sequence unknown). With the addition of
Ad5-MCMV-Dvll the levels ofDvll rose steadily (Figure 5.9A).
In the mouse Swiss 3T3 fibroblasts a baseline level ofDvll was detectable. This rose
proportionally in response to the Dvll adenovirus with peak levels (moi 100 at
72hrs) at almost 40 fold greater than baseline (Figure 5.9B).
When Ad5-MCMV-Dvllwas added to a mouse Clara cell line (Figure 5.10) the level
ofDvll expression greatly increased with the higher moi's (100). As with the Swiss
3T3 fibroblasts Dvll was detectable in untreated cells (this is not clear in Figure 5.10
due to the graph scale). The relative Dvll mRNA level rose to ~ 240 fold at 24hrs
and -1300 fold at 48hrs, compared to expression in untreated cells.
The real time PCR and northern blot data therefore concur. It is clear that Ad5-
MCMV-Dvll increases murine Dvll mRNA levels in vitro in several cell lines.
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Figure 5.9: Ad5-MCMV-Dvl1 increases Dvl1 mRNA expression in vitro as
assessed by real time PCR
A) Relative Dvl1 mRNA expression in A549 cells 48hrs after treatment with
either Ad5-MCMV-Dvl1 or a control adenovirus (dl70-3). Each point is
representative of an average of 2 identically treated samples. As murine Dv!1
was undetectable in both the untreated (NONE) and control virus (CON)
groups, remaining results are expressed relative to the expression in the DVL
moi 1 (Dvl1) samples, which were given a value of 1(n=3) B) Relative Dv!1
mRNA expression in mouse Swiss 3T3 fibroblasts after treatment with either
Ad5-MCMV-Dvl1 or a control adenovirus (dl70-3). All values are expressed
relative to the baseline expression in untreated (NONE) cells at 24hrs: given a
value of 1. RNA levels are shown at 24hrs, 48hrs and 72hrs (n=3)
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Figure 5.10: Ad5-MCMV-Dvl1 increases Dvl1 mRNA expression in murine
Clara Cells
Relative murine Dvl1 mRNA expression in mouse Clara cells after treatment
with either Ad5-MCMV-Dvl1 or a control adenovirus (dl70-3). At each time-point
all values are expressed relative to the baseline expression in untreated
(NONE) cells: given a value of 1. A) 24hrs and B) 48hrs (n=3)
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5.4.2 AD5-MCMV-DVL1 RAISES DVL1 PROTEIN EXPRESSION IN VITRO
The data presented above demonstrates that Ad5-MCMV-Dvll induces Dvll mRNA
production in vitro. However it is possible for an adenovirus to produce mRNA
without protein translation (Prof Gauldie, personal communication). It was therefore
important to confirm whether or not Ad5-MCMV-Dvll also induces Dvll at protein
level.
To address this A549 and murine Clara cells were transfected with Ad5-MCMV-
Dvll or control adenovirus (dl70-3) at a range of moi's. At time-points from 6hrs to
72hrs cells were harvested and the cytoplasmic lysate separated, which also
contained a large proportion of the membranous proteins. Following quantification
equal amounts of each sample were loaded onto SDS-Page gels for Western blotting.
The blots were then incubated with the anti-Dvll polyclonal antibody (Roel Nusse)
before ECL development.
The addition of Ad5-MCMV-Dvll to both A549 and Clara cells lead to a dose-
dependant rise in Dvll protein (Figure 5.11). Dvll was barely detectable in either
untreated cells or in those treated with the control adenovirus. The Dvll antibody
recognised several bands at ~80kDa, as had previously reported by others 567. As
already mentioned the antibody is known to cross-react with Dvl2, and it is not
known if it recognises Dvl3.
Cytospins made from Clara cells transfected with Ad5-MCMV-Dvll or dl70-3, at
moi's of 100, were stained immunocytochemically using the same anti-Dvll
antibody. These clearly showed positive membrane staining in cells treated with the
Dvll adenovirus but not in the control cells (Figure 5.11 A and B). This is a
significant observation in that it is known that Dvll migrates to the cell membrane
upon upregulation 186
Therefore Ad5-MCMV-Dvll induces Dvll protein synthesis in vitro.
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Figure 5.11: Ad5-MCMV-Dvl1 increases Dvl1 protein expression in A549
and Clara Cells
In each of the radiographs C represents control adenovirus (dl70-3) and D, Ad5-
MCMV-Dvl1. The numbering is indicative of the moi of virus used. 0 indicates
untransfected cells.
The top radiograph is a western blot of transfected A549 cells and the lower of
transfected Clara cells incubated with the anti-DvM antibody. In both cases the
visible bands are ~80kDa; correct size for Dvl1 (n=3)
The images A and B are cytospins of transfected Clara cells stained
immunocytochemically with the anti-DvM antibody. Positive staining is brown
against a haemotoxylin (blue) counterstain. A) Cells transfected with control
adenovirus (dl70-3) at a moi of 100. B) Cells transfected with Ad5-MCMV-Dvl1
moi 100 (n=3)
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5.4.3 DVL1-AD RAISES CYTOSOLIC BETA-CATENIN LEVELS IN A549
CELLS BUT NOT IN CLARA CELLS
As described in more detail in chapter 1, P-Catenin levels are known to rise in the
presence ofWnt signalling, probably through protection from ubiquitination 170. As a
result, increases in P-Catenin are regarded as indicative of active Wnt signalling, and
dishevelled (Dvl) upregulation. However the baseline expression of P-Catenin in the
cell membrane far exceeds that in the cytosol, and it is mainly cytosolic P-catenin
which is seen to rise with upregulation of the Wnt pathway. Therefore, looking at
cellular p-Catenin levels as a whole, any increase in the cytosolic component may
well be masked by the large stable membranous pool. To address this issue other
groups have separated the membranous and cytosolic pools (subcellular
fractionization) to allow P-Catenin to be analysed in separately 25 \ These fractions
were separated in a similar manner to that described in chapter 2.
No difference in either membranous or cytosolic P-Catenin was seen between Clara
cells transfected with Ad5-MCMV-Dvll, control adenovirus (dl70-3) or
untransfected cells (Figure 5.12A). It would, therefore, appear that upregulation of
Dvll in murine Clara cells does not result in increased P-catenin stabilization.
However this was not the case in A549 cells. Membranous P-Catenin levels were
greater in cells treated with Ad5-MCMV-Dvll than in control samples (control virus
or untransfected) (Figure 5.12B). In the figure shown, expression appears to be
greater in control treated cells than in untransfected. This was not a consistent
finding. More significantly the cytosolic P-catenin levels were greater in Ad5-
MCMV-Dvll transfected cells (Figure 5.12B; upper bands). This would imply that,
unlike in Clara cells, Dvll upregulation increases P-catenin stabilization in A549
cells. The nuclear P-Catenin levels in A549 cells were unaffected by Dvll
upregulation (Figure 5.12C). The slightly weaker band seen in the untransfected
sample (0) was due to less protein loading as confirmed by Ponceau S staining.
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Figure 5.12: Ad5-MCMV-Dvl1 and p-catenin levels
In each of the radiographs C represents control adenovirus (dl70-3) and D, Ad5-
MCMV-Dvl1. The numbering is indicative of the moi of virus used. Membranous
and cytosolic fractions are labelled accordingly. 0 indicates untransfected cells.
The positive p-catenin bands were consistently found to be at the correct
predicted size of ~92kDa (n=3)
A) P-catenin western blot of membranous and cytosolic fractions of transfected
Clara cells.
B)P-catenin western blot of membranous and cytosolic fractions of transfected
A549 cells.
C) p-catenin western blot of nuclear fractions of transfected A549 cells. +ve
indicates positive control lysate; Hela cell extract provided with the antibody
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5.4.4 DVL1-AD AND CELL PROLIFERATION
The aim of producing an adenovirus expressing Dvll was to upregulate the Wnt
signalling pathway. As increased Wnt signalling is normally associated with greater
cell proliferation it was important to assess the effect of Ad5-MCMV-Dvll on
proliferation. This was particularly relevant in view of recently published data
suggesting Dvll overexpression results in increased cellular apoptosis, not
proliferation 262.
The appearance of murine Clara cells transfected with Ad5-MCMV-Dvll differed
from control wells in that, from 24hrs post-transfection, there were consistently more
"rounded up" and loosely adherent cells in the presence ofDvll (Figure 5.13 A+B).
These cells were distinct from the main adherent monolayer and were easily
displaced. Unfortunately, possibly because of their fragility, it was not possible to
make cytospins of these cells to look at their morphology more closely. Many were
lost even during in situ Hoechst staining (Figure 5.13D).
In Figure 5.13 (C and D) a few of these loosely adherent cells are shown as they
appeared under light microscopy and following staining with Hoechst. These cells
appeared to be apoptotic under light microscopy, with evidence of cyoplasmic
shrinkage and blebbing of membranes. With Hoechst staining, the nuclei were
condensed and intensely stained in keeping with apoptosis. However, as already
mentioned, very few of these cells remained following staining which made general
observations about the rate of apoptosis very difficult. In addition, particularly when
2 such cells were adjacent as in Figure 5.13 (arrow), it was difficult to discriminate
between apoptotic and post-mitotic cells. Thus there was no conclusive evidence that
the observed loosely adherent cells were apoptotic, and therefore that Dvll increased
the percentage of apoptotic cells. It was also possible that the loosely adherent cells
were due to Dvll overexpression driving increased proliferation with subsequent cell
detachment from a confluent cell monolayer.
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Figure 5.13: Ad5-MCMV-Dvl1 and Clara cell morphology
A) Clara cells transfected with control (dl 70-3) adenovirus; moi 100
B) Clara cells transfected with Ad5-MCMV-Dvl1; moi 100
C) Clara cells transfected with Ad5-MCMV-Dvl1; moi 100
D) Clara cells transfected with Ad5-MCMV-Dvl1; moi 100; Hoechst stain
(n=3)
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To investigate the effects of Dvll expression on cell proliferation/survival more
quantitatively a number of methods were employed. These included cell counting
following trypan blue exclusion, tritiated thymidine incorporation and the
colorimetric One Solution Cell Proliferation Assay (Promega).
There appeared to be no difference in Clara cell proliferation between transfections
with Ad5-MCMV-Dvll or dl70-3, as assayed by both thymidine incorporation and
the colorimetric assay (Figure 5.14). These results were unaffected by variations in
the concentration of foetal calf serum in the post-transfection culture medium, from
0% to 5%.
There was also no detectable difference in A549 proliferation between transfections
with Ad5-MCMV-Dvll or dl70-3, as assessed by cell counts and the colorimetric
assay (Figure 5.15). No variation was noted at time-points from 8hrs to 72hrs. Data
shown is representative of the pattern seen at all time-points for both cell types.
These observations were consistent regardless of the cell confluency at transfection,
which was varied between 50-80%, thus controlling for growth arrest through
contact inhibition.
Therefore, as measured by the chosen assays, Dvll adenoviral expression did not
alter Clara or A549 cell proliferation.
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Figure 5.14: Ad5-MCMV-Dvl1 and Clara cell proliferation
In each of the above cells were transfected with dl 70-3 (CON), Ad5-MCMV-
Dvl1 (DVL) or not transfected (NONE). Each virus was used at a moi of 100.
A) Clara cell proliferation as measured by tritiated thymidine incorporation at
72hrs post-transfection. The cells were cultured in media containing either 0.5%
or 0% foetal calf serum (FCS) following transfection. Each point is the mean of
triplicate wells. B) Clara cell proliferation as measured by One Solution Cell
Proliferation Assay (Promega) at 48hrs post-transfection. The cells were
cultured in media containing either 5% or 0.5% FCS following transfection. Each
point is the mean of triplicate wells (n=3)
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Figure 5.15: Ad5-MCMV-Dvl1 and A549 cell proliferation
In each of the above cells were transfected with dl 70-3 (CON), Ad5-MCMV-
Dvl1 (DVL) or not transfected (NONE). Moi's varied from 1-100 as stated eg.
CON 50 represents dl 70-3 at a moi of 50.
A) A549 cell counts (duplicates) by trypan blue exclusion at 72hrs post-
transfection.
B) A549 cell proliferation as measured by One Solution Cell Proliferation Assay
(Promega) at 8hrs post-transfection. Each point is the mean of triplicate wells.
(n=3)
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5.4.5 DVL1-AD AND THE SHH SIGNALLING PATHWAY
Wnt signalling is a direct target of Shh signalling 3. It has also been suggested,
largely based studies using Drosophila, that Wnt signalling itself leads to an increase
* * 238 239 •in Shh signalling ' , probably in a paracrine or autocrine manner. Assuming that
Dvll upregulation mimics Wnt signalling, these experiments were designed to
determine if increased Dvll expression would lead to upregulation of the Shh
pathway.
Shh protein was not detectable either in A549 or Clara cells whether they were
untransfected, treated with Ad5-MCMV-Dvll or control adenovirus, dl70-3 (Figure
5.16). The positive control sample (mouse brain) did contain detectable Shh
confirming that the anti-Shh antibody worked. This was reinforced in a further
Western blot in which the same antibody recognised the recombinant amino-
terminus Shh peptide (Figure 5.16), used in chapter 4. In this case the stronger band
was ~19kDa (arrow B) in keeping with N-Shh, and a weaker band was noted at
~45kDa (arrow A) consistent with full length Shh.
In Clara cells mouse Shh mRNA was detectable even in the untreated cells.
Expression did not alter in the presence of either adenovirus (data not shown). This
could not be verified in A549 cells, as suitable human Shh real time PCR primers
were unavailable.
Expression of mouse Ptc mRNA was not significantly changed by transfection with
either Ad5-MCMV-Dvll or dl 70-3 (Figure 5.17), based on the assumption that only
differences >2 fold are significant in real time PCR analysis 557>558 as discussed
further in Chapter 4. This was evident in (A) Clara cells and (B) Swiss 3T3
fibroblasts throughout time-points from 24 to 72hrs. Likewise, human Ptc mRNA
expression was unaltered in A549 cells (not shown). There was therefore no evidence
that Ad5-MCMV-Dvll upregulates Shh signalling.
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Figure 5.16: Ad5-MCMV-Dvl1 and Shh protein expression
In each of the radiographs C represents control adenovirus (dl70-3) and D, Ad5-
MCMV-Dvl1. The numbering is indicative of the moi of virus used. The +ve
control used was mouse brain lysate; Dvl1 is highly expressed in neural tissue.
The top 2 radiographs show expression of Shh in A549 and clara cells
transfected with adenovirus; 48hrs post-transfection. The bottom radiograph
shows the recombinant Mouse Shh amino-terminal peptide (N-Shh) as used in
chapter 4. Arrow A is ~45kDa, the size of full length Shh. Arrow B is ~19kDa,
the size of the active amino-terminal Shh peptide (n=3)
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Figure 5.17: Ad5-MCMV-Dvl1 and Ptc mRNA expression
In the above graphs each point is an average of duplicate wells; hence no error
bars. NONE indicates untransfected cells, CON: cells transfected with the
control adenovirus (dl 70-3) and DVL: cells transfected with Ad5-MCMV-Dvl1.
The numbering is indicative of moi used. In each graph expression is relative to
that in untreated cells (NONE), which is given a value of 1 (n=3)
A) Relative murine Ptc mRNA expression in Clara cells at 72hrs as assessed by
real time PCR.
B) Relative murine Ptc mRNA expression in Swiss 3T3 cells at 24hrs as
assessed by real time PCR.
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5.5 Effects of the Dvl1 Adenovirus in vivo
The Ad5-MCMV-Dvll was made to allow both in vitro and in vivo expression of
Dvll. As the hypothesis was centred on the Wnt pathway playing a role in ILD,
overexpression ofDvll in mouse lungs was a major objective.
Unlike in vitro work the number of "target cells" for an adenovirus cannot be
controlled when performing in vivo experiments. The treatments are therefore not
expressed as multiplicities of infection (moi); rather as plaque forming units (pfu).
The titres of adenovirus used for in vivo mouse lung work vary between different
groups and different adenovirus constructs. The doses chosen in these experiments
were based on preliminary experiments trying a range of doses from 3xl07 to 8x10s
pfu.
5.5.1 THE DVL1 ADENOVIRUS RAISES DVL1 RNA EXPRESSION IN VIVO
As the in vitro adenovirus work demonstrated, Northern blot data and real time PCR
analysis correlate well for Dvll expression. Therefore real time PCR was used to
assessDvll mRNA expression in vivo.
A single intra-tracheal instillation of sterile phosphate buffered saline (PBS), control
dl70-3 adenovirus or Ad5-MCMV-Dvll was given in a final volume of 40pl. The
mice were killed, and lungs removed for RNA extraction, at time-points ranging
from 1 to 7 days. The data shown illustrates relative mRNA expression in these
mouse lungs. In Figure 5.18 and 5.19A the viral dose given was 3x10s pfu.
The administration of Ad5-MCMV-Dvll resulted in greater Dvll mRNA expression
than either control (dl 70-30) adenovirus or PBS alone (Figure 5.18). This was more
notable at (A) 24hrs than (B) 72hrs post-instillation. However, the level of
expression varied greatly between different animals receiving the same treatment.
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This may have been due to a number of factors including the general well-being of
the individual mouse, its response to the adenovirus and, more directly, the division
of the lungs from each treated mouse for RNA extraction, protein extraction and
immunohistochemistry. As a result, the data obtained from lung tissue may vary
depending on the portion of lung chosen, and the distribution of the instilled virus.
Even with this experimental variation the Dvll expression in individual mice was
consistently higher in the Ad5-MCMV-Dvll treated group (Figure 5.18). Averaging
the data from each treatment group revealed a trend toward greater Dvll expression
in the Ad5-MCMV-Dvll group (Figure 5.19A). Flowever, it must be stressed that
error bars were not included in this averaged data because of the wide variation,
particularly in the Ad5-MCMV-Dvll group.
Comparing the lung Dvll expression in Ad5-MCMV-Dvll (8x108 pfu) treated mice
alone, Dvll mRNA levels tended to be greater at 3 days post-instillation than 7 days
(Figure 5.19B). This is consistent with reported expression made using a similar
adenoviral construct 568. Again there was a great deal of variation between animals.
The group averages were calculated to reveal the trend (Figure 5.19B). Significantly,
the relative Dvll mRNA expression (compared with PBS controls) at this higher
dose of Ad5-MCMV-Dvll (8x10s pfu) was much greater than seen with the lower
dose (3xl08 pfu) (Figure 5.18), up to in excess of 100 fold with the former against
little more than 10 fold with the latter.
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Figure 5.18: Ad5-MCMV-Dvl1 increases Dvl1 mRNA expression in vivo as
assessed by real time PCR
Relative Dvl1 mRNA expression in BALB/c mouse lungs following intra-tracheal
instillation of PBS (white bars), control dl 70-3 adenovirus (blue bars) or Ad5-
MCMV-Dvl1 (green bars). Both viruses were given at a dose of 3x10® pfu. Each
bar represents an individual mouse. All RNA levels are expressed relative to
mouse 1 (for each time-point), which is itself given a value of 1. Each point is an
average of duplicate wells.
A) Relative Dvl1 expression at 24hrs post-instillation
B) Relative Dvl1 expression at 72hrs post-instillation
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Figure 5.19: Ad5-MCMV-Dvl1 increases Dvl1 mRNA expression in vivo as
assessed by real time PCR
A) Averaged Dvl1 mRNA expression 24hrs and 72hrs post-instillation of PBS,
dl70-3 (CON) or Ad5-MCMV-Dvl1 (DVL). Data is averaged individual BALB/c
mouse lung data for each treatment; summary of data in Figure 5.18
B) Relative Dvl1 mRNA expression in BALB/c mouse lungs following intra¬
tracheal instillation of Ad5-MCMV-Dvl1at a dose of 8x108 pfu. Green bars
represent individual mice at 3 days (1-4) and 7 days (5-7) post-instillation. Each
is an average of duplicate wells and all values are relative to Dvl1 expression 3
days following PBS treatment: given a value of 1 (not included in graph shown).
White bars represent averaged individual mouse expression at each time-point
i.e green bar data averaged.
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5.5.2 THE DVL1 ADENOVIRUS RAISES DVL1 PROTEIN EXPRESSION IN
VIVO
It was important to show that Ad5-MCMV-Dvll increased Dvll expression at
protein as well as mRNA level in vivo. In order to address this PBS, Ad5-MCMV-
Dvll or control adenovirus (dl 70-3) were instilled intra-tracheally into BALB/c
mice. Portions of lungs from the same mouse were often divided for RNA, protein
and immunohistochemistry. In the data shown 30pg of each sample was loaded onto
the original SDS gel for Western blotting.
At 3 days DVL-1 protein was detected at the highest dose of Ad5-MCMV-Dvll
(8xl08 pfu) but not at a lower dose (3xl08 pfu), (Figure 5.20A). Importantly, it was
not detectable at equivalent doses of the control virus. It was also evident that Dvll
protein levels were higher at 3 days than at 7 days post-instillation; again with the
highest dose ofAd5-MCMV-Dvll (8xl08 pfu), (Figure 5.20B). This peak expression
correlates with previous work 568, and indeed with the RNA expression data (Figure
5.19B). In terms of the doses required it would appear that the lower 3xl08 pfu dose
of Ad5-MCMV-Dvll is sufficient to increase Dvll mRNA, but does not cause




Figure 5.20: Ad5-MCMV-Dvl1 increases Dvl1 protein expression in vivo
Western blots showing Dvl1 expression in BALB/c mouse lungs following intra¬
tracheal instillation of Ad5-MCMV-Dvl1 or control (dl 70-3) virus. Dvl1 bands
detected at ~80kDa as expected.
A) Radiograph of Dvl1 expression 3 days following instillation of virus. 1+2:
dl70-3 (3x10 pfu). 3+4: Ad5-MCMV-Dvl1 (3x108 pfu). 5+6: dl 70-3 (8x108 pfu).
7+8: Ad5-MCMV-Dvl1 (8x10® pfu). Dvl1 band is indicated by arrow.
B) Radiograph of Dvl1 expression 3 and 7 days following instillation of Ad5-
MCMV-Dvl1 at a dose of 8x10s pfu.1-3: 3 days. 4-7: 7 days. 8: positive control
(mouse brain lysate).
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5.5.3 DVL1-ADENOVIRUS AND DVL1 IHC IN MOUSE LUNGS
As with the FITC model (Figure 5.1) tissue sections ofBALB/c mice receiving PBS,
control adenovirus (dl70-3) or Ad5-MCMV-Dvll were stained by IHC for Dvll;
using the anti-Dvll polyclonal antibody. Doses of virus ranged from 108 to 8x108
pfu; the latter having been shown to increase Dvll expression by Western blotting
(Figure 5.20).
The specific and intense staining of bronchial airway epithelial cells noted previously
in both PBS and FITC treated mice (Figure 5.1) was also seen in mice receiving both
control and Dvll adenovirus (Figure 5.21). This strong baseline staining made any
further interpretation of possible changes in Dvll expression impossible. As
discussed later this feature may have been due to antibody characteristics or related
to Dvl protein expression in mouse lungs. In any case Dvll IHC was generally
unhelpful.
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Figure 5.21: Dvl1 expression in mouse lungs following adenoviral
instillation
Dvl1 expression by immunohistochemistry in BALB/c mouse lungs (n=6)
A) 7 days after dl70-3 (108 pfu); (x400 magnification)
B) 7 days after Ad5-MCMV-Dvl1 (108 pfu); (x400)
C) 7 days after Ad5-MCMV-Dvl1 (8x108 pfu); (x400)
D) 3 days after Ad5-MCMV-Dvl1 (8x108 pfu); (x400)
E) 7 days after Ad5-MCMV-Dvl1 (108 pfu); -ve IHC control (x400)
F) 7 days after Ad5-MCMV-Dvl1 (108 pfu); (x200)
- 250 -
5 .5 .4 DVL1 DOES NOT AFFECT LUNG MORPHOLOGY IN VIVO
Sections of mouse lung following treatment with either dl 70-3 or Ad5-MCMV-Dvll
were also stained with haematoxylin and eosin to allow examination of lung
morphology.
At day 3 following intra-tracheal instillation there was no apparent difference
between control and Ad5-MCMV-Dvll sections, the only abnormality being slight
disruption (some denudation and "peg-like" cells) of the bronchial airway
epithelium, suggestive of damage (Figure 5.22 A and B).
By day 7 the most notable additional feature was the presence of marked
peribronchial and perivascular predominantly mononuclear cell infiltrates (Figure
5.22 C and D). Again both viruses appeared to have similar effects.
By 8 weeks the lungs in both groups were essentially normal with no evidence of
fibrosis in either. In some cases patches of cellular infiltrates, similar to those noted
at day 7, persisted (Figure 5.22 E and F).
Both dl 70-3 and Ad5-MCMV-Dvll had similar effects when instilled intra-
tracheally into BALB/c mouse lungs. These features were similar at viral doses ofup
to 8x108 pfli (3x108 pfu shown). Parallel experiments in which the viruses were
instilled intra-nasally (not shown) produced comparable results.
It has been suggested that different strains of mice have different potentials to
develop lung fibrosis. In particular, C57 BL6 mice have been shown to be more
susceptible to bleomycin-induced fibrosis 569. With this in mind dl70-3 and Ad5-
MCMV-Dvl 1 were given intra-tracheally to a group of C57 BL6 mice. The features
were similar to those observed with the BALB/c mice; again with no difference
between treatment arms.
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Figure 5.22: Mouse lung morphology following adenoviral instillation
BALB/c mouse lung sections stained with haematoxylin and eosin. All x200
magnification
A) 3 days after dl 70-3 (3x108 pfu)
B) 3 days after Ad5-MCMV-Dvl1 (3x108 pfu)
C) 7 days after dl 70-3 (3x108 pfu)
D) 7 days after Ad5-MCMV-Dvl1 (3x108 pfu)
E) 8 weeks after dl 70-3 (3x108 pfu)
F) 8 weeks after Ad5-MCMV-Dvl1 (3x108 pfu)
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5 .5 .5 DVL1 DOES NOT AFFECT CELL PROLIFERATION IN VIVO
Dvll did not appear to affect proliferation of either A549 or Clara cells (Figures 5.15
and 5.16). It was also important to determine if Dvll expressed in vivo altered cell
proliferation. To address this lung sections from mice treated with dl 70-3 or Ad5-
MCMV-Dvll were stained with the nuclear proliferation marker Ki67.
3 days following instillation many of the bronchial airway epithelial cells were
positive for Ki67 indicating they were undergoing proliferation (Figure 5.23 A and
B). This was true following both dl 70-3 and Ad5-MCMV-Dvll treatments.
By day 7 the bronchial airway epithelial cells were predominantly negative. At this
time there was a marked cellular infiltrate as noted before (Figure 5.22). Many of
these cells stained positively for Ki67 (Figure 5.23 C and D). Again there was little
difference between treatment groups.
There was therefore no evidence that Dvll expression has any effect on cell
proliferation in vivo as assessed by Ki67 staining. As the observed effects were also
seen with the control virus, it would seem likely that they were a response to the
presence of adenovirus itself rather than Dvll expression. The increased airway
epithelial proliferation may be a response to adenovirally induced epithelial damage
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Figure 5.23: Ki67 expression in mouse lungs following adenoviral
instillation
BALB/c mouse lung sections stained with Ki67 antibody. All x400 magnification
A) 3 days after dl 70-3 (3x108 pfu)
B) 3 days after Ad5-MCMV-Dvl1 (3x108 pfu)
C) 7 days after dl 70-3 (3x108 pfu)
D) 7 days after Ad5-MCMV-Dvl1 (3x108 pfu)
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5 5 6 AD5-MCMV-DVL1 AND THE EXPRESSION OF SHH AND TGF-BETA IN
VIVO
Dvll does not appear to upregulate Shh expression in vitro. This question was also
addressed in vivo by IHC. Lung tissue sections from BALB/c mice post-adenovirus
instillation were stained with a Shh antibody; as used in Chapter 3.
As illustrated 7 days after instillation, Shh expression was unaffected by treatment
with either the control adenovirus (dl70-3) or Ad5-MCMV-Dvll (Figure 5.24 A-C).
This was consistent all time-points. It would therefore appear that Shh expression is
not increased either in vitro or in vivo by Ad5-MCMV-Dvll.
As discussed, the Wnt pathway and TGFP are known to be associated. Therefore it
was important to determine whether or not Ad5-MCMV-Dvll altered TGFP
expression in vivo. This was particularly relevant in view of the strong links between
TGFP and pulmonary fibrosis 351>352-358.
TGFpi expression was unaffected by treatment with either the control adenovirus
(dl70-3) or Ad5-MCMV-Dvll (Figure 5.24 D-F). As with Shh this was the case at all
time-points. In addition, ELISAs of bronchoalveolar lavage (BAL) fluid revealed no
significant active or latent levels of TGFpi in mice treated with dl70-3, Ad5-
MCMV-Dvllor PBS (data not shown).
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Figure 5.24: Shh and TGF(31 expression in mouse lungs following
adenoviral instillation
BALB/c mouse lung sections stained with anti-Shh antibody. All x400
magnification
A) 7 days after dl 70-3 (108 pfu)
B) 7 days after Ad5-MCMV-Dvl1 (108 pfu)
C) 7 days after Ad5-MCMV-Dvl1 (8x108 pfu)
BALB/c mouse lung sections stained with anti-TGFpi antibody. All x200
magnification
D) 7 days after dl 70-3 (10® pfu)
E) 7 days after Ad5-MCMV-Dvl1 (10® pfu)




As described in the introduction, the main aim of the work presented in this chapter
was to upregulate the Wnt pathway by constructing a virus expressing murine Dvll.
However, at the time of planning the project much of the work on the mammalian
Wnt pathway was in its infancy. Since that time a great deal of progress has been
made in this field. With particular relevance to this body of work, Dvll has been
associated with more than just the Wnt pathway. It has also been shown to interact
with the JNK (c-Jun kinase) and Notch pathways 188>217'218. in addition, whereas it
was initially thought that Dvll overexpression lead to increased cell proliferation,
recent work has shown that it can actually result in increased cell death by apoptosis
262
It would, therefore, appear that the effects ofDvll overexpression are more complex.
Regardless, the experiments in this chapter were designed to determine if an
adenovirus expressing Dvll affected cell proliferation and Shh pathway activity, and
if it would induce lung fibrosis.
Dvll Immunohistochemistry (IHC) in the FITC lung fibrosis model and with
Ad5-MCMV-Dvll
Though presented at the beginning of the chapter the Dvll IHC was not carried out
until late in the project, due to the lack of a suitable anti-Dvll antibody. Notably, the
antibody used is also known to recognise Dvl2; it is possible that it may also
recognise Dvl3 (not known). It had been previously used for immunoblotting but not
for IHC.
IHC for Dvll proved unhelpful. Even in PBS treated mice there was strong and
specific staining of the bronchiolar airway epithelial cells (Figure 5.1). This staining
pattern remained unchanged with FITC treatment and with adenoviral instillation,
including Ad5-MCMV-Dvll (Figures 5.1 and 5.21). This may have been due to the
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basal expression of Dvll in airway epithelium, the characteristics of the anti-Dvll
antibody or a combination of the two.
It may well be that Dvll is already expressed at high levels in normal mice. The
staining was certainly appeared to be very specific. Against this assumption, the
Western data following adenoviral instillation in vivo (Figure 5.20) suggested that
the level ofDvll was low unless the highest dose of 8x108 pfu of Ad5-MCMV-Dvll
was given.
It is also possible that the anti-Dvll antibody recognises another protein by IHC. It
cross-reacts with Dvl2, which may be present in the airway epithelium. The antibody
may therefore be binding to this making interpretation of any changes in Dvll
expression impossible. The antibody may even be recognising another protein
altogether, whose expression is unrelated to Dvll. Against this, the antibody was
raised specifically to the C-terminal 46 amino acids of Dvll and has been proven to
recognise Dvll in Western blotting 567, though it did recognise several bands of
similar size both in previous work and this project (Figure 5.10). It is possible,
though difficult to prove without available Dvl proteins, that these bands include
Dvl2 amongst others. However, it is reassuring that specific upregulation of Dvl 1
was detected by this antibody after induction with the Dvll expressing adenovirus
and not with control virus.
P-Catenin Immunohistochemistry (IHC) in the FITC lung fibrosis model
P-Catenin IHC staining was the same in both FITC and PBS treatment arms (Figure
5.2). There was no evidence of cytoplasmic staining as would be expected if the Wnt
Signalling pathway was upregulated in the FITC treated mice. Therefore there is no
evidence from the presented data, that the Wnt pathway is upregulated in ELD. At
least not via P-Catenin stabilization, which of course does not exclude Wnt
interacting with other pathways/genes involved in lung fibrosis.
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Construction of DVL-1 Adenovirus (Ad5-MCMV-Dvll)
The construction of the Dvll expressing adenovirus is described both in this chapter
and in chapter 2. The murine cytomegalovirus promoter (MCMV) was chosen as this
promoter had been demonstrated to be particularly efficient in published work 550
The work shown here summarises the important cloning and expression experiments
involved in the rescue of the crude, unhanded Ad5-MCMV-Dvll.
Ad5-MCMV-Dvll in vitro
At the outset the main objective was to determine whether or not Ad5-MCMV-Dvll
transfections resulted in Dvll expression at both RNA and protein level. As shown
by Northern blotting, the Dvll adenovirus specifically upregulates Dvll at RNA
level, in both A549 cells and Rat-2 fibroblasts (Figures 5.6, 5.7 and 5.8). The reason
for the double bands noted in both Northern blots remains unclear. It may well be
that the Dvll probe binds to spliced variants of Dvll, though none have been
identified to date. Importantly the same doublet was also noted in the positive control
(mouse brain RNA, Figure 5.8). It would therefore be reasonable to assume that the
binding is real and is not to any non-specific adenoviral effect.
The Northern blot data was further supported by real time PCR analysis, confirming
upregulation of Dvll mRNA in A549 cells, mouse Clara cells and Swiss 3T3
fibroblasts (Figure 5.9 and 5.10). This latter technique also allowed direct
quantification of the relative increases in mRNA, of which the highest was up to
1300 fold in Clara cells 48hrs post-transfection. Additionally relative Dvll mRNA
rose to different degrees in each of the cell types transfected. This may have been
due to different efficiencies of adenoviral transfection 550 and/or characteristics of the
Wnt pathway itself, in the chosen cell types.
Ad5-MCMV-Dvl 1 transfections also lead to an increase in Dvll at protein level in
both A549 and Clara cells (Figure 5.11). Interestingly, the Dvll antibody proved to
be discriminatory when used in immunocytochemistry when it had been of little use
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in IHC sections. Only Clara cells transfected with Ad5-MCMV-Dvll stained
positively for Dvll (Figure 5.11). When used in IHC the Dvll antibody recognised
the airway epithelial cells even in control (PBS treated) mice. Many of these cells are
Clara cells in mice 570 and the cell line illustrated was derived from mouse Clara
cells. The reason for this difference is unclear. It may be a feature of using a
transformed cell line as such. If this were the case one might expect primary murine
Clara cells to stain positively with this antibody without transfection. Alternatively,
the discrepancy may be related to the different in vitro and in vivo environments in
which the cells were transfected 570
The ICC staining was specifically localised to the cell membrane. This correlates
with previous findings implying that Dsh (Drosophila dishevelled) is recruited to the
cell membrane compartment upon overexpression 185.
Having confirmed Dvll overexpression in response to Ad5-MCMV-Dvll, the next
priority was to determine if this in turn lead to upregulation of the Wnt pathway. As
described this has often been confirmed by a specific increase in cytosolic P-Catenin
levels. The findings suggested that Ad5-MCMV-Dvll causes an increase in P-
Catenin in A549 cells but not in Clara cells (Figure 5.12). This may be a feature of
the different cell types, as A549 cells are phenotypically type II pneumocytes. It may
be that Dvll, and the Wnt pathway, function differently in each cell type. These are
both derived cell lines in which the Wnt pathway may behave differently than in
primary cells and, of course, A549 cells are of human origin and the Clara cells are
derived from mice. On this final point one might have expected murine Dvll (as
expressed in Ad5-MCMV-Dvll) to prove more effective in a mouse than a cell line,
and not the opposite as observed.
As P-Catenin translocates to the nucleus upon Wnt signalling 194 the levels of nuclear
P-Catenin following adenovirus transfection of A549 cells were also determined
(Figure 5.12). They did not appear to be increased with the Ad5-MCMV-Dvll
compared with d!70-3. The reason for this is unclear.
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The effects of Ad5-MCMV-Dvll on cell proliferation were minimal. The original
hypothesis had been that Dvll upregulation would lead to increased cell
proliferation. This was later countered by published data implying that it may result
in cellular apoptosis 262. Morphologically there appeared to be differences between
Clara cells transfected with Ad5-MCMV-Dvll, dl70-3 and untransfected cells.
Consistently, only in Ad5-MCMV-Dvll treated wells, many loosely adherent, friable
cells were noted (Figure 5.13). Morphologically these cells appeared to be apoptotic
though too few remained adherent during Hoechst staining to make any firm
conclusions. Notably there was no clear morphological difference in A549 cells
between treatment groups (not shown). More objective measures of cell proliferation
by trypan blue cell counts, thymidine incorporation and a colorimetric assay were
also employed. By these methods there was no consistent difference in proliferation
between untransfected and adenovirally (both Dvll and control) transfected A549 or
Clara cells (Figures 5.14 and 5.15).
These findings would suggest that Dvll expression does not affect cell proliferation.
This of course could be influenced by several factors. The observed morphological
changes associated with Ad5-MCMV-Dvll could not be translated into objective
data, largely because the cells of interest were too fragile and loosely adherent to be
satisfactorily isolated and analysed. However these cells were still accounted for in
the colorimetric assay in which no difference in treatment groups was noted. It may
be that the basal high level of proliferation of the chosen cell lines masked any
changes exerted by the presence of Dvll. When the percentage of foetal calf serum
was reduced in an attempt to limit baseline proliferation rates, similar results were
obtained. As both were adherent cell lines measuring proliferation at all was
technically difficult. Finally, it is also possible that Dvll overexpression affects each
cell type differently; neither A549 nor the Clara cell line were used by other groups
investigating the effects ofDvll on apoptosis. It may be that proliferation/survival is
not affected in the same way in these cell lines as in those previously used 262.
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Based on the assumption that increased Wnt signalling may upregulate the Shh
pathway, the expression of Shh and Ptc were analysed in response to Ad5-MCMV-
Dvll. Of course, the evidence suggesting that the Wnt pathway is itself upregulated
by Ad5-MCMV-Dvll is conflicting as determined by P-Catenin expression (Figure
5.12). Regardless, the possibility of an interaction between Dvll overexpression and
the Shh pathway was assessed. Neither Shh or Ptc expression was significantly
altered by treatment, of A549 or Clara cells, with Ad5-MCMV-Dvll (Figures 5.16
and 5.17). Ptc expression in Swiss 3T3 cells was also unaffected. Therefore, it would
appear that, in the chosen cell lines, Dvll overexpression does not affect Shh
signalling.
Ad5-MCMV-Dvll in vivo
As in the in vitro experiments the starting point for the in vivo work was to determine
if Ad5-MCMV-Dvll caused an increase in Dvll at both RNA and protein level. By
real time PCR Dvll mRNA expression was increased in the lungs of mice treated
with Ad5-MCMV-Dvll from 24hrs (first time-point chosen) onwards (Figures 5.18
and 5.19) at doses as low as 3xl08 pfu. In addition expression at 3 days was greater
than at 7 days (Figure 5.19), as demonstrated by others with similar constructs 568.
In vivo Dvll protein expression was also confirmed, by Western blotting, in BALB/c
mouse lungs following Ad5-MCMV-Dvll instillation (Figure 5.20). Unlike RNA
expression Dvll protein was only detectable at the highest 8xl08 pfu dose of virus
used. This may have been in some part due to the sensitivity of the Western blot.
Dvll IHC, as with staining ofFITC fibrosis sections, was uninformative.
The lungs of mice receiving Ad5-MCMV-Dvll or dl70-3 intra-tracheally were
morphologically very similar (Figure 5.22). There was a non-specific viral effect in
both, in the form of sloughed and reactive airway epithelial cells at day 3 and
significant mononuclear cell infiltrates from day 7. By the later 8-week time-point,
other than some residual infiltrates, the lungs were essentially normal with no
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evidence of fibrosis. Similar observations were made using the intranasal route of
adenovirus administration, and in C57 BL6 mice treated intra-tracheally.
Cell proliferation was analysed in the mouse lungs by staining with Ki67 (Figure
5.23). In lung sections of mice following adenoviral instillation many of the
"reactive" airway epithelial cells were positive, indicating a high rate of
proliferation; possibly compensatory hyperplasia following viral damage. This
contrasts with the largely negative epithelial staining of lung sections from mice
treated with the SPC plasmids shown in chapter 3 (Figure 3.9), which equates with
the appearance of normal, untreated mouse lungs. As proliferation was equally
marked in both the Dvll and the control adenovirus it was likely to be a virus related
effect. Indeed, it would be difficult to appreciate any additive effects due to Dvll
expression against this viral response. By day 7 the airway epithelium was largely
negative again as in untreated lungs. Not surprisingly many of the infiltrating
mononuclear cells were positive at this later time-point; predominantly lymphocytes
as one would expect in response to an adenovirus.
Essentially Dvll expression itself does not appear to have any effect on either lung
morphology or cell proliferation. Although not shown, preliminary IHC on lungs
from mice treated with Ad5-MCMV-Dvll showed no evidence of increased
cytoplasmic (3-catenin staining, again consistent with a failure to augment Wnt
signalling, at least via the Wnt/(3-catenin pathway. Several possible explanations
exist. Dvll protein was only detected at the highest dose of Ad5-MCMV-Dvll
(8x108 pfu) used. This was the highest dose that could be given as a single 50pl
intra-tracheal treatment, and repeat adenoviral administration is inadvisable due to
the associated immune response as discussed in Chapter 1. It may be that a higher
dose may have resulted in more significant in vivo effects in terms ofWnt signalling
and lung morphology, though it should be stressed that the dose given was
appreciable. It is also possible that the observed Dvll overexpression was driving
alternative pathways such as the c-Jun N-terminal kinase/stress-activated protein
kinase (JNK/SAPK) cascade 217'218. Due to time constraints, this issue was not
addressed in this thesis.
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Finally, further lung sections stained with specific antibodies confirmed that Ad5-
MCMV-Dvll does not upregulate either Shh or TGFpi (Figure 5.24). Shh
expression in vivo would have been particularly relevant in view of the findings
presented in chapter 3. The TGFpi IHC data was supported by TGFpi ELISA
analysis of the BAL fluid in similarly treated mice, in which no significant active or
latent TGFpi was detected (not shown). As the evidence presented suggests, Dvll
overexpression may not increase expression of these two proteins, but this does not
necessarily mean that Wnt upregulation does not.
Summary
The work presented in this chapter details the successful rescue of a replication
deficient adenovirus expressing murine DVL-1 (Ad5-MCMV-Dvll). This virus
allows upregulation ofDvll at both mRNA and protein level in vitro and in vivo. The
evidence presented does not prove that overexpression of Dvll in this manner
mimics Wnt signalling, as was the original prediction. In addition, the adenovirus
does not cause significant, objective changes in cell proliferation when used in cell
culture or instilled into mouse lungs. Neither the Shh signalling pathway nor TGFpi
are stimulated by Ad5-MCMV-Dvll. Finally, when used in vivo, any observed
effects were consistent with a non-specific adenoviral reaction, and the treated mice
did not develop any features of pulmonary fibrosis. Using available tools there was
no evidence of Dvll upregulation (IHC), or of cytosolic P-Catenin stabilisation, in
the mouse model of ILD.
It would appear that, based on the work presented, that Ad5-MCMV-Dvll neither
upregulates Wnt/p-catenin signalling in all lung epithelial cell types, nor influences
cell proliferation. There is certainly no evidence that it causes lung fibrosis.
Additionally the Wnt pathway itself does not appear to be upregulated in ILD.
Whether or not Wnt signalling upregulation by another route would cause lung
fibrosis isn't known, but at present would seem unlikely. Of course, this does not
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exclude the possibility that upregulation of the Wnt pathway has an anti-fibrotic
effect, as is possible for Shh signalling, and as implied by preliminary experiments
* 275 276
looking at (3-catenin expression in models of ILD and airway epithelial repair
Essentially, although the desired genetic tool has been created, its application to date
has produced largely negative data. It may well be that Ad5-MCMV-Dvll can be




In the work described in this thesis the role of the Shh pathway in ILD and human
CD4+ T cell activation was investigated. In addition, the potential involvement of the
Wnt pathway in the pathogenesis of ILD was studied, and an attempt made to
upregulate this pathway using a recombinant adenoviral vector expressing Dvll.
In chapter 3, the expression of Shh and its receptor, Ptc, was assessed both in a
murine model of pulmonary fibrosis, induced by FITC instillation, and in archival
biopsy sections taken from patients with IPF. It was demonstrated that Shh
expression was increased in the remodelling airway epithelium of FITC treated mice
and in IPF sections suggesting that the Shh pathway is upregulated in ILD.
Curiously, Ptc was constitutively expressed in the airway epithelium with no
evidence of increased expression in fibrotic lung. Expression of both Shh and Ptc
was noted in the infiltrating mononuclear cells in mouse and human sections.
Furthermore, the FITC model was reproduced in mice containing heterozygous
mutations of Gli2 and 3 to determine if dysregulated Shh signalling altered the
fibrotic response. There was no demonstrable difference in the severity of fibrosis
between the wild type and mutant mice, though the latter were far from ideal
research tools, as described. An attempt to increase Shh expression, and hence
pathway activity, in vivo was also made. Flowever, as assessed by IHC and
morphology this was unsuccessful, possibly as a result of inefficient gene transfer
and/or a sub-optimal promoter. Finally, increased TGFpi expression was noted in
the remodelling airway epithelial cells in mouse and human sections, in keeping with
established correlations between TGFP and the fibrotic process.
The expression of Shh and Ptc in mononuclear cells demonstrated in fibrotic tissue
sections in chapter 3 was paralleled by their observed expression in human T cells,
described in chapter 4. Having confirmed that the pathway was present in these cells,
a N-Shh peptide and an anti-Shh neutralizing antibody (5E1) were used to upregulate
and inhibit Shh signalling respectively, in purified human CD4+ T cells, activated
with anti-CD3 and anti-CD28 antibodies. It was thus demonstrated that increased
Shh signalling enhances TCR mediated T cell activation as evidenced by
proliferation, cytokine secretion and expression of the surface activation markers,
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CD25 and CD69. Conversely, reduced Shh signalling inhibits activation as assessed
by these same assays. However, such manipulation of the Shh pathway did not affect
T cell survival, nor did it have any influence on non-activated T cells. Of those
tested, only T cells from approximately 50% of donors were affected by altered Shh
signalling. This may have been due to a Ptc or Smo polymorphism rendering the
pathway inactive in these 'non-responding' donors.
As discussed, Shh signalling promotes, whereas the profibrotic cytokine, TGF(3,
inhibits branching morphogenesis of the developing lung. It may therefore be the
case that the observed upregulation of the Shh pathway in ILD is more indicative of
an attempted repair process by the lungs, thus antagonising TGFp. Further
experiments, in particular aimed at upregulating the Shh pathway in vivo, would be
necessary to determine this. However, it should be stressed that the observed
upregulation of Shh in ILD is not in itself proof that the pathway is specifically
linked to the fibrotic process. Indeed the in vivo Gli mutant and intra-tracheal SPC-
Shh cDNA experiments, accepting their weaknesses, if anything suggested that Shh
signalling does not influence fibrosis in murine lungs. It certainly would have been
worthwhile expanding the in vitro Shh experiments to structural cells such as
fibroblasts in order to provide more proof of such a link. For example, as already
described, TGFP is known to stimulate in vitro expression ofECM proteins, such as
collagen and fibronectin, and to induce the myofibroblast phenotype from classical
fibroblasts 351!352. Similar experiments designed to look at the production of such
ECM proteins and myofibroblast differentiation, characterized by a smooth muscle
actin expression, in the context of Shh signalling could have been performed. As in
the T cell work described, the pathway could be stimulated or inhibited by the
addition of the N-Shh peptide or the anti-Shh neutralizing antibody (5E1),
respectively. Although some preliminary experiments of this nature were carried out
they were not sufficient to warrant inclusion in this thesis.
The presence of the Shh pathway in infiltrating mononuclear cells, and its effects on
TCR mediated T cell activation, suggest that Shh signalling may be involved in
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communication between T cells, macrophages and indeed epithelial cells.
Furthermore, such communication may play a role in the pathogenesis of ILD, or
alternatively in the body's attempt to attenuate the fibrotic response. In essence, it
would be fascinating to link the two main positive findings from this thesis: the
observed increase in Shh expression in ILD and the presence and function of the
pathway in mature T cells. As outlined in the introductory chapter, lymphocytes and
their cytokines have been closely associated with ELD. It may be that any influence
Shh signalling exerts on the fibrotic process is dependent on the manipulation of T
cell activation. If so, the discrimination between "responder" and "non-responder" T
cell donors (to altered Shh signalling) may define whether or not individuals are
likely to develop ILD.
The Wnt pathway also plays a role in embryonic lung branching morphogenesis, and
has recently been associated with TGF(3 signalling. In chapter 5, it was shown that
neither (3-catenin nor Dvll expression was altered in the FITC model of ILD. A
replication deficient adenovirus expressing murine Dvll (Ad5-MCMV-Dvll) was
successfully rescued. This drove increased Dvll expression in vitro and in vivo, but
did not induce upregulation ofWnt or Shh signalling, nor did it result in objective
changes in cell proliferation. Finally, increased Dvll expression, in the lungs of
BALB/c and C57 B16 mice, did not cause pulmonary fibrosis. Therefore, from the
data presented in this chapter there is no evidence of a correlation between the Wnt
pathway and ILD. As Shh and Wnt signalling have been shown to drive each other,
this would suggest that any link between Shh and ILD is independent of Wnt
signalling. It may be related to other targets of the Shh pathway, such as the Bmp's,
which are afterall members of the TGFP superfamily.
Future work could be addressed at upregulating the Shh pathway in the lungs of
mature mice using either a gene vector, such as an adenovirus, or an inducible Shh
transgenic mouse. This, in addition to the potential in vitro experiments discussed
above, may answer the question of whether or not Shh signalling contributes to the
development of fibrosis. Such experiments could be combined with a fibrosis model,
such as the FITC model, in which either Shh or a Shh antagonist (eg. Hip) could be
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overexpressed during the fibrotic response. It would be interesting to determine if
Shh expression is also increased in fibrosis of other organs such as the liver and gut.
It would also be informative to analyse the mechanism of action of the Shh pathway
in CD4+ T cells and to determine how this is linked to existing mechanisms of T cell
signalling. Furthermore, one could analyse the activity of Shh signalling in T cells
isolated from mice with lung fibrosis and compare this with normal controls. Similar
studies could be carried out comparing T cells from patients with ILD with matched
controls. The role of the Shh pathway in macrophage function is also yet to be
determined; a project that is now ongoing within the group. Finally, although much
of the data produced using Ad5-MCMV-Dvll has been negative to date, it did
successfully drive Dvll expression. It could therefore be used to establish the effects
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